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ABSTRACT 
 
EPIGENETIC REGULATION OF GENES INVOLVED IN VASCULAR DYSFUNCTION IN 
PREECLAMPTIC WOMEN 
 
By Ahmad Mousa, BDS 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2012 
Major Director: Dr. Scott W. Walsh 
 
Professor, Departments of Obstetrics and Gynecology, Physiology and Biophysics 
 
DNA methylation is the most recognizable epigenetic mechanism. In general, DNA hypomethylation is 
associated with increased gene expression whereas DNA hypermethylation is associated with decreased 
gene expression. To date, little is known about the role of DNA methylation in the pathophysiology of 
preeclampsia. In this study, we examined the differences in DNA methylation in omental arteries of 
normal pregnant and preeclamptic women using the high throughput Illumina HumanMethylation27 
BeadChip assay. We found 1,685 genes with a significant difference in DNA methylation at a false 
discovery rate of < 10% with many inflammatory genes having reduced methylation. The thromboxane 
synthase gene was the most hypomethylated gene in preeclamptic women as compared to normal 
pregnant women. When we examined the expression of thromboxane synthase in omental arteries of 
normal pregnant and preeclamptic women we found it to be significantly increased in preeclamptic 
women. The increased expression was observed in vascular smooth muscle cells, endothelial cells and 
infiltrating neutrophils. Experimentally induced DNA hypomethylation increased the expression of 
thromboxane synthase in the neutrophil-like HL-60 cell line, whereas tumor necrosis factor α (TNFα), a 
 
 
xviii 
 
neutrophil product, increased its expression in cultured human vascular smooth muscle cells (VSMC). 
These finding suggest that DNA methylation and release of TNFα by infiltrating neutrophils could 
contribute to the increased expression of thromboxane synthase in systemic blood vessels of preeclamptic 
women, contributing to the hypertension and coagulation abnormalities. We also explored the possible 
contribution of DNA methylation to the altered expression of genes involved in collagen metabolism in 
preeclampsia. Several matrix metalloproteinase (MMP) genes, including MMP1 and MMP8, were 
significantly less methylated in preeclamptic women, whereas TIMP and COL genes were either 
significantly more methylated or had no significant change in their DNA methylation status. 
Experimentally induced DNA hypomethylation increased the expression of MMP-1, but not TIMP-1 or 
COL1A1, in cultured VSMCs and increased the expression of MMP-1 and MMP-8 in HL-60 cells. These 
findings suggest that DNA methylation contributes to the imbalance in genes involved in collagen 
metabolism in blood vessels of preeclamptic women.    
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CHAPTER 1: GENERAL INTRODUCTION 
 
A. Definition of preeclampsia, its clinical symptoms and complications 
 
Preeclampsia is the clinical definition of a multisystemic syndrome that is diagnosed by new 
onset of hypertension (systolic blood pressure of equal to or more than 140 mmHg, and/or diastolic blood 
pressure of equal to or more than 90 mmHg) and proteinuria (300 mg or more of protein in the urine for at 
least twenty four hours), which occur after twenty weeks of gestation in pregnant women who are 
otherwise normal1.  
Preeclampsia involves almost every system in the maternal body, with special involvement of the 
cardiovascular, hepatic, renal, cerebral, and coagulation systems2. Preeclampsia is associated with a 
widespread vasoconstriction, which results in increased total peripheral resistance and mean arterial blood 
pressure and decreased cardiac output, causing hypertension to occur3. Preeclamptic women also have 
exaggerated sensitivity to vasopressors such as angiotensin II4 and impaired endothelium-dependent 
vasorelaxation5. Hepatic edema occurs in most of preeclamptic women2. Other liver complications in 
preeclampsia can range from reversible supcapsular and intrahepatic hemorrhage to rupture of the liver 
capsule and acute intraabdominal bleeding6. Hepatic complications are responsible for approximately 
20% of maternal mortality in preeclampsia.  
Glomerular endotheliosis, glomerular hypertrophy due to swelling of the glomerular endothelium, 
is the classical lesion of the kidneys in preeclampsia2. Proteinuria occurs in part due to impaired integrity 
of glomerular barrier and loss of size selectivity causing plasma proteins to leak into the urine. 
Preeclampsia is also associated with decreased renal blood flow and decreased uric acid secretion2. 
Cerebral edema is the most common finding in preeclampsia when the brain is involved2. Visual 
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disturbances that are most often reversible can occur in preeclamptic women2. Preeclampsia is also 
associated with a chronic disseminated intravascular coagulation indicated by platelet activation, 
increased thrombin-antithrombin III complexes and fibrin degradation products, and decreased platelets 
and antithrombin III7,8.  
Acute maternal complications of preeclampsia includes eclampsia, Hemolysis, elevated liver 
enzymes, low platelets (HELLP syndrome), liver rupture, pulmonary edema, renal failure, disseminated 
intravascular coagulopathy (DIC), hypertensive emergency, hypertensive encephalopathy and blindness9. 
Eclampsia is a life threatening condition which is characterized by the development of generalized 
convulsions with or without coma that cannot be explained by causes other than pregnancy10. HELLP 
syndrome is another serious complication of preeclampsia9. It has been estimated that 6% of women with 
severe preeclampsia develop one of the three clinical manifestations of this syndrome with elevated liver 
enzymes or low platelet count being the most common, 12% develop two of them, and 10% develop all of 
them. Perinatal and maternal death rates associated with preeclampsia are significantly increased when 
preeclampsia is complicated by HELLP syndrome9. Liver rupture is a severe complication of 
preeclampsia that occurs most frequently in multiparas of advanced age11. Liver rupture is rare, however, 
when it occurs, it is associated with high maternal and fetal mortality rate.  
Pulmonary edema complicates up to 3% of preeclamptic pregnancies with up to 80% of cases 
occurring after delivery12. Acute renal failure is a rare complication of preeclampsia that is characterized 
by a sudden decrease in glomerular filtration rate, which causes retention of water and urea9. Up to 90% 
of the cases are due to acute tubular necrosis. In these cases, renal damage is often reversible and 
completely resolves after delivery, however, 10 to 29% of cases of acute renal failure as a complication of 
preeclampsia are due to bilateral renal cortical necrosis9. These cases are much more severe and 
associated with significantly increased maternal and fetal mortality rate.  
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Disseminated intravascular coagulopathy (DIC) is another possible complication of 
preeclampsia9. DIC is characterized by abnormal activation of the coagulation system which leads to 
widespread formation of fibrin microthrombi that can compromise adequate blood flow to the organs and 
cause organ failure9. In addition, the continuous activation of coagulation results in excessive 
consumption of coagulation factors and platelets, which causes bleeding tendency13. Thrombocytopenia 
(low platelet count of less than 100,000 per µl of blood), which is estimated to occur in 10% of 
preeclamptic women, is usually the first indication of DIC9.  Hypertensive emergencies, which predispose 
to cerebrovascular accident (stroke) and hypertensive encephalopathy, may also complicate 
preeclampsia14. Hypertensive encephalopathy is characterized by neurological disturbances, such as 
headache, convulsions and visual disturbances, in the presence of hypertension9. Hypertensive 
encephalopathy can cause blindness in 1% to 15% of women with severe preeclampsia15. Although 
cerebrovascular accident is rare in pregnancy, it is a leading cause of death in preeclampsia and 
eclampsia15. 
 
B. Epidemiology 
 
Preeclampsia and eclampsia are among the leading causes of obstetrical mortality and 
morbidity16. Preeclampsia occurs in approximately 6% to 8% of pregnant women and is estimated to be 
responsible for 15% of obstetrical deaths in the United States17. The incidence of preeclampsia in 
developed countries is estimated to be 4.5% to 11.2% of pregnancies2. However, the incidence of 
preeclampsia in developing countries is as high as 27%18. Preeclampsia more frequently affects pregnant 
women at both extremes of reproductive age, however, women who are less than 20 years old are at a 
higher risk19. 
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Eclampsia accounts for about 15% of maternal mortality in the United States of America20 and is 
the cause of approximately 10% of maternal deaths per year worldwide21. The incidence of eclampsia is 
estimated to be at 4 to 5 cases per 10,000 live births in developed countries22 and 6 to 100 per 10,000 live 
births in developing countries23. 
 
C. Prevention and treatment 
 
Multiple strategies have been proposed for prevention of preeclampsia24. These include dietary 
sodium restriction, dietary supplementation (fish oil, vitamin C, vitamin E and calcium), bed rest, and 
pharmacologic agents (diuretics, antihypertensive medications, heparin and other medications). However, 
none of these strategies has proven to be helpful in prevention of preeclampsia.  
Meta-analysis of low-dose aspirin trials revealed that aspirin is effective in preventing 
preeclampsia25,26, and its effectiveness is related to patient compliance27.  A recent study demonstrated 
that supplementation during pregnancy with L- arginine, the substrate for nitric oxide synthesis, and 
antioxidant vitamins caused significant decrease in the incidence of preeclampsia in a high-risk 
population28. However, the same study indicated that supplementation with antioxidants alone was not 
effective.      
To date, delivery of the fetus and placenta is the only cure for preeclampsia, which can occur at 
any time after 20 weeks gestation, therefore, preeclampsia is a common cause of preterm birth, low birth 
weight babies and increased fetal morbidity and mortality1.        
 
D. Pathophysiology of preeclampsia 
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Despite the extensive research efforts to understand the pathophysiology of preeclampsia, the 
exact process in not well understood, however, it has been proposed that the etiology of preeclampsia is 
divided into two stages where the first stage is associated with placentation issues, and the second stage 
involves development of maternal clinical manifestations29.  
 
1. Poor placentation in preeclampsia 
 
The placenta has a fundamental role in the pathophysiology of preeclampsia because 
preeclampsia occurs only in the presence the placenta or placental tissue, and symptoms disappear soon 
after delivery of the placenta29. For example, a case report of a woman with abdominal pregnancy and 
retained placenta remained preeclamptic for months after delivery until the placenta was absorbed30. Also 
hydatidiform moles, which are masses of abnormal placental tissue, are associated with increased risk of 
preeclampsia1.  
Normal placentation is characterized by the invasion of spiral arterioles by a specialized subset of 
trophoblast cells called extravillous cytotrophoblasts. These cells replace maternal endothelium and much 
of the highly muscular tunica media of the spiral arterioles changing their morphology from narrow, 
muscular, vasoconstrictor responsive arterioles to wide, low-resistance, vasoconstrictor unresponsive 
canals in a process known as pseudovascularization or spiral remodeling10. This process extends to the 
inner third of the endometrium and is more or less completed by 20 weeks gestation31. Spiral remodeling 
enhances blood flow to the intervillous space where physiological exchange of nutrients and gases takes 
place between the maternal and the fetal circulations. In many cases of preeclampsia, invasion and 
remodeling of spiral arterioles by cytotrophoblasts is shallow and incomplete, a process called poor 
placentation, which results in reduced blood flow and placental hypoxia that is associated with placental 
oxidative stress due to an imbalance of increased production of reactive oxygen species and decreased 
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antioxidant defenses. Poor placentation, however, does not always cause preeclampsia10, so other 
mechanisms are involved.   
 
2. Neutrophil activation in preeclampsia 
 
Neutrophils are the most abundant leukocytes in the blood comprising up to 70% of white blood 
cells32. Neutrophils are part of the innate immune system and they are highly mobile and phagocytic 
immune cells. Neutrophils are the first line of defense in the body against bacterial and fungal infections 
after physical barriers, such as skin, have been broken32. They are the first immune cells that extravasate 
to the site of inflammation in response to infection or tissue injury. Neutrophils play a key role in 
inflammation32. Beside their ability to respond to chemokines and cytokines, neutrophils can release 
chemokines that attract other immune cells such as dendritic cells and monocytes to sites of inflammation. 
Neutrophils also produce Tumor necrosis factor α (TNFα) and other cytokines that promote the 
differentiation and activation of dendritic cells and macrophages. Furthermore, they produce other ligands 
that are involved in proliferation and maturation of T and B lymphocytes. Neutrophils function against 
bacterial and fungal infections by isolating, phagocytizing and destroying the invading pathogens32. The 
latter is accomplished by two types of mechanisms: 1) oxidative mechanisms, which involve the 
production of reactive oxygen species (ROS), such as superoxide and hypochlorite ions, and 2) non-
oxidative mechanisms, which involve synthesis and release of a variety of proteolytic enzymes. However, 
neutrophil destructive machineries are not exclusively directed against the invading pathogens and they 
can also destroy self-tissues. Thus, although neutrophils are generally thought to be a first line of defense 
for our bodies, there is a growing evidence of neutrophil involvement in a variety of inflammatory 
diseases that are not associated with infection33.   
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Normal pregnancy is associated with neutrophil activation, which is exaggerated in preeclampsia. 
This was first demonstrated by measuring plasma levels of neutrophil elastase, a marker of neutrophil 
activation. Plasma elastase levels were significantly higher in normal pregnant women as compared to 
normal non-pregnant women, and were significantly higher in preeclamptic women as compared to 
normal pregnant women34. Increased neutrophil activation in preeclampsia was later confirmed by 
evaluating other markers of neutrophil activation such as increased intracellular free ionized calcium35, 
increased plasma levels of defensins  and lactoferrin36, increased expression of CD11b37, and increased 
release of intracellular reactive oxygen species38. Neutrophil activation in preeclampsia is limited to the 
maternal circulation39. Plasma from normal pregnant women significantly inhibited superoxide production 
by neutrophils from non-pregnant women, but did not inhibit superoxide production by neutrophils from 
preeclamptic women40. 
Neutrophil activation in preeclampsia most likely occurs as neutrophils circulate through the 
placental intervillous space and are exposed to increased levels of lipid peroxides41. Neutrophils can also 
be activated by syncytiotrophoblast microvillus membrane micro-particles as indicated by the induction 
of superoxide generation42. Increased levels of these micro-particles have been detected in the maternal 
circulation in preeclampsia43. Preeclampsia is also associated with increased plasma levels of small dense 
low-density lipoprotein, very low-density lipoprotein44 and oxidized low-density lipoprotein45. Incubation 
of isolated neutrophils with oxidized low-density lipoprotein resulted in their activation as indicated by 
increased expression of CD11b and decrease expression of L-selectin suggesting an other possible cause 
of neutrophil activation in preeclampsia46. 
 
3. Endothelial Dysfunction 
 
Endothelium is a layer of flattened cells that line the luminal surface of blood vessels. 
Endothelium is not an inert tissue; rather, it is involved in a variety of physiological and pathological 
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processes. Endothelium permits the physiological exchange of products between blood and interstitial 
fluid47. It is also involved in controlling vessel tone, and therefore blood pressure, through the production 
of vasoactive substances which can be vasodilators such as nitric oxide, prostacyclin and endothelial 
derived hyperpolarizing factor, or vasoconstrictors such as endothelium-derived contracting factors, 
thromboxane and endothelin48. Endothelium also plays an essential role in hemostasis49 and 
inflammation50. 
Normal endothelial functions favor vasodilation, anti-coagulation and anti-inflammation. 
However, endothelial injury results in abnormal alterations in the vascular properties of endothelium 
characterized by a shift toward reduced vasodilation, pro-inflammation and pro-coagulation, a condition 
known as “endothelial dysfunction”51. Endothelial dysfunction is associated with cardiovascular diseases 
such as hypertension, coronary artery disease, chronic heart failure, peripheral artery disease, diabetes and 
chronic renal failure. Preeclampsia is also associated with endothelial dysfunction52,53 demonstrated by 1) 
increased production of vasoconstrictors and pro-coagulants such as Von Willebrand’s factor54, 
endothelin-155, thromboxane, prostaglandin F2α56 and platelet derived growth factor, and 2) decreased 
production of vasodilators and anti-coagulants such as prostacyclin57,58 and nitric oxide59.  Endothelial 
dysfunction precedes the clinical manifestations of preeclampsia5 and can help explain some of them such 
as hypertension, proteinuria and hypercoagulation.   
The cause of endothelial dysfunction in preeclampsia is thought to be of placental origin with 
several candidates being proposed to be released from the placenta to the maternal circulation and cause 
endothelial dysfunction60. These include TNFα, interleukin -6, interleukin -1α, interleukin -1β, oxidized 
lipid products, neurokinin-B, syncytiotrophoblast debris and soluble fms-like tyrosine kinase 1, a soluble 
receptor for vascular endothelial growth factor. These factors have been reported to induce endothelial 
dysfunction in in vitro models, however, they are not increased in all preeclamptic cases and are not 
sufficient by themselves to explain the complex pathophysiology of preeclampsia.  
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Neutrophil activation is another possible mechanism by which the placenta can cause endothelial 
dysfunction through the direct interaction between activated neutrophils and endothelium. Recently, 
neutrophil infiltration of resistance-sized systemic blood vessels associated with activation of nuclear 
factor-kappa B (NF-ĸB) and increased expression of cyclooxygenase-2 (COX-2), intercellular adhesion 
molecule-1 (ICAM-1) and interleukin-8 (IL-8) in endothelial and vascular smooth muscle cells was 
demonstrated in preeclampsia61-63.  
 
4. Oxidative stress 
 
Preeclampsia is associated with an imbalance of increased lipid peroxidation along with decrease 
antioxidant protection leading to oxidative stress. This imbalance is present in the maternal and placental 
compartments64. Lipid peroxides are produced when polyunsaturated fatty acids interact with free radicals 
such as oxygen free radicals64. Oxygen free radicals, also called reactive oxygen species (ROS), include 
superoxide, hydroxyl radical, alkoxy radical, peroxyl radical, nitric oxide, and hydrogen peroxide. 
Although hydrogen peroxide is not a radical, it is considered as a reactive oxygen species due to its high 
reactivity. Sources of reactive oxygen species include mitochondria, oxidative enzymes such as xanthine 
oxidase, activated neutrophils, and arachidonic acid metabolism by the lipoxygenase and the 
cyclooxygenase pathways. In turn, lipid peroxides can generate reactive oxygen species through their 
interaction with molecular oxygen64. Once the lipid peroxidation process is initiated, it becomes self 
propagating, unless stopped by an antioxidant, such as vitamin E64.   
Antioxidants neutralize the toxic effects of lipid peroxides and oxygen free radicals, and limit 
their formation64. Antioxidants can be divided into extracellular (plasma) antioxidants and intracellular 
antioxidants. The major mechanism of action for plasma antioxidants is to bind transition metals such as 
iron and copper, which stimulate free radical reactions. These plasma antioxidants include transferrin, 
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lactoferrin, ceruloplasmin, albumin, uric acid, haptoglobin and hemopexin. Ascorbic acid, uric acid and 
albumin provide additional antioxidant activity in the plasma through the scavenging of water-soluble 
peroxyl radicals. Vitamin E is the most important lipid soluble antioxidant in plasma and cells. Because 
of its solubility in lipids, vitamin E becomes a part of plasma lipoproteins, cell membranes and 
membranes of the intracellular organelles. Vitamin E is essential in protecting against lipid peroxidation 
by interfering with its self propagation. Vitamin E is consumed during lipid peroxidation and its levels are 
decreased when lipid peroxidation is increased. Intracellular antioxidants include superoxide dismutase, 
which converts superoxide to hydrogen peroxide, catalase, which inactivates hydrogen peroxide, and 
glutathione peroxidase, which inactivates hydrogen peroxide as well as lipid peroxides.  
Normal pregnancy is associated with increased maternal blood levels of lipid peroxides65, 
however, several antioxidants such as vitamin E, ceruloplasmin, glutathione peroxidase activity and the 
net antioxidant activity are increased, which nullify the toxic effects of increased lipid peroxides. In 
contrast to normal pregnancy, preeclampsia is associated with a greater increase in maternal blood levels 
of lipid peroxides, which is not off-set by an increase in antioxidants65. Tissue levels and production rates 
of lipid peroxides are also significantly increased in the placenta65. Some of the lipid peroxides that are 
produced by placenta are stable enough to function in the maternal circulation such as oxidized 
polyunsaturated fatty acids in low-density lipoproteins, which have a half-life of 3 hours. In contrast to 
normal pregnancy, preeclampsia is associated with a significant decrease in various maternal circulating 
antioxidants such as vitamin E and net antioxidant activity. Vitamin E levels and the activities of 
glutathione peroxidase and superoxide dismutase are also significantly decreased in preeclamptic 
placentas64.  
Reactive oxygen species, particularly superoxide, are also abnormally increased in 
preeclampsia66. Neutrophils are a major source of superoxide67. Neutrophils isolated from preeclamptic 
women showed enhanced superoxide production in response to stimulus as compared to neutrophils from 
normal pregnant women68. Superoxide interacts with nitric oxide to form peroxynitrite69. Peroxynitrite 
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formation is increased in the placenta and in the maternal vasculature in preeclampsia70,71. Peroxynitrite is 
a potent oxidant72  that can damage endothelial cells directly and impair their function73. Because nitric 
oxide is a potent vasodilator and platelet aggregation inhibitor that is continuously released by 
endothelium74, peroxynitrite formation can result in impaired endothelium-mediated relaxation75 observed 
in preeclampsia through the consumption of nitric oxide. Also, decomposition of peroxynitrite 
generates hydroxyl radical which is a potent free radical that can directly impair cell function and mediate 
vascular dysfunction76.  
Lipid peroxides and reactive oxygen species can cause a variety of effects that are relevant to the 
pathophysiology of preeclampsia such as endothelial dysfunction, induction of platelet aggregation and 
neutrophil activation64. Lipid peroxides increase the production of thromboxane through a 
cyclooxygenase dependent mechanism77, and decrease the production of prostacyclin through the 
inhibition of prostacyclin synthase78. Preeclampsia is associated with an imbalance of increased 
thromboxane and decreased prostacyclin79. Therefore, lipid peroxides contribute to this imbalance, which 
can explain major manifestations in preeclampsia such as hypertension, coagulopathy and reduced 
uteroplacental blood flow. Preeclampsia is also associated with maternal systemic inflammation80-82. 
Increased lipid peroxides and reactive oxygen species in preeclampsia can contribute to maternal 
inflammation through the activation of NF-ĸB and induction of COX-283 which are hall marks of 
inflammation. Recently, activation of NF-ĸB and induction of COX-2 was demonstrated in system blood 
vessels of preeclamptic women62. 
 
5. Thromboxane / prostacyclin imbalance 
 
Thromboxane A2 is an unstable metabolite of arachidonic acid that is implicated in a wide range 
of physiological and pathological processes. Thromboxane A2 half-life is approximately 30 seconds84. 
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Therefore, thromboxane A2 levels are measured indirectly by measuring the levels of its more stable 
metabolite thromboxane B2. In addition to production by platelets, thromboxane can be produced by a 
variety of cells and tissues such as placenta, vascular smooth muscle cells, endothelial cells and 
neutrophils84-87. Arachidonic acid, which is released from membrane phospholipids by the action of 
phospholipase A2, is metabolized by cyclooxygenase into prostaglandin H2, which is further metabolized 
by thromboxane synthase into thromboxane A2. Thromboxane A2 acts through its receptor, thromboxane 
A2 receptor or TP receptor, a G-protein coupled receptor that has a wide distribution thought the body. 
Thromboxane A2 is a potent vasoconstrictor, potent stimulator of platelet activation84 and an important 
inflammatory mediator88.  
Preeclampsia is also characterized by neutrophil activation36, oxidative stress89, increased lipid 
peroxidation27, and increased plasma levels of linoleic acid90, the fatty acid precursor of arachidonic acid. 
An oxidizing solution enriched with linoleic acid (OxLA), which is similar to the conditions of oxidative 
stress and elevated plasma linoleic acid levels in preeclampsia, significantly increased thromboxane and 
TNFα production by neutrophils86. TNFα production was thromboxane dependent because pinane 
thromboxane, which is an inhibitor of thromboxane synthase and an antagonist of thromboxane receptor, 
abolished OxLA stimulated TNFα production by neutrophils. Moreover, OxLA stimulated IL-8 
production by cultured human vascular smooth muscle cells, which was attenuated by the inhibition of 
the cyclooxygenase pathway suggesting a role of thromboxane in IL-8 response85. IL-8, a potent activator 
and chemoattractant of neutrophils, is over expressed by vascular smooth muscle cells and endothelium in 
systemic vasculature of preeclamptic women61. Thromboxane is also involved in neutrophil generation of 
superoxide because pinane thromboxane significantly lowered superoxide production by neutrophils 
isolated from pregnant women or activated by arachidonic acid91. Inhibition of thromboxane receptor 
suppressed the expression of ICAM-I in human vascular endothelial cells that were stimulated by TNFα92. 
Preeclampsia is also associated with an increase in the expression of thromboxane synthase in 
trophoblasts and decidua of preeclamptic placentas93. 
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Prostacyclin is another unstable metabolite of arachidonic acid that is primarily produced by 
endothelial cells of maternal, placental, uterine and umbilical vessels27. However, it can also be produced 
by the avascular amnion and chorion. Both thromboxane and prostacyclin are synthesized from the same 
precursor, which is prostaglandin H2, by two different enzymes which are thromboxane synthase and 
prostacyclin synthase, respectively94. Production of prostacyclin can be determined by measuring its 
stable metabolite, 6-keto PGF1α. Prostacyclin is a potent vasodilator and potent inhibitor of platelet 
aggregation27, and thus oppose the actions of thromboxane.  
In normal pregnancy, maternal plasma levels of prostacyclin progressively increase with 
advancing gestation, whereas those of thromboxane progressively decrease. Therefore, the ratio of 
prostacyclin to thromboxane progressively increases during normal pregnancy indicating that the 
vasodilating and platelet inhibition actions of prostacyclin are progressively favored with advancing 
gestation in normal pregnancy65. Preeclampsia is characterized by an imbalance of increased thromboxane 
and decreased prostacyclin that was first described by Walsh et al in the placenta95 and later confirmed for 
the maternal compartment in blood and urine96,97. This imbalance predates and can explain some of the 
main clinical manifestations of preeclampsia, such as hypertension and thrombosis. The same imbalance 
has been reported in other pathological conditions that involve the cardiovascular system such as 
atherosis98, myocardial infarction99 and diabetes100.  
 
E. Inflammation and preeclampsia 
 
Normal pregnancy is associated with mild systemic inflammatory changes which increase as 
pregnancy progresses82. These changes include increased plasma levels of fibrinogen101, plasminogen 
activator inhibitor type 1102 ceruloplasmin103, interleukin-6104, and tumor necrosis factor-α105,106. They also 
include leukocytosis35, leukocyte activation38, increased circulating markers of oxidative stress such as 
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lipid peroxides and malondialdehyde107, and hypertriglyceridemia108. All these inflammatory changes are 
exacerbated in preeclampsia109. Elevation in inflammatory markers predates and may contribute to the 
presentation of the clinical signs and symptoms of preeclampsia. Therefore, a possible explanation for 
preeclampsia could be the inability of the body to compensate for an exaggerated pregnancy induced 
systemic inflammatory response. 
Recently, inflammation of the systemic vasculature was demonstrated in women with 
preeclampsia indicated by significant activation of NF-ĸB and significant increase in the expression of 
inflammatory markers including ICAM-1, IL-8, and COX-2 in endothelium and vascular smooth 
muscle61,62. These inflammatory changes were associated with significant neutrophil infiltration. 
Infiltrating neutrophils can provide plausible explanation for endothelial and vascular smooth muscle 
dysfunction associated with preeclampsia through their ability to release toxic substances such as ROS, 
TNFα, thromboxane and Matrix metalloproteinase-8.  
 
F. Epigenetics and DNA methylation 
 
Epigenetics is the study of heritable changes in gene expression patterns, which are mediated 
through mechanisms other than changes in the nucleotide sequence of the DNA110. Epigenetic regulation 
contributes to phenotype by mediating genomic adaptation to environmental changes and insults. 
Epigenetic mechanisms include histone modification, small interfering RNAs, DNA methylation and 
other mechanisms.  
DNA methylation is essential for mammalian embryogenesis, genome stability, maintaining of 
imprinting and X chromosome inactivation110. DNA methylation occurs at the 5’ position of a cytosine in 
a CpG dinucleotide context. Methylated cytosine accounts for approximately 1% of all DNA bases111. 
About 75% of CpG dinucleotides in mammalian genomes are methylated and about 88% of active 
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promoters are associated with CpG rich sequences. To date, four DNA methyltransferases (DNMT) have 
been reported which are DNMT1, DNMT2, DNMT3A and DNMT3B112. Except for DNMT2, which acts 
probably as an RNA methyltransferase, all other DNA methyltransferases are required for embryonic 
vitality. Unlike DNMT3A and DNMT3B which are responsible for de novo DNA methylation, DNMT1 
prefers hemimethylated DNA and functions as a maintenance methyltransferase. In general, DNA 
methylation is associated with decreased gene transcription and DNA hypomethylation is associated with 
increased gene transcription113. DNA-methyl-binding-domain proteins, or methyl-CpG-binding proteins, 
and DNMTs themselves can recognize methylated DNA and bind to it. This prevents binding of 
transcriptional activators through steric hindrance. These proteins can also recruit transcriptional co-
repressors, such as histone deacetylases and polycomb proteins, resulting in heterochromatin formation 
and gene silencing. Both active and passive DNA demethylation undoubtedly occurs, such as during 
embryonic development, however, the exact mechanisms of global and/or gene specific DNA 
demethylation are not well understood114.  
DNA methylation is a reversible process and DNA methylation patterns are affected by age, diet, 
oxidative stress and environmental stimuli110. In monozygotic twins, who are genetically identical, 
differences in DNA methylation increase with age and different environmental influences cause different 
patterns of DNA methylation115.  Aging is associated with global DNA hypomethylation accompanied 
with hypermethylation of specific genes116. DNA methylation is dependent on dietary intake of folic 
acid117. Folic acid is a methyl donor required for the synthesis of S-adenosylmethionine which is the 
substrate for DNMTs. DNA methylation levels correlate with the availability of folic acid and the activity 
of enzymes involved in folic acid metabolism such as 5,10-methylenetetrahydrofolate reductase. High 
folic acid intake in mice results in DNA hypermethylation of an allele at the agouti locus, which 
determines whether a mouse coat is banded (agouti) or solid in color (non-agouti)118. Chemical and 
environmental toxins such heavy metals and aromatic compounds can also influence patterns of DNA 
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methylation119,120. Vinclozolin, which is an antiandrogenic compound, affects DNA methylation patterns 
in sperm and its effect can last at least for four generations121.  
Changes in DNA methylation patterns have been linked to a variety of complex diseases 
including cancers122, inflammatory bowel disease123, neural tube defects124, schizophrenia, bipolar 
disorder125, autoimmune diseases such as systemic lupus erythematosus126 and rheumatoid arthritis127, 
type II diabetes, metabolic syndrome128 and cardiovascular diseases such as atherosclerosis129 and 
ischemic heart disease and stroke130.  
DNA methyltransferases use S-adenosylmethionine as a donor of methyl group in their 
reactions131. When the methyl group is transferred, S-adenosylmethionine is converted to S-
adenosylhomocysteine which is hydrolyzed, under physiological conditions, to homocysteine and 
adenosine. The equilibrium of this reversible reaction strongly favors S-adenosylhomocysteine synthesis 
rather than hydrolysis and an increase in intracellular homocysteine levels can eventually increase S-
adenosylhomocysteine levels132. S-adenosylhomocysteine has a higher affinity to DNA 
methyltransferases than S-adenosylmethionine, which makes it a potent inhibitor of DNA methylation 
reactions133. One study demonstrated that increased plasma levels of total homocysteine and S-
adenosylhomocysteine correlated with decreased global DNA methylation in white blood cells of patients 
with advance atherosclerosis134. Interestingly, a group of studies reported that plasma levels of 
homocysteine and S-adenosylhomocysteine are significantly elevated in preeclamptic women as 
compared to normal pregnant women135-137.  
Methylenetetrahydrofolate reductase is the enzyme that catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for re-methylation of 
homocysteine to methionine. Pertinent to this is a study that showed methylenetetrahydrofolate reductase 
knockout mice had either significantly decreased S-adenosylmethionine levels or significantly 
increased S-adenosylhomocysteine levels, or both, associated with global DNA hypomethylation138. 
 
 
17 
 
These knockout mice also showed abnormal aortic lipid deposition similar to those observed in early 
atherosclerosis.  
In another study, apolipoprotein E knockout mice, which are prone to atherosclerosis, showed 
both DNA hypermethylation and hypomethylation with slightly more but significant DNA 
hypomethylation in their aortae and peripheral blood cells at age of 4 weeks and 6 month139. These DNA 
methylation events were associated with the initial stages of atherogenesis. The same study also showed 
that relatively short stimulation of the human macrophage cell line, THP-1, with mixtures of lipoproteins 
of high VLDL and LDL ratio to HDL, similar to lipoprotein ratios in apolipoprotein E knockout mice, 
caused significant DNA hypermethylation compared to untreated cells, or cells treated with mixtures of 
lipoproteins of low VLDL and LDL ratio to HDL, similar to lipoprotein ratios in wild-type mice.  
Another study demonstrated that a low protein diet in rats was associated with global 
hypomethylation140. Deficiency of amino acids required to generate methyl donors, such as glycine, may 
underline this phenomena. Supplementation of a low protein diet with glycine or folate reversed the effect 
on DNA methylation. The same study showed that offspring of female rats which were placed on a low 
protein diet during conception developed upregulation of angiotensin II receptor b1 (ATb1) in their 
adrenal glands and they became more responsive to angiotensin II and later developed hypertension. The 
proximal promoter of the AT1b gene in the adrenal glands of these rats was significantly less methylated, 
and in vitro experiment demonstrated that AT1b gene expression was highly correlated with its promoter 
methylation.  
DNA methylation patterns can also be influenced by reactive oxygen species141. Hydroxyl radical 
can result in base modification, deletions, strand breakage and other DNA lesions, which can interfere 
with methylation of DNA by DNMTs. The presence of 8-hydroxy-2'-deoxyguanosine and O6-methyl 
guanine in a CpG dinucleotide inhibits methylation of the adjacent cytosine. 8-Hydroxy-2'-
deoxyguanosine and O6-methyl guanine also decrease the binding affinity of DNA-methyl-binding-
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domain proteins to methylated CpG dinucleotides attenuating the DNA methylation dependent silencing 
of gene transcription. Furthermore, 8-hydroxy-2'-deoxyguanosine or O6-methyl guanine may not be 
recognized by the DNA proof reading enzymes and can be mispaired with thymine contributing to 
hypomethylation of DNA. On the other hand, single stranded DNA formation due to DNA strand 
breakage by ROS can stimulate de novo DNA methylation. A number of studies have shown a clear 
association between decreased expression of critical antioxidant enzymes and hypermethylation mediated 
gene silencing in tumorigenesis122. 
 
G. Epigenetics and preeclampsia  
 
Little is known about the role of epigenetics in preeclampsia. It has been suggested that early 
epigenetic alterations in gametes and/or the embryo can result in placental defects and predispose to 
preeclampsia in assisted reproductive technology pregnancies, which are associated with increased risk of 
preeclampsia142. Deletion of imprinted gene p57-Kip2 in mice is associated with hypertension and 
proteinuria, which are the main manifestations in preeclamptic women, during pregnancy143. Epigenetic 
alterations in imprinted and non-imprinted genes were demonstrated in preeclamptic placentas. Imprinted 
gene H19 is a member of a group of growth regulators where the paternal allele is imprinted while the 
maternal allele is expressed. A study showed significantly higher percentage of preeclamptic women with 
loss of imprinting, and therefore biallelic expression of the H19 gene in placental tissues during the third 
trimester of pregnancy as compared to normal pregnant women who showed monoallelic expression in all 
of the cases144. The same study also showed that loss of imprinting of the H19 gene was associated with 
more severe clinical symptoms in preeclamptic women. The investigators suggested that the loss of 
imprinting of the H19 gene may attribute to reduce invasive capacity of trophoblasts resulting in poor 
placentation.  
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Epigenetic alterations of non-imprinting genes were also reported in preeclamptic placentas. The 
expression of serine protease inhibitor A3 (SERPINA3) was increased and its promoter methylation was 
decreased in preeclamptic placentas as compared to normal pregnant women145. The increased expression 
of SERPINA3 protease inhibitors could possibly disrupt extracellular matrix solubilization by inhibiting 
elastase activity. This could reduce trophoblastic invasion leading to poor placentation. Furthermore, the 
expression of matrix metalloproteinase-9 was increased and its promoter methylation was decreased in 
preeclamptic placentas as compared to normal pregnant women146. Increased expression was well 
correlated with promoter hypomethylation.  
A study that investigated global DNA methylation profiles of placentas revealed promoter 
hypomethylation of multiple genes in early-onset preeclampsia, which is a severe form of preeclampsia, 
as compared to placentas from normal pregnancy147. Another study demonstrated that X chromosome 
inactivation, which is essentially maintained by DNA methylation, was extremely disturbed in peripheral 
blood cells collected from preeclamptic women as compared to normal pregnant women148.  
 
H. Thromboxane synthase 
 
Thromboxane synthase is an inducible microsomal enzyme that catalyzes two distinct but 
simultaneous reaction of the same substrate, which are isomerization of PGH2 into thromboxane A2 and 
cleavage of PGH2 into 12-L-hydroxy-5, 8, 10- heptadecatrienoic acid and malondialdehyde149. These 
reactions are extremely rapid. Therefore, the primary regulation of thromboxane A2 production is largely 
dependent on the availability of thromboxane synthase and PGH2. Both transcriptional and post-
transcriptional levels of regulation for thromboxane synthase have been reported150,151. Epigenetic factors 
may influence the expression of thromboxane synthase as suggested by the distinctive methylation 
patterns of thromboxane synthase promoter that were found in several human cell lines expressing the 
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enzyme152. Moreover, aging is associated with increased expression of thromboxane synthase in 
endothelial cells which also suggest an epigenetic mechanism in the regulation of expression of this 
enzyme153.  
 
I. Matrix metalloproteinases 
  
 Matrix metalloproteinases (MMPs) are a family of more than twenty Zn-dependent 
endopeptidases that are involved in several physiological and pathological processes including wound 
healing154, development155, inflammation156, atherosclerosis157, cancer biology158, leukocyte activation154 
and regulation of vessel tone159,160. MMPs can be produced by a variety of cells including neutrophils, 
vascular smooth muscle cells and endothelial cells161. Almost all components of the extracellular matrix 
can be cleaved and degraded by MMPs, however, MMPs process and regulate the biological activity of a 
large number of non-extracellular matrix proteins including growth factors such as connective tissue 
growth factor and transforming growth factor β, cytokines such as pro-TNFα and IL-1β, chemokines such 
as monocyte chemotactic protein 3, cell membrane receptors such as protease activated receptor-1 and IL-
2 receptor α, vasoactive ligands such as big endothelin, serine proteinase inhibitors, lipoproteins and other 
MMPs162,163. MMPs are regulated at three major levels which are gene expression, activation of newly 
synthesized MMPs (pro-MMPs), and inhibition of activated MMPs by tissue inhibitors of matrix 
metalloproteinases (TIMPs)161. Several genes encoding for MMPs can be induced by a number of factors 
including cytokines and growth factors. On the other hand, these genes can be inhibited by other factors 
such as glucocorticoids and retinoids.  Activation of MMPs involves the removal of the propeptide 
domain. This domain contains a cysteine residue that coordinates with the Zn++ ion in the catalytic 
domain and therefore inactivates it. Removal of the propeptide domain can be catalyzed by other 
proteases such as trypsin, plasmin and other MMPs especially membrane associated MMPs. Oxidants 
such peroxynitrite can also activate pro-MMPs by disrupting the cysteine- Zn interaction162. TIMPs act by 
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binding MMPs to form non covalent complexes and, thereby, mask the substrate cleavage binding sites of 
MMPs.  
 
J. Matrix metalloproteinase-1 
 
Matrix metalloproteinase-1 (MMP-1) is an interstitial collagenase that is implicated in a number 
of physiological and pathological processes. Recently, Estrada et al reported that MMP-1 gene and 
protein expression are increased in omental fat blood vessels of preeclamptic women as compared to 
normal pregnant women159. The same study also showed that MMP-1 plasma levels were also increased 
in preeclamptic women. Increased expression of MMP-1 in systemic blood vessels was detected in 
vascular smooth muscle cells, endothelial cells and infiltrating leukocytes as indicated by 
immunohistochemistry staining. In contrast, vascular expression of TIMP-1 and collagen 1 α 1(COL1A1), 
which encodes the principle component of collagen type I, were unaffected or decreased in preeclamptic 
women suggesting an imbalance of increased collagen degradation and decreased collagen synthesis in 
preeclampsia. By affecting the integrity of the blood vessel wall, these findings might explain proteinuria 
and edema that occur in preeclampsia.  
Oxidative stress, neutrophil infiltration of systemic blood vessels and vascular inflammation 
which are associated with preeclampsia are likely responsible for the imbalance in collagen synthesis and 
degradation159. Treatment of primary cultures of human vascular smooth muscle cells with an oxidizing 
solution composed of hypoxanthine and xanthine oxidase, activated neutrophils or TNFα significantly 
increased MMP-1 expression and secretion but decreased or did not change the expression of TIMP-1 and 
COL1A1, which is similar to what was found in preeclamptic vessels.  
MMP-1 expression in systemic blood vessels of preeclamptic women might explain neutrophil 
infiltration and vasoconstriction159. For example, supernatants taken from vascular smooth muscle 
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primary cultures treated with MMP-1 stimulated neutrophil migration in modified Boyden chambers. This 
was associated with increased vascular smooth muscle cell secretion of IL-8 and collagen Type I C 
terminal telopeptide fragment, which are known neutrophil chemoattractants. Furthermore, MMP-1 
induced contraction of omental arteries in a dose dependent manner demonstrating a previously 
unrecognized mechanism by which MMPs can modify vessel tone. Vasoconstriction was mediated by 
activation of PAR-1, which was found in the same study to be overexpressed in these arteries, as 
indicated by the loss of contraction in response to MMP-1 in the presence of PAR-1 inhibitor.  
MMP-1 may be regulated by DNA methylation. A study showed that MMP-1 expression in 
amnion fibroblasts is regulated by DNA methylation as indicated by a significant increase in MMP-1 
gene and protein expression caused by inhibition of DNA methylation in primary cultures of amnion 
fibroblasts with 5-Aza-2-deoxycytidine (5-Aza)164. The increased MMP-1 expression was correlated with 
a decrease in methylation at a particular site (-1538) in the MMP-1 promoter. DNA methylation at the 
same site in amnion was significantly decreased in a larger percentage of preterm prematurely ruptured 
fetal membranes where MMP-1 expression was increased.  
 
K. Specific Aims 
1. Specific Aim 1 
 
To determine if preeclampsia is associated with hypomethylation of CpG dinucleotides in the 
promoter regions of inflammatory genes associated with vascular dysfunction using global DNA 
methylation analysis. 
Hypothesis: Preeclampsia is associated with hypomethylation of CpG sites in promoter regions 
of inflammatory genes associated with vascular dysfunction. 
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Omental arteries will be dissected of omental fat samples obtained from normal pregnant and 
preeclamptic women during cesarean section. DNA will be extracted from omental arteries. DNA will be 
bisulfite treated and then DNA methylation profiles will be investigated using the high throughput 
Infinium HumanMethylation27 BeadChip assay. 
 
2. Specific Aim 2 
 
To target genes of interest identified in Aim 1 to have hypomethylated CpG sites in their 
promoter regions for further study to determine if their gene and protein expression correlates with the 
methylation status of their promoters.  
Hypothesis: Inflammatory genes identified in Specific Aim 1 to be hypomethylated are 
overexpressed in systemic vasculature of preeclamptic women as compared to normal pregnant women.  
Omental arteries will be dissected of omental fat samples obtained from normal pregnant and 
preeclamptic women during C-section. Both RNA and protein will be extracted from omental arteries. 
Quantitative real-time polymerase chain reaction will be used to examine the gene expression of genes of 
interest and Western blot or ELISA will be used to examine the protein expression of these genes.  
 
3. Specific Aim 3 
 
To determine if gene and protein expression of genes of interest are regulated by DNA 
methylation in human cell culture models.  
Hypothesis: Decreased DNA methylation causes increased gene and protein expression of genes 
of interest in cell culture models.  
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Cell cultures will be treated with 5-Aza which inhibits DNA methylation. After that, cells will be 
collected and both RNA and protein will be extracted from omental arteries. Quantitative real time 
polymerase chain reaction will be used to examine the gene expression and Western blot will be used to 
examine protein expression. 
In summary, this dissertation will examine if preeclampsia is associated with differences in DNA 
methylation profiles of arteries of preeclamptic women as compared with normal pregnant women. It will 
also examine the gene and protein expression of genes that are hypomethylated in preeclamptic women to 
determine if the decrease in DNA methylation is associated with increased gene and protein expression. 
Finally, cell cultures will be used to examine the role of DNA methylation in gene expression.   
 
L. Significance of this research 
 
This study is the first to examine DNA methylation in systemic blood vessels of normal pregnant 
and preeclamptic women. If differences in DNA methylation were identified in preeclamptic women, 
these differences might help explain why some pregnant women develop preeclampsia and others do not. 
For example, decreased DNA methylation in the promoter regions of inflammatory genes might make 
these women more responsive to the pregnancy induced inflammatory response increasing their risk of 
preeclampsia. Alterations in DNA methylation might be preexisting, however, neutrophil infiltration of 
systemic blood vessels of preeclamptic women could also cause alterations in DNA methylation which 
may help explain the increased risk of cardiovascular diseases later in life in women who have had 
preeclampsia.  
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CHAPTER 2: MATERIALS AND METHODS 
 
A. Study subjects 
 
Omental fat biopsies (approximately 2 cm X 2cm X 2cm) were collected during cesarean section 
(C-section) from previously consented normal pregnant and preeclamptic women at the Medical College 
of Virginia (MCV) Hospitals, Virginia Commonwealth University (VCU) Medical Center, Richmond, 
Virginia. Biopsies were submerged in normal saline in a sterile jar and kept in a refrigerator (4˚C) until 
transferred to the laboratory as soon as possible for processing. Omental fat was selected for this study 
because it is highly vascular, accessible during a C-section and omental vessels contribute to total 
peripheral vascular resistance.  
Women recruited for the study were 28 to 38 weeks of gestation. Women were classified by the 
clinicians based on their clinical signs and symptoms into normal pregnant, mild preeclamptic or severe 
preeclamptic women. Mild preeclampsia is diagnosed when the blood pressure is ≥ 140 mmHg systolic or 
≥ 90 mmHg diastolic and 0.3 g of protein is collected in the urine within 24 hours, whereas severe 
preeclampsia is diagnosed when blood pressure is ≥ 160 mmHg systolic or ≥ 110 mmHg diastolic and 5 g 
of protein is collected in the urine within 24 hours1. Clinical characteristics of the patients are given in 
tables for each chapter. Women who were excluded from the study included those with chorioamnionitis, 
maternal infections, active sexually transmitted diseases (e.g. HIV), lupus or diabetes. Also, women who 
were obese (body mass index ≥ 30), smoked or were in labor were excluded from the study. These 
exclusion criteria were chosen because they are known to cause inflammation. 
 
B. Vessel dissection 
  
 
 
26 
 
Dissection of omental arteries was done under a dissection microscope (Olympus, B061) on a silicone 
dissection dish pre-cooled to 4˚C (NESLAB - RTE-7 Refrigerated Bath/Circulator, Thermo Scientific, 
Asheville, NC). The fat biopsy was spread and pinned down on the silicone dissection dish in cold (4˚C) 
phosphate buffered saline (PBS, pH=7.4, Gibco, Invitrogen, Carlsbad, CA), and the dissection 
microscope was used to visualize the blood vessels.  
Omental arteries were distinguished from omental veins based on their morphology and 
branching points. In general, arteries are narrower with thicker walls than veins. Also, the branching 
points of an artery tend to be more acute, whereas those of a vein tend to be more rounded.  An artery and 
a vein often ran together making it easier to discern differences. Comparison was done after the fat was 
cleared to allow for proper inspection of the vessels. Maintaining the integrity of the vessels to keep the 
blood inside their lumens facilitated the localization of the vessels within the fat during dissection and the 
discrimination between an artery and a vein.    
Vessels were fixed and gently stretched on the silicon dissection dish using two pins at either end. 
Initially, the fat around a vessel was cut as close as possible to the vessel wall keeping the cutting plane of 
the scissor (0.255 mm, Science Tools, Foster City, CA) parallel to the long axes of the vessel and the 
curved tip of the scissor pointing away from the vessel wall but carefully leaving about 1 mm of fat 
around the vessel to avoid damaging its wall. A fine tip scissor (0.075 mm, Fine Science Tools, Foster 
City, CA) was used for the fine dissection and final cleaning of the vessel. A Dumont #55 forceps 
(Science Tools, Foster City, CA) was used to hold the fat and gently pull it away from the vessel. This 
usually resulted in formation of a transparent zone between the vessel wall and the fat, most likely loose 
connective tissues that surround the tunica adventitia of the vessel. The fine tip scissor was used to cut 
through this zone while keeping the cutting plane parallel to the length of the vessel and the curved tip 
away from the wall. Adherent fat was cleaned from all sides of the vessel. Finally, the vessel was held 
from one end with a forceps and another forceps was used to squeeze the blood out of the vessel from the 
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other end. Collected arteries (10-50 mg) were kept in a 2 ml Eppendorf tube placed on ice until the end of 
the procedure and then frozen at -80˚C.   
 
C. Vascular smooth muscle cell isolation and cell culture 
  
 Vascular smooth muscle cells (VSMC) were isolated from human placental chorionic plate 
arteries as described by Leik et al165. Briefly, placentas of consented normal pregnant women who 
delivered by C-section were collected and transferred to the lab as quick as possible. Chorionic plate 
arteries were identified based on the observation that these arteries cross over their counterpart veins. 
Arteries were dissected from the placental tissue, rinsed of blood with Hank’s balanced salt solution 
containing 2% antibiotics and antimycotics (200 U/ml penicillin, 200 µg/ml streptomycin, 50 µg/ml 
amphotericin B, Gibco, Carlsbad, CA) for 3 times and cut from one side along its long axis to open the 
arterial lumen. Small pieces of the arterial sheet were cut and placed on their endothelial surface on 10 cm 
culture plates and left for few minutes to adhere to the plate surface. After that, 5 ml of Medium-199 (M-
199, Gibco, Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS, Gibco, Invitrogen, 
Carlsbad, CA), and 1% antibiotics and antimycotics (100 U/ml penicillin, 100 µg/ml streptomycin, 
25µg/ml amphotericin B, Gibco, Invitrogen, Carlsbad, CA) was carefully added to the plates without 
disturbing the adherent explants. Explants were incubated at 37˚C with 5% CO2 in a cell culture incubator 
(Thermo Fisher, Waltham, MA) and medium was replaced every 2 days. At the end of the first week, 
cells started to grow from the explants and after about 4 weeks cells were confluent. At this stage, cells 
were treated with M-199 without FBS for one day to eliminate the presence of contaminating endothelial 
cells and fibroblasts because, unlike smooth muscle cells, these cells cannot survive without a serum-
enriched medium. Cultured VSMCs were then either passaged or frozen in liquid nitrogen for future use. 
Cells were used between passage 3 and 6. 
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D. HL-60 cells 
 
HL-60 cells (ATCC, Manassas, VA), a neutrophil-like cell line, were cultured in  
Iscove's Modified Dulbecco's Medium (IMDM, ATCC, Manassas, VA) supplemented with 10% fetal 
bovine serum (Gibco, Invitrogen, Carlsbad, CA) and 1% antibiotics and antimycotics (100 U/ml 
penicillin, 100 µg/ml streptomycin, 25µg/ml amphotericin B, Gibco, Invitrogen, Carlsbad, CA) as 
recommended by ATCC. Approximately 500,000 cells per ml were seeded in 5 ml of media in a T-25 
flask for treatments. 
 
E. Treatments of cell cultures 
1. Control  
 
Control flasks consisted of medium appropriate for the type of cells being cultured. 
 
2. Neutrophils  
a. Neutrophil isolation 
 
Histopaque density gradient centrifugation was used for neutrophil isolation from whole blood 
obtained from normal nonpregnant or normal pregnant women. Five ml of Histopaque 1119 (Sigma-
Aldrich, Saint-Louis, MO) were added to a 50 ml conical tube. Then, 5 ml with of Histopaque 1077 
(Sigma-Aldrich, Saint-Louis, MO) were carefully layered on the top of the Histopaque 1119.  After that 
10 ml of fresh blood were carefully layered over the top of the Histopaque 1017. The tube was 
centrifuged at 700 x g for 30 minutes at room temperature. This resulted in the formation of 6 distinct 
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layers which are from the top to the bottom: plasma; mononuclear cell layer, which includes lymphocytes, 
monocytes and platelets; Histopaque 1077; granulocyte layer, which includes neutrophils; Histopaque 
1119; and red blood cells (RBC). In addition to neutrophils, the granulocyte layer also includes basophils 
and eosinophils, however, these cells comprise only approximately 4% of the cells. The plasma, 
mononuclear cell layer, and Histopaque 1077 to within 0.5 cm of the granulocyte layer were carefully 
aspirated and discarded. The granulocyte layer cells were carefully transferred to a new 50 ml tube. To 
wash the cells, 10 ml of PBS were added to the cells and the tube was centrifuged at 200 x g for 10 
minutes at 4˚C. The PBS was carefully aspirated and the cell pellet re-suspended in another 10 ml of PBS. 
The tube was centrifuged at 200 x g for 10 minutes at 4˚C to pellet the cells. To lyse the RBCs, which 
cause the pellet to be red in color, 3 ml of ice-cold sterile filtered double deionized water (ddH2O) were 
added and the pellet was gently re-suspended. After exactly 30 seconds, 1 ml of 0.6 M potassium chloride 
(KCl) was added to restore tonicity, and then the tube was centrifuged at 200 x g at 4˚C for 4 minutes. 
The lysing step was repeated one more time if necessary. The supernatant was discarded and the pellet re-
suspended in 1 ml of M-199. 
 
b. Neutrophil counting 
 
To count the neutrophils, 50 µl of cell suspension was added to 350 µl of trypan blue dye (Sigma-
Aldrich, Saint-Louis, MO) and pipetted up and down several times to mix well. This resulted in a dilution 
factor of 8. Roughly 10 µl of the mixture was loaded onto a hemocytometer and neutrophils were counted 
in all four quadrants of the hemocytometer. The number of neutrophils in the four chambers was divided 
by four to get the average number of neutrophils per square. The volume of each square with the cover 
slip in place is 0.1 mm3. So, to calculate the number of neutrophils in 1 ml, the average number of 
neutrophils per square was multiplied by 104 then by the dilution factor of 8.  
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Number of neutrophils per ml = average count per square x dilution factor x 104 x number of ml. 
 
c. Neutrophil activation 
 
Neutrophils were activated with 100 µM of arachidonic acid. Solution A was made by adding 10 
µl of a 50 mg in 100 µl ethanol stock solution of arachidonic acid (Cayman Chemical, Ann Arbor, MI) to 
1.08 ml of PBS. After that, 16.6 µl of solution A was added to 1 ml M-199 containing neutrophils isolated 
by Histopaque and the cell suspension was incubated in a rotator for 30 minutes at 37˚C. 
 
d. Treatment with neutrophils 
 
Neutrophils were counted on a hemocytometer and a volume containing 62,500 activated 
neutrophils were added to VSMCs in a T-25 flask containing 5 ml of M-199 with 10% FBS and 1% 
antibiotics/antimycotics. 
 
3. ROS  
 
Reactive oxygen species (ROS) were generated by using 0.05 mM hypoxanthine (Sigma, Saint-
Louis, MO) and 0.003 U/ml xanthine oxidase (Calbiochem, Darmstadt, Germany) in M-199 with 10% 
FBS. A 1 mM stock solution of hypoxanthine was prepared by adding 0.003 gm of hypoxanthine (MW 
136.1) into 20 ml of ddH2O. To dissolve the hypoxanthine, the solution was sonicated for 45 minutes in a 
water bath sonicator. To make a 20 ml stock of the ROS generating solution with a final concentration of 
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0.05 mM of hypoxanthine, 1 ml of the 1 mM hypoxanthine stock solution was added to 19 ml of M-199 
with 10% FBS and 1% antibiotics/anti-mycotics. Xanthine oxidase was provided as a 20 U/ml buttermilk 
stock solution. For a final concentration of 0.003 U/ml xanthine oxidase in the 20 ml hypoxanthine stock 
solution, 3 µl of the 20 U/ml xanthine oxidase stock was added. The ROS generating solution was added 
to VSMCs in T-25 flasks.  
 
4. Tumor necrosis factor α (TNFα)  
 
Ten µg of recombinant human TNFα (R&D Systems, Minneapolis, MN) was reconstituted in 1 
ml of sterile PBS containing 1% bovine serum albumin, aliquoted into 0.5 µg/50 µl aliquots and stored in 
-80˚C. For a final concentration of 1 ng/ml of TNFα, 0.5 µl of 0.5µg/50µl aliquot was added to VSMCs in 
a T-25 flask containing 5 ml of medium M-199 with 10% FBS and 1% antibiotics/anti-mycotics.  
 
5. 5-Aza-2-deoxycytidine (5-Aza) 
 
A 25 mM stock solution was prepared by adding 0.88 ml of ddH2O to 5 mg of 5-Aza (Sigma-
Aldrich, Saint-Louis, MO). The stock was divided into 20 µl aliquots. For a final concentration of 10 µM 
of 5-Aza, 2 µl of the stock were added to VSMCs or HL-60 cells in a T-25 flask containing 5 ml of 
medium with 10% FBS and 1% antibiotics/anti-mycotics. 
 
6. Phorbol 12-myristate 13-acetate (PMA) 
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A first stock solution of 8 M was made by adding 1ml of dimethyl sulfoxide (DMSO, Sigma-
Aldrich, Saint-Louis, MO) to 5 mg of PMA (Sigma-Aldrich, Saint-Louis, MO). A second stock solution 
of 0.1 mM was made by adding 1 µl of the first stock solution to 799 µl of DMSO. First and second stock 
solutions were divided into 50 µl aliquots, light protected and stored at -20˚C. For a final concentration of 
10-8 M of PMA, 0.5 µl of 0.1 mM stock was added to HL-60 cells in a T-25 flask containing 5 ml of 10% 
FBS medium and 1% antibiotics/anti-mycotics.         
 
7. Linoleic acid 
 
A 0.11 M stock solution of linoleic acid was made by adding 1,520 µl of 100% ethanol to a vial 
containing 50 mg of linoleic acid in 200 µl ethanol (Cayman Chemicals, Ann Arbor, MI). For a final 
concentration of 70 µM, 3.18 µl of the stock solution was added HL-60 cells in a T-25 flask containing 5 
ml of 10% FBS medium and 1% anti-biotics/anti-mycotics.   
 
F. Cell Collection 
 
T-25 flasks were kept on ice during the process of cell collection. For cultured VSMCs, medium 
was aspirated from the attached VSMCs on the floor of a T-25 flask and either saved for future analysis 
or discarded. To wash the cells on the floor of the flask from residual medium, FBS and dead cells, 2 ml 
of ice cold sterile PBS (Gibco, Carlsbad, CA) was added to the T-25 flask and the flask was mixed for a 
few seconds in an orbital motion, and the PBS was aspirated. The washing step was repeated once more. 
After that, cells were scraped in 1 ml of ice cold PBS and transferred to a 2 ml Eppendorf tube. For HL-
60 cells, a T-25 flask was mixed gently and 2 ml of media were transferred to a 2 ml Eppendorf tube. 
When a treatment that caused cell activation and adhesion to the bottom of the flask was performed, cells 
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were scraped before collecting the media. Cells were pelleted down by centrifuging the tube at 3,000 x g 
for 10 minutes at 4˚C. The supernatant was aspirated, and cells were either processed immediately or 
stored at -80˚C for later use. For HL-60 cells, media (supernatant) was either discarded or saved at -20˚C.  
 
G. Immunohistochemistry 
1. Sample preparation and formalin-fixation 
 
Omental fat biopsies were fixed in formalin within one day from the time of collection. Fat was 
cut into smaller pieces (approximately 1cm X 1cm X 0.5 cm) with scissors. One to two of these pieces 
were placed in a tissue cassette (Tissue-Tek Uni-Cassette, Sakura, Torrance, CA). Cassette were then 
closed, labeled and submerged in a jar of 10% neutral buffer formalin (Sigma-Aldrich, Saint-Louis, MO). 
The jar was kept rotating in an Excella E24 incubator shaker (New Brunswick Scientific, Edison, NJ) at 
250 rpm for five days at room temperature in order to fix the tissue. On the fifth day, cassettes were 
opened and tissue was inspected for proper fixation based on appearance and touch. Cassettes were then 
washed from formalin with running ddH2O and placed in 100 mM phosphate buffer (pH=7.5), and then 
cassettes were kept in the refrigerator (4˚C) until time for paraffin embedding.   
 
2. Paraffin embedding and tissue block preparation   
 
For paraffin embedding, an automated tissue processor (Shandon Citadel 2000 tissue processor, 
Shandon Scientific limited, Cheshire, England) was used. The machine first dehydrated the samples by 
passing them through a graded alcohol series of 70%, 85%, 95%, 95%, 100%, and 100%. Tissues were 
then cleared with CitriSolv (Fisher Scientific, Malvern, PA) and finally embedded with paraffin. The 
paraffin embedded tissue was removed from the cassette and placed on a metal tray partially filled with 
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warm paraffin. The metal tray was then filled with paraffin and covered with the porous surface of the 
tissues cassette. More paraffin was added through the porous surface of the cassette and the metal tray and 
cassette unit was placed on ice so that the paraffin would cool down and solidify. Once the paraffin 
solidified, the tissue block was removed from the metal tray.  
 
3. Tissue sectioning and slide preparation 
 
Before the blocks were sectioned, paraffin that surrounded the embedded tissue was beveled with 
sharp blade to limit the amount of paraffin that the blade of the microtome had to cut during the 
sectioning process. Once the block was prepared, it was mounted on a microtome (Shandon AS325 
Microtome), and the tissue was cut into 8 µm thick sections that were continuous with each other to form 
a ribbon. Ribbons were carefully transferred onto the surface of 37˚C ddH2O bath (floating bath model 
135, Fisher Tissue Prep, Fisher Scientific, Malvern, PA). The ribbon was carefully separated into pieces 
of 2 or 3 sections and each section was placed on a Superfrost plus glass slide (Fisher Scientific, Malvern, 
PA). To ensure firm adherence of the tissue sections on the slides, the glass slides were placed on a 37˚C 
slide warmer overnight.   
 
4. Immunohistochemical staining  
a. Tissue preparation 
 
Slides were labeled and placed in a slide holder. Slides were submerged in three separate 
champers of Histoclear (National Diagnostics, Atlanta, GA) for 5 minutes each, to deparaffinize the 
tissues. Tissues were then hydrated in a graded alcohol series of 100%, 100%, 95%, 95%, 85, and 50% 
for 2 minutes each. After that, slides were incubated in 100 mM phosphate buffer (pH=7.5) for 10 
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minutes. To quench the endogenous peroxidase activity of the tissues, slides were incubated in 3% 
hydrogen peroxide in methanol for 30 minutes. After that, the slides were washed in 100 mM phosphate 
buffer (pH=7.5) for 5 minutes and then in ddH2O for 6 minutes. 
 
b. Antigen retrieval 
 
For antigen retrieval, slides were place in a plastic container containing 250 ml of 10 mM citrate 
buffer (pH=6). The plastic container was placed in an 8-quarter programmable pressure cooker (Cook 
Essentials, CPE800) filled with 2-3 L of ddH2O and the slides were pressurized on low setting for 5 min. 
Once finished, the pressure was released and the plastic container was removed from the pressure cooker 
and cooled to room temperature for 15 minutes. 
 
c. Blocking  
 
A hydrophobic glue marker (Pap Pen, Research Products International Corp, Mt. Prospect, IL) 
was used to draw a hydrophobic barrier around each tissue specimen. Ten percent normal goat serum 
blocking solution (Invitrogen, Carlsbad, CA) was applied on each specimen and incubated for 30 minutes 
in a humidity chamber. Slides were then washed 3 times with phosphate buffer saline containing 0.05% 
Tween-20, 2 minutes each.  
 
d. Staining 
 
 
 
36 
 
Rabbit anti-human thromboxane synthase  (1:50, Proteintech group, Chicago, IL) or rabbit anti-
human MMP-8 antibody (1:100, Proteintech group, Chicago, IL) were pre-diluted with 100 mM 
phosphate buffer (pH=7.5). Slides were placed in a humidity chamber and 100 µl of diluted antibody 
were added onto each tissue specimen and incubated for 1 hour. A negative control slide from a 
preeclamptic patient was stained along with the other slides. For the negative control slide, 100 µl of 
rabbit primary antibody isotype control (Invitrogen, Carlsbad, CA) was applied on each tissue specimen. 
Slides were then washed 3 times in 0.05% Tween-20 PBS, 2 minutes each, and placed back into the 
humidity chamber. After that, 2 drops (~100 µl) of horseradish peroxide polymer conjugate (SuperPicture 
kit, Invitrogen/Zymed laboratories, South San Francisco, CA) were applied on each specimen and 
incubated for 10 minutes. Slides were then washed in 0.05% Tween-20 PBS 3 times, 2 minutes each, and 
placed back in the humidity chamber. After that, 2 drops (~100 µl) of diaminobenzidine substrate 
(SuperPicture kit, Invitrogen/Zymed laboratories, South San Francisco, CA) were applied on each 
specimen and incubated for 5 minutes. Lastly, slides were washed in 0.05% Tween-20 PBS 3 times, 2 
minutes each. 
 
e. Counterstaining 
 
For counterstaining, slides were dipped once in 1:5 dilution of hematoxylin (Hematoxylin QS, 
Vector Laboratories, Burlingame, CA) and removed quickly. This was followed immediately with two 
separate rinses in ddH2O. Then the slides were dipped 5 times in 0.05% acetic acid in acetone, 2 seconds 
each. 
 
5. Tissue preservation 
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Slides were dehydrated in graded alcohol series of 50%, 85%, 95%, 95%, 100%, and 100%, 2 
minutes each, and then placed in Histoclear twice, 3 minutes each. After the slides were removed from 
Histoclear, 2 drops of Vectomount (Vector Laboratories, Burlingame, CA) were added onto each slide 
and a coverslip was carefully placed on each slide without trapping air bubbles. Slides were left to dry 
overnight before being analyzed under the microscope.  
 
6. Data analysis for immunohistochemistry 
 
Slides were analyzed under a light microscope (Olympus BH2, Opelco, Washington, DC) 
equipped with a digital camera (Olympus QColor5, Canada). Vessel diameter was measured by image 
analysis software (CellSens Digital Imaging Software, Olympus America, Center Valley, PA) and vessels 
between 10 µm and 200 µm in diameter were analyzed since these vessels represent resistance-sized 
blood vessels. An average of 35 vessels were analyzed per slide. Vessel staining for thromboxane 
synthase or MMP-8 was evaluated using a visual score ranging from 0 to 4 where 0 means no staining 
and 4 means dark and extensive staining. Visual scoring was verified by a second investigator and by 
measuring the optical density of staining (OD) using the image analysis software. Optical density of 
staining in vessels was normalized to the optical density of the background. Slides were also analyzed for 
percentage of vessels stained and percentage of vessels with leukocyte staining for thromboxane synthase 
or MMP-8. The percentage of stained vessels and the percentage of vessels with stained leukocyte were 
calculated by the following equations: 
 
Percentage of stained vessels =   Number of stained vessels x 100% 
                                                               Total # of vessels  
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Percentage of vessels with stained leukocytes = Number of vessels with stained leukocytes x 100% 
                                                                                                Total # of vessels  
 
H. DNA extraction from omental arteries or cells, and DNA concentration measurement 
 
DNA was extracted from omental arteries or cells using QuickGene DNA tissue kit and 
QuickGene-Mini80 system (AutoGen, Holliston, MA) according to the manufacture’s protocol. For 
omental arteries, about 10 mg of arteries were cut into small pieces and lysed by incubating the arteries in 
180 µl of tissue lysing buffer and 20 µl of proteinase K on a rotary shaker at 55˚C for 2 hours (Eppendorf 
Thermomixer Shaker, Eppendorf, Hauppauge, NY). Cells (around 106 cells) were lysed in the same way 
but were incubated for 30 minutes. RNase treatment was done by adding 20 µl of RNase A (100 mg/ml, 
Qiagen, Valencia, CA) to the lysate and incubating the mixture for 2 minutes at room temperature. DNA 
was eluted in 50 µl of the elution buffer to insure a high amount of DNA at low volumes.  
 DNA concentration was measured and DNA quality was assisted by using the NanoDrop 
1000 Spectrophotometer (Thermo Scientific, Asheville, NC). Samples with an A260/280 ratio of 1.8 were 
considered to be pure and used for study.  
 
I. Bisulfite treatment 
 
Genomic DNA was bisulfite treated using MethylEasy™ Xceed kit (Human Genetic Signatures, 
Randwick, Australia) as indicated by the user manual. Bisulfite treatment of genomic DNA causes 
hydrolytic deamination of unmethylated cytosines resulting in their conversion into uracils. Methylated 
cytosines are resistant to the effect of bisulfite and remain as cytosines. The amount of starting genomic 
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DNA used per reaction was 1000 ng. Based on the kit standard protocol, the combined volume of DNA 
solution and nuclease free water was 20 µl. The minimum DNA concentration required for each sample to 
have 1000 ng of DNA in 20 µl is 50 ng/µl. When the DNA concentration was less than 50 ng/µl, the 
sample was concentrated by using Savant DNA 120 Speed Vac Concentrator (Thermo Scientific, 
Asheville, NC). 
  
J. Illumina Infinium Human Methylation27 BeadChip assay  
 
The high throughput Illumina Infinium HumanMethylation27 BeadChip assay (Illumina, San 
Diego, CA) was used for DNA methylation analysis. This assay allows the examination of 27,578 CpG 
dinucleotides located within the proximal promoters of 14,495 genes. The BeadChip was run by the 
Nucleic Acids Research Facility at VCU using the standard protocol provided by Illumina. In brief, 10 µl 
of bisulfite treated DNA (50 ng/ µl) was isothermally amplified at 37˚C for 24 hours. The amplification 
product was enzymatically fragmented and the fragmented DNA was purified, and applied to BeadChip 
for hybridization. During hybridization, DNA anneals to specific single stranded oligonucleotides, which 
are covalently linked to different types of beads. Each CpG site is presented by 2 types of beads, which 
correspond to the nucleotide identity, and thus the methylation status, of the bisulfite treated cytosine at 
that site. Hybridization was followed by single-base extension of the oligonucleotides where the 
hybridized DNA was used as a template to incorporate hapten labeled dideoxynucleotides. After that, the 
chip was fluorescently stained, and then scanned for the intensities of the methylated and the 
unmethylated bead types using the Illumina BeadArray Reader. The raw data was analyzed with the 
Illumina Bead Studio software. DNA methylation values (β values) were assigned to each CpG site by 
subtracting the background intensity of negative controls from both the methylated and unmethylated 
intensities and then taking the ratio of the methylated intensity to the sum of both methylated and 
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unmethylated intensities. Therefore, the β value can be anywhere between 0 and 1 where 0 means no 
methylation and 1 means full methylation. 
 
1. Statistical analysis 
 
Statistical analysis for the Illumina Infinium Human Methylation27 BeadChip assay was done by 
Dr. Kellie Archer (Department of Biostatistics, VCU). For each CpG site a two-sample t-test was 
performed comparing the seven severe pre-eclampsia samples to the five normal samples with respect to 
proportion methylated. Specifically, for CpG sites i=1,…,27,578, the hypotheses tested were: 
H0: , ,i pre eclampsia i normalβ β− =  
HA: , ,i pre eclampsia i normalβ β− ≠  
The p-values from the two-sample t-tests were obtained for all CpG sites. The p-value is the 
probability of obtaining a test statistic as or more extreme as the one observed under the conditions of the 
null hypothesis. In most scientific endeavors, an α = 0.05 threshold is customarily applied so that a p-
value < 0.05 is considered as evidence for the alternative hypothesis, that is, p < 0.05 typically indicates a 
significant finding. However, application of an α = 0.05 threshold to univariable tests of significance in 
high-throughput genomic settings will yield a large number of Type I errors simply by chance. When 
analyzing high-throughput genomic data, the multiple comparison problem is most often addressed 
through estimation of the false discovery rate (FDR). To control for multiple hypothesis testing, the p-
values were subsequently used in estimating FDR using the q-value method166.  More specifically, when 
testing m null hypotheses, we may want to control the number of rejected null hypotheses that are truly 
null (F) among all those null hypotheses that are rejected (S). The q-value is such a method that for a 
particular feature is defined to be the expected proportion of false positives among all features as or more 
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extreme than the one observed166. For a given p-value threshold t where 0 ≤ t ≤ 1, we want to estimate 
FDR(t) = E (F(t)/S (t)) ≈ E(F(t))/E(S (t)).  
 
F(t) represents the number of false discoveries at threshold t while S (t) represents the number of 
null hypotheses considered significant at threshold t. Formally, FDR(t) is estimated as 
FDR t( ) =
!
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S t( )
=
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mt
I p
g
! t( )
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"
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where π0 represents the proportion of hypotheses for which the null is true and ( )gI p t≤  is 1 if the p-
value for the gth CpG site is less than or equal to the threshold t. For application datasets, π0 is typically 
unknown and so is estimated using the distribution of raw p-values using either a smoothing or bootstrap 
method. In this study CpG sites with a FDR < 10% were considered significant. 
 
2. Gene Ontology terms  
 
For CpG sites identified as significant, the CpG sites were mapped to Gene Ontology terms, 
molecular function (MF) and biological process (BP), and a hypergeometric test was performed to 
determine whether any term was over-represented among those CpG sites identified as significant 
compared to the number of CpG sites mapping to that term on the entire array. For MF and BP terms, a p-
value of less than 0.05 was considered significant 
 
3. Canonical pathway and network identification 
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Genes with statistically differentially methylated CpG sites were imported into Ingenuity 
Pathways Analysis software (IPA, v9; Ingenuity Systems, Redwood City, CA) to identify canonical 
pathways and gene-to-gene interaction networks within our dataset. Canonical pathways and gene 
networks were algorithmically constructed based on published literature in the Ingenuity Knowledge 
Base, where each relation was supported by at least one reference. 
 
K. Bisulfite Sequencing 
 
The bisulfite treated DNA was amplified with primers that flank the region of interest (first round 
primers). Another set of primers (second round or nested primers) was used to amplify a region within the 
first PCR product, which included the CpG dinucleotides that were studied. The second round (nested) 
PCR was performed to reduce the contamination caused by nonspecific primer annealing and to increase 
the amount of the desired product. Methyl Primer Express Software (Applied Biosystems) was used to 
design the first round primers and the sound round (nested) primers. Primers were synthesized by 
Integrated DNA Technologies (IDT) and provided in a lyophilized form.  The lyophilized primers were 
reconstituted with nuclease free water. The volume of the added nuclease free water was calculated to 
have a final concentration of 150 pMol/µl of the primers. The first round PCR was prepared with 12.5 µl 
of 2 X PCR master mixes (AmpiTaq Gold PCR master, Applied Biosystems), 5 µl of the bisulfite treated 
DNA (20ng/µl), 2 µl of the first round primers and 5.5 µl of nuclease free water. The following thermal 
cycling profile was used: 1 cycle of 95˚C for 3 minutes for initial denaturation and polymerase activation; 
30 cycles of 95˚C for 1 minute for denaturation, 58˚C for 2 minutes for annealing, and 72˚C for 2 minutes 
for elongation; and 1 cycle of 72˚C for 10 minutes for final elongation. The first round PCR product was 
purified using QIAquick PCR Purification kit (Qiagen, Valencia, CA), and then subjected to a second 
round of PCR using the nested primers. The second round PCR was prepared with 12.5 µl of master mix 
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(FastStart High Fidelity PCR System, Roche), 2 µl of nested primers, 2 µl of the first round PCR product, 
and 8.5 µl of nuclease free water. The following thermal cycling program was used: one cycle of 95˚C for 
2 minutes for initial denaturation and polymerase activation; 35 cycles of 95˚C for 30 seconds for 
denaturation, and 58˚C for 30 seconds for annealing, and 72˚ C for 3 minutes for final elongation; and 
72˚C for 7 minutes for final elongation. A Mastercycler ep Thermal Cycler (Eppendorf, Hauppauge, NY) 
was used to run the first and the second round PCR reactions.   
Before purifying the second PCR product, 5 µl of the second PCR product was mixed with 1 µl 
of Gel Loading Dye Blue (6X) (New England BioLabs, Ipswich, MA) and loaded on 2% Tris-Acetate-
EDTA (TAE) agarose gel. To make 2% agarose gel, 0.2 g of agarose (Invitrogen, Carlsbad, CA) were 
added to 10 ml of 1X TAE buffer (Cellgro, Manassas, VA) and microwaved for 1 minute. The solution 
was left to cool for a few minutes, and then poured into gel casters. Gels were left to solidify for 20 
minutes and used immediately or soaked in 1X TAE buffer and stored at 4˚C until used. To determine the 
size of the bands on the gel, 6 µl of 1kb DNA Ladder (New England BioLabs, Ipswich, MA) were loaded 
into the first lane. The gel was run in 1X TAE buffer at 100 V for 45 minutes. The gel was stained with 
ethidium bromide by soaking it in 100 ml of 1X TAE buffer containing 10 µl ethidium bromide 
(Invitrogen, Carlsbad, CA) for 20 minutes and then destained by soaking it in 100 ml of 1X TAE buffer 
without ethidium bromide for 5 minutes. After that, the gel was scanned and viewed with Molecular 
Imager Gel Doc XR+ System (Bio-Rad Laboratories, Hercules, CA).   
MethylEasy™ Xceed kit is provided with a control sample of untreated genomic DNA (control 
sample 1), a control sample of bisulfite treated DNA (control sample 2), control first round PCR primers 
(3A), and control second round PCR primers (3B) for nested PCR. Control Sample 1 and a no template 
control sample were processed in parallel with the test samples. Control Primers 3A and 3B are validated 
PCR primers that are specific for converted DNA. These primers were used to check the integrity of the 
recovered DNA. Treated control sample 1, control sample 2, treated no template control sample, and 
selected treated test samples were amplified with control primers 3A and 3B, and the second round PCR 
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products were run on 2% agarose gel. The expected amplicon size for the control second round PCR 
primers was 240 base pair. Second round PCR product was purified using QIAquick PCR Purification kit 
(Qiagen, Valencia, CA).  
The second round PCR product was cloned using TOPO TA Cloning kit (Invitrogen, Carlsbad, 
CA). In brief, 1µl of the second round PCR product was added to 1 µl of TOPO cloning vector and the 
mixture was incubated for 10 minutes.  TOPO cloning vector is a linearized vector with a single 
overhanging 3´ thymidine (T) residue on each end. The enzyme blend used in the FastStart High Fidelity 
PCR System used in the second round PCR has a non-template-dependent terminal transferase activity 
that results in the addition of a single adenosine (A) residue to the 3´ end of the PCR product, making this 
system compatible for T/A cloning. This allows PCR inserts to ligate efficiently with the vector. After 
ligation, competent E.coli bacteria provided by the kit were transformed and then plated on selective 
Lysogeny broth (LB) agar plates. To make LB Agar plates, 40 g of LB agar and 20 g of LB broth (Fisher 
Scientific, Pittsburgh, PA) were added to 1 L of ddH2O and stirred with a magnetic stirrer on a hot plate 
(70°C) until dissolved. The suspension was transferred to a bottle and autoclaved. After that, 2 ml of 25 
mg/ml ampicillin (Fisher Scientific, Pittsburgh, PA) were added to the suspension, which was gently 
swirled to mix. Before adding the ampicillin, the suspension was cooled down to avoid damaging the 
ampicillin with high temperature. Ten ml of the suspension was add into a sterile petri dish (Fisher 
Scientific, Pittsburgh, PA) and evenly distributed by gentle agitation. Plates were left to cool and solidify 
and then stored in a sterile bag at 4˚C until used. Before culturing the bacteria on LB agar, 20 µl of 
IPTG/X-Gal solution (Fisher Scientific, Pittsburgh, PA) was added to each plate and evenly distributed. 
X-gal was added for blue/white screening of colonies. Blue color results when the X-gal is cleaved by the 
β-galactosidase enzyme encoded by a gene engineered into the plasmid. Insertion of the clone DNA 
disturbs the reading frame of the β- galactosidase gene making the bacteria unable to cleave X-gal which 
results in the white colony. Ten white colonies were randomly selected and each was cultured in 1.5 ml of 
LB media at 37˚C overnight. LB media was prepared by following the same protocol for LB agar palettes, 
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except no agar was added to the suspension. Plasmid was purified using QIAprep Spin Miniprep Kit 
(Qiagen, Valencia, CA) and screened with M13 primer system provided by TOPO TA Cloning kit. PCR 
products were run on 2% agarose gel to verify the presence of the insert in the vector. Clones were sent to 
VCU nucleic acid research facilities for sequencing. Sequencing data were analyzed using MacVector 
software (MacVector, Cary, North Carolina). The following formula was used to calculate the percentage 
of methylation: 
 
Percentage of methylation of a given CpG site = # of clones where that site was methylated x 100%   
                                                                                          # of total clones 
 
L. RNA extraction, cDNA synthesis and quantitative real time PCR (qRT-PCR) 
 
RNA was extracted from omental arteries using RiboPure kit (Ambion, Austin, TX) according to 
the manufacturer’s method. About 25 mg of arteries were cut into small pieces with a scissor and 
homogenized in 1 ml of the TRI reagent solution with a rotor stator homogenizer (PRO 200, PRO 
Scientific, Germantown, TN) at 200 rpm for 30 seconds divided into six 5 seconds intervals. Processed 
samples were loaded into spin columns, washed 3 times and RNA was eluted in 50 µl of the elution 
buffer. DNase treatment was performed after the first washing step by adding 40 µl of DNase solution 
(TURBO DNase, Ambion, Austin, TX) to each spin column and incubating for 5 minutes. 
For cultured VSMC or HL-60 cells, RNA was extracted using QuickGene RNA cultured cell HC 
kit and Quick gene Mini-80 (AutoGen, Holliston, MA) according to the manufacturer protocol. For 
DNase treatment, 40 µl of DNase solution (TURBO DNase, Ambion, Austin, TX) were add to each 
cartridge and incubated for 5 minutes. RNA was eluted in 50 µl of the elution buffer.  
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RNA concentration was measured and RNA quality was assessed by using the NanoDrop 
1000 Spectrophotometer (Thermo Scientific, Asheville, NC). Samples with an A260/280 ratio of 1.8 - 2 were 
considered pure and used for cDNA synthesis. RNA was reverse transcribed to cDNA using the iScript 
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA). Quantitative RT-PCR reactions were 
performed with RT² SYBR® Green qPCR Mastermix (SABiosciences, Frederick, MD) on Mastercycler 
ep realplex S thermal cycler (Eppendorf, Hauppauge, NY). As recommended by SABiosciences, 8 ng of 
cDNA was used for each qRT-PCR reaction. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene 
was used as a housekeeping gene. qRT-PCR primers are listed in Table 1. Melting curve analysis was 
used to verify there was no DNA contamination, which is indicated by the presence of more than one 
peak leading to false positive data. Fold changes were calculated by the ΔΔCT method using Microsoft 
Excel.  
 
M. Microarrays 
 
The expression of 84 transcription factor genes was assessed by using Human Transcription 
Factors PCR Array (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Data analysis 
was performed by using the Excel based RT² Profiler PCR Array Data Analysis Template v3.3 provided 
Qiagen.   
 
N. Protein extraction from blood vessels  
 
Radio Immuno Precipitation Assay buffer (RIPA) containing 150 mM sodium chloride, 1.0% 
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate (SDS) was used as a lysing buffer. For 
each 1 ml of RIPA buffer, 10 µl of Halt protease and phosphatase inhibitor cocktail (Pierce, Rockford, IL) 
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was added before use. Fresh or frozen omental arteries (40-50 mg) were cut into small pieces to avoid 
trapping the vessels between the blades of the rotor stator homogenizer. Arteries were cut with a clean 
curved tip scissor while keeping the tissue on ice. RIPA buffer (100-150 µl) was added to the cut arteries. 
Arteries were then homogenized by a rotor stator homogenizer (PRO 200, PRO Scientific, Germantown, 
TN) for 1 minute at a speed of 300 rpm while keeping them on ice. The homogenate was consistently 
agitated for 2 hours at 4˚C using an orbital shaker (Orbit LS, Labnet, Edison, NJ) then centrifuged at 
14000 x g for 10 minutes at 4˚C. Supernatant was transferred to a new microcentrifuge tube and stored at 
-20˚C. 
 
O. Protein extraction from cells  
 
RIPA buffer (50 µl) containing Halt protease and phosphatase inhibitor cocktail was added to the 
cell pellet and the cells were lysed by sonicating the pellet for 2 seconds for 10 times with a sonicator 
probe (1/8” Microtip, EpiShear Sonicator, Active Motif, Carlsbad, CA). Lysate was constantly agitated 
for 30 minutes at 4˚C using an orbital shaker (Orbit LS, Labnet, Edison, NJ) then centrifuged at 14000 x g 
for 10 minutes at 4˚C. Supernatant was transferred to a new microcentrifuge tube and stored at -20˚C.  
 
P. Measurement of protein concentration 
 
Protein concentrations were measured using the bicinchoninic acid (BCA) protein assay (Thermo 
Scientific, Asheville, NC) in plate format. Absorbance measurements were captured with FLUOstar 
OPTIMA plate reader (BMG Labtech, Cary, NC). Using MARS software provided with the machine, the 
standard samples were used to derive a standard curve of absorbance versus micrograms of protein and 
the protein concentrations of the unknown samples were determined from the standard curve in µg/ml.  
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Q. Western blot 
1. Gel Casting 
 
Bio-Rad casting apparatus and 1.5 mm combs were used to cast Tris-Glycine SDS gels of 
standard size (3" x 5" x 0.2"). Each gel consisted of 2 parts: An upper part of about 2 cm of stacking gel 
and a lower part of resolving gel. Ten ml of 10% resolving gel were made by mixing 4 ml of ddH2O, 3.3 
ml of 30% acrylamide mix (Bio-Rad, Hercules, CA), 2.5 ml of 1.5 M Tris-HCL (pH 8.8) (Bio-Rad, 
Hercules, CA), 100 µl of 10% SDS (Bio-Rad, Hercules, CA), and 100 µl of 10% ammonium persulfate 
(Fisher Scientific, Fair Lawn, NJ). To initiate the polymerization process of the mixture, 10 µl of N, N, 
N’, N’- teramethylethylenediamine (TEMED, Sigma-Aldrich, Saint Louis, MO) were added and then 
about 8 ml of the mixture were poured into the gel caster, leaving about 2 cm of space for the stacking 
gel. The mixture was layered with a few drops of 1-butanol (Sigma-Aldrich, Saint-Louis, MO) and 
allowed to set. To make 10 ml of (4%) stacking gel, 3.4 of ml H2O, 850 µl of 30% acrylamide mix, 625 
µl 1.5 Tris (pH 8.8) (Bio-Rad, Hercules, CA), 50 µl 10% SDS and 10 µl 10% ammonium persulfate were 
mixed together and 10 µl of TEMED was added. The mixture was poured into the gel caster on the top of 
the resolving gel until the space that was left over was filled, and then a comb was inserted to form the 
wells and define the lanes in the gel. The gel was left to set for 15 minutes, and then it was either used 
immediately or soaked in PBS and stored in 4˚C overnight to be used in the next day.         
 
2. Sample preparation and loading 
 
Fermentas protein loading buffer pack (Thermo Scientific, Asheville, NC) was used for sample 
loading. A total volume of 50 µl was loaded per lane. This included: the volume of lysate required to get 
50 or 100 µg of protein per lane (calculated for each sample), 2.5 µl (1/20th of the final volume) of 20X 
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Fermentas reducing agent, 10 µl (1/5th of final volume) of 5X Fermentas loading buffer, and the volume 
of ddH2O required to bring the final volume to 50 µl. Samples were vortexed for a few seconds, flash 
spined, and boiled at 95-100˚C for 5 minutes. Samples were cooled to room temperature and then loaded 
into the wells of the gel using gel loading pipette tips. Ten µl of precision plus all blue protein standards 
(Bio-Rad, Hercules, CA) were used to determine the molecular weight of the detected bands. They also 
served as a positive control for the electrophoresis and transfer steps.  
 
3. Gel electrophoresis 
 
The XCell SureLock Mini-Cell system (Invitrogen, Carlsbad, CA) was used for gel 
electrophoresis. The comb was removed and the wells were rinsed with ddH2O, then with running buffer 
and the gel was assembled with the other parts of the electrophoresis cell. A 1X dilution of 10x 
Tris/Glycine/SDS buffer (Bio-Rad, Hercules, CA) was used as the running buffer. The inner chamber of 
the cell assembly was filled with running buffer so that the buffer level was above the level of the wells, 
and checked for any leak. After loading the samples into the gel, the outer chamber was filled with about 
650 ml of running buffer and the cell was hooked to a power supply (PowerEase 500, Invitrogen, 
Carlsbad, CA) inside a refrigerator. The gel was run at 120 V for 1.5 hour, or until the dye front reached 
the bottom of the gel. A magnetic stirrer was used to constantly move the buffer in the outer chamber to 
enhance heat dissipation. 
 
4. Preparation of the transfer membrane, plotting pads and filter papers 
 
Polyvinylidene Fluoride (PVDF) membrane (0.2 µ pore size, Millipore) was pre-wetted in 100% 
methanol for 30 seconds, or until the membrane became translucent gray in color, rinsed in ddH2O and 
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soaked in ice cold 40% methanol transfer buffer for 15-20 minutes for equilibration. The blotting pads 
were also soaked in ice cold 40% methanol transfer buffer and pressed to remove air bubbles. Filter 
papers were soaked briefly in ice cold 40% methanol transfer buffer immediately before their use.  
 
5. Protein Transfer 
 
XCell II Blot Module along with XCell SureLock Mini-Cell (Invitrogen, Carlsbad, CA) was used 
for protein transfer. A 25X tris-glycine transfer buffer was made by dissolving 18.2 g (12 mM final 
concentration) of tris base (Research Organics, Cleveland, Ohio) and 90.0 g (96 mM final concentration) 
of glycine (Caledon, Georgetown, Ontario, Canada) in 500 ml of ddH2O. On the day before the run, 1L of 
40% methanol 1X tris-glycine transfer buffer was made by mixing 40 ml of 25X tris-glycine transfer 
buffer, 200 ml of methanol and 760 ml of ddH2O. The 40% methanol 1X tris-glycine transfer buffer was 
kept in the refrigerator overnight to cool it down to 4˚C before use. The gel was transferred immediately 
without soaking it into transfer buffer.  The gel, along with the blotting pads, filter papers and PVDF 
membrane were assembled in the XCell II Blot Module as indicated by the user manual, and then the 
XCell Blot Module was placed into the XCell SureLock Mini-Cell. The inner chamber was filled with 
about 200 ml of the 40% methanol 1X tris-glycine transfer buffer and checked for any leaks. The outer 
chamber was filled with approximately 650 ml of ddH2O. The cell was hooked to PowerEase 500 power 
supply placed inside a refrigerator and the gel was run at 25 V for 2 hours. A magnetic stirrer was used to 
constantly move the buffer in the outer chamber to enhance heat dissipation. 
 
6. Blotting 
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The Odyssey blotting system (Li-cor, Lincoln, NE) was used for blotting of the membrane. The 
face of the membrane in approximation with the gel was marked. The membrane was blocked with 10 ml 
of 1:1 solution of Odyssey Blocking buffer (Li-cor, Lincoln, NE) and PBS for 1 hour at room temperature 
in a 50 ml conical tube placed on a rotator (Labquake rotator, Barnstead, Dubuque, IA). The membrane 
was then washed three times with PBS containing 0.1% Tween-20 for 5 minutes each.  
The primary antibody was diluted in 10 ml of Odyssey buffer containing 0.1% Tween-20. After 
that, the membrane was incubated with the primary antibody solution overnight at 4˚C in 50 ml conical 
tube placed on the rotator. The membrane was then washed 4 times for 5 minutes each with 0.1% Tween-
20 PBS. Secondary antibodies were diluted in 10 ml of 0.1% Tween-20 Odyssey blocking buffer in an 
amber 50 ml conical tube. Because the secondary antibodies are light sensitive, the membrane was 
protected from light from this step on. The membrane was incubated with the secondary antibody solution 
for 45 min at 4˚C. After that, the membrane was washed 4 times for 5 minutes each with 0.1% Tween-20 
PBS. Then the membrane was washed 4 times for 5 minutes each with PBS alone and 4 times 5 minutes 
each with ddH2O. Primary and secondary antibodies used are shown in Table 2.   
 
7. Image analysis 
 
The Odyssey infrared imaging system (Li-cor, Lincoln, NE) was used for scanning the membrane 
to detect and analyze immune reactive proteins on the blot. Before placing the membrane on the Odyssey 
scanner, the glass and silicon mat were carefully cleaned from dust. The scanning parameters were 
adjusted to obtain the highest possible image quality. Each band was surrounded by a rectangle and the 
intensity value of the band was calculated by multiplying the average intensity of the band by the area of 
the rectangle. The intensity value of a target protein band was divided by the intensity value of the 
corresponding β-actin band to normalize for loading errors. Normalized intensity value of the control 
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experiment was set as 100% and the change in the intensity of the target protein for each treatment was 
calculated relative to the control.       
 
R. Enzyme-linked immunosorbent assay (ELISA) 
 
Commercial ELISA kits were used to quantify total MMP-1 (pro-MMP-1 and active MMP-1) and 
TIMP-1 in VSMC culture medium. Medium was not concentrated, diluted or filtered before it was used in 
ELISA. Amersham human MMP-1 ELISA Biotrak System kit (GE Healthcare, Piscataway, NJ) was used 
for measuring total MMP-1, and Amersham human TIMP-1 ELISA Biotrak system kit (GE Healthcare, 
Piscataway, NJ) was used for measuring TIMP-1. Absorbance measurements were captured with 
FLUOstar OPTIMA plate reader (BMG Labtech, Ortenberg, Germany). MARS data analysis software 
was used to derive a standard curve of absorbance versus ng/ml of protein from the standard samples and 
determine the protein concentration (ng/ml) of the unknown samples from the curve. At the time of media 
collection, cells from the same T-25 flask were collected and processed for DNA extraction as explained 
above. For normalization, the total amount of MMP-1 or TIMP-1 protein (ng) in 5ml (volume of medium 
used in a T-25 flask) was divided by the total amount of DNA (µg) extracted from the cells of the same 
flask.    
 
S. Enzyme immunoassay (EIA)  
 
Thromboxane B2 (TXB2) Enzyme Immunoassay kit (Assay Designs, Ann Arbor, MI) was used to 
measure thromboxane B2 in media as indicated by the manufacturer’s protocol. Media was diluted by a 
factor of 1:1 before it was used in the assay. Absorbance measurements were captured using FLUOstar 
OPTIMA plate reader (BMG Labtech, Ortenberg, Germany) and thromboxane B2 concentrations were 
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calculated in pg/ml using MARS data analysis software. For normalization, the total amount TXB2 (pg) in 
5ml (volume of medium used in a T-25 flask) was divided by the total amount of DNA (µg) extracted 
from the cells of the same flask.    
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Table 1: List of qRT-PCR primes used for gene expression. 
Gene Forward primer Reversed primer 
MMP1 SA Biosciences, Frederick, MD 
MMP8 SA Biosciences, Frederick, MD 
TBXAS1 SA Biosciences, Frederick, MD 
COL1A1 ACG AAG ACATCCCACCAA TCAC CGTTGTCGCAGACGCAGA 
GAPDH GATTCCACCCATGGCAAATT AGATGGTGATGGGATTTCCATT 
TIMP1 CTGTGGCTCCCTGGAACA CCAACAGTGTAGGTCTTGGTGAAG 
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Table 2: List of primary and secondary antibodies used for protein expression. 
Protein Primary antibody Secondary antibodies 
TBXAS1 
Rabbit anti-human TBXAS1 (1:1000, 
Proteintech, Chicago, IL) 
Alexa Fluor 680 donkey anti-rabbit 
(1:10,000, Invitrogen, Carlsbad, CA) 
MMP-1 
Goat anti-human MMP-1 (0.2 µg/ml, R&D 
Systems, Minneapolis, MN) 
IRDye800 donkey anti-goat (1:20,000, 
Rockland, Gilbertsville, PA) 
MMP-8 
Rabbit anti-human MMP-8 (1:500, 
Proteintech, Chicago, IL) 
Alexa Fluor 680 donkey anti-rabbit 
(1:20,000, Invitrogen, Carlsbad, CA) 
COL1A1 
Goat anti-human COL1A1 (1:1,000, Santa 
Cruz Biotechnology, Santa Cruz, CA) 
IRDye800 donkey anti-goat (1:20,000, 
Rockland, Gilbertsville, PA) 
β-actin 
Rabbit anti-human β-actin (1:1,000, Sigma, 
Saint Louis, MO) 
Alexa Fluor 680 donkey anti-rabbit 
(1:20,000, Invitrogen, Carlsbad, CA) 
β-actin 
Mouse anti-human β-actin (1:1,000, Sigma, 
Saint Louis, MO) 
IRDye800 goat anti-mouse (1:20,000, 
Rockland, Gilbertsville, PA) 
  
 
 
56 
 
CHAPTER 3: DNA METHYLATION IS ALTERED IN MATERNAL BLOOD VESSELS OF 
PREECLAMPTIC WOMEN 
  
A. Abstract 
 
Methylation of cytosine in genomic DNA, especially cytosines clustered in gene promoters (CpG 
islands), is a major epigenetic alteration controlling gene expression. In general, hypomethylation of 
cytosines is associated with increased gene expression, whereas hypermethylation is associated with 
reduced gene expression. Little is known about the role of DNA methylation in preeclampsia. We 
analyzed 27,578 CpG sites that map to 14,495 genes in omental arteries of normal pregnant and 
preeclamptic women for DNA methylation status using the Illumina platform. We found 1,685 genes with 
a significant difference in DNA methylation at a false discovery rate of < 10% with many inflammatory 
genes having reduced methylation. Unsupervised hierarchical clustering revealed natural clustering by 
diagnosis and methylation status. Of the genes with significant methylation differences, 236 were 
significant at a false discovery rate of < 5%. When data were analyzed more stringently to a false 
discovery rate of < 5% and difference in methylation of > 0.10, 65 genes were identified, all of which 
showed reduced methylation in preeclampsia. When these genes were mapped to Gene Ontology for 
Molecular Functions and Biological Processes, 75 molecular functions and 149 biological processes were 
over-represented in the preeclamptic vessels. These included smooth muscle contraction, thrombosis, 
inflammation, redox homeostasis, sugar metabolism and amino acid metabolism. We speculate that 
reduced methylation may contribute to the pathogenesis of preeclampsia, and that alterations in DNA 
methylation resulting from preeclampsia may increase maternal risk of cardiovascular disease later in life. 
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B. Introduction 
 
Preeclampsia is a pregnancy disorder that remains a worldwide health problem and a leading 
cause of preterm delivery and of maternal and infant mortality and morbidity1. It is a complex, 
multisystem disease which is diagnosed clinically by new onset of hypertension and proteinuria that occur 
after twenty weeks gestation in pregnant women who are otherwise healthy1. Preeclampsia is often 
associated with other end organ problems, such as cerebral, pulmonary and systemic edema, activation of 
the coagulation system, reduced utero-placental blood flow and intrauterine growth restriction. The 
pathophysiology of preeclampsia is not well understood. It has been considered as a two-stage disease 
where the first stage is poor placentation and the second stage is development of exaggerated maternal 
systemic inflammatory response167.  
Many studies have reported possible genetic contribution to preeclampsia based on inheritance 
patterns or mutations in candidate genes168,169, however, few studies have examined the possible 
contribution of epigenetic mechanisms. Epigenetics is the study of changes in gene expression, which are 
mediated through mechanisms that do not involve changes in the DNA sequence. DNA methylation is the 
best characterized epigenetic mechanism170. It refers to the reversible addition of a methyl group (CH3) at 
the 5’ carbon of a cytosine in a CpG dinucleotide context. DNA methylation patterns can change in 
response to age, environmental stimuli, diet and oxidative stress110,116,141. The pattern of DNA methylation 
is maintained by DNA methyltransferase enzymes during future cell divisions110. In general, DNA 
hypomethylation is associated with increased gene expression whereas DNA hypermethylation is 
associated with decreased gene expression171. DNA methylation is involved in important biological 
processes such as tissue-specific gene regulation during development, X-chromosome inactivation and 
genomic imprinting172. 
Changes in DNA methylation patterns have been detected in a growing number of complex 
diseases including cancer173, schizophrenia174, neural tube defect175 and cardiovascular diseases such as 
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atherosclerosis129, ischemic heart disease and stroke130. Little information is available regarding DNA 
methylation in preeclampsia, but it might be an important pathologic mechanism because preeclampsia is 
associated with oxidative stress41,89 and obesity176, both of which can influence DNA methylation. It has 
been suggested the increased risk of preeclampsia in assisted reproductive technology pregnancies may be 
due to early epigenetic changes in gametes and/or embryos that contributes to abnormal placentation and 
development of preeclampsia177. Epigenetic changes associated with imprinted and non-imprinted genes 
have been demonstrated in preeclamptic placentas144,145,178 and deletion of imprinted gene p57-Kip2 in 
mice is associated with hypertension and proteinuria143, which are manifestations of preeclampsia1. In a 
study that investigated global DNA methylation profiles of placentas using Illumina GoldenGate 
Methylation Cancer panel I array, investigators reported promoter hypomethylation of 34 CpG sites in 
early-onset preeclampsia147.  
To date, there have been no reports dealing with DNA methylation in systemic blood vessels of 
the mother with preeclampsia. In this study, we used the Illumina HumanMethylation27 platform to 
simultaneously profile more than 27,000 CpG sites representing more than 14,000 genes in samples of 
omental fat arteries isolated from normal pregnant and preeclamptic women. Omental arteries were used 
because these arteries are a component of maternal systemic vasculature, and they play a role in blood 
pressure regulation by contributing to total peripheral vascular resistance. 
 
C. Materials and methods 
1. Study subjects 
 
Omental fat biopsies of approximately 2 cm x 2 cm x 0.5 cm in size were collected from normal 
pregnant (n = 5) and preeclamptic (n = 7) women during medically indicated cesarean sections performed 
at MCV Hospital, Virginia Commonwealth University Medical Center, Richmond, VA. Once obtained, 
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the biopsy was placed in a sterile container on ice and transferred to the lab for processing as soon as 
possible. Preeclampsia was diagnosed in gravid females by new onset of hypertension (systolic blood 
pressure of ≥ 140 mmHg and/or diastolic blood pressure ≥ 90mmHg) and proteinuria (300 mg or more of 
protein in the urine per 24 h collection) that occurred in women who were otherwise normal 1. Women 
with chorioamnionitis, maternal infections, active sexually transmitted diseases, lupus, or diabetes, and 
women who were smokers or in labor were excluded because these conditions are associated with 
inflammatory changes.  Patient clinical data are shown in Table 3. All subjects gave informed consent. 
The Office of Research Subjects Protection at Virginia Commonwealth University approved this study.  
 
2. Sample processing, DNA extraction, and bisulfite treatment 
 
Fat biopsies from normal pregnant and preeclamptic women were dissected for omental arteries 
under a dissection microscope. Arteries and veins were distinguished from each other based on their 
morphology. In general, arteries were thicker, narrower and their branching points were more acute as 
compared to veins. Omental arteries were dissected and cleared carefully of adhering fat. DNA was 
extracted from the arteries (~10 mg in weight) using QuickGene DNA tissue kit S kit and QuickGene-
Mini80 system (AutoGen, Holliston, MA) as recommended by the user manual. RNase treatment was 
performed with RNase A (Qiagen, Valencia, CA). DNA concentration was measured and its quality was 
assessed using NanoDrop 2000 spectrophotometer (Thermo Scientific, Wilmington, DE). DNA samples 
with A260/280 ratio of 1.8 were considered to be pure and used in the study. DNA (1µg) was bisulfite 
treated using MethylEasy Exceed kit (Human Genetic Signatures, Randwick, Australia). DNA was eluted 
in 20 µl elution buffer for a final concentration of 50 ng/µl   
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3. Methylation assay 
  
 The high throughput Illumina Infinium HumanMethylation27 BeadChip assay (Illumina, San 
Diego, CA) was used for DNA methylation analysis. This assay allows the examination of 27,578 CpG 
dinucleotides located within the proximal promoters of 14,495 genes. The BeadChip was run by the 
Nucleic Acids Research Facilities at VCU using the standard protocol provided by Illumina. In brief, 10 
µl of bisulfite treated DNA (50 ng/µl) was isothermally amplified at 37˚C for 24 h. The amplification 
product was enzymatically fragmented and the fragmented DNA was purified, and applied to the 
BeadChip for hybridization. During hybridization, DNA anneals to specific single stranded 
oligonucleotides, which are covalently linked to different types of beads. Each CpG site is presented by 2 
types of beads, which corresponds to the nucleotide identity, and thus the methylation status, of the 
bisulfite treated cytosine at that site. Hybridization was followed by single-base extension of the 
oligonucleotides where the hybridized DNA was used as a template to incorporate hapten labeled 
dideoxynucleotides. After that, the BeadChip was fluorescently stained, and then scanned for the 
intensities of the methylated and the unmethylated bead types using the Illumina BeadArray Reader. The 
scanned arrays were processed using Illumina’s GenomeStudio Methylation Analysis Module to obtain 
the β values for each CpG site, where βij represents proportion methylated for the ith CpG site and the jth 
array, and where β = 1 would indicate complete methylation and β = 0 would indicate no methylation. 
Validation of the BeadChip assay was performed by evaluating the quality of the hybridizations for six X-
linked genes, and by using COBRA179-181 for the -1538 CpG site upstream from the transcription start site 
for the matrix metalloproteinase-1 gene as we previously described164.  
 
4. Statistical analysis 
 
 
 
61 
 
For each CpG site a two-sample t-test was performed comparing the seven severe preeclampsia 
samples to the five normal samples with respect to proportion methylated. Specifically, for CpG sites i = 
1,…,27,578, the hypotheses tested were:  
 
H0:  
HA:  
The p-values from the two-sample t-tests were obtained for all CpG sites. The p-value is the 
probability of obtaining a test statistic as or more extreme as the one observed under the conditions of the 
null hypothesis. In most scientific endeavors, an α = 0.05 threshold is customarily applied so that a p-
value < 0.05 is considered as evidence for the alternative hypothesis, that is, p < 0.05 typically indicates a 
significant finding. However, application of α = 0.05 threshold to univariable tests of significance in high-
throughput genomic settings will yield a large number of Type I errors simply by chance. When analyzing 
high-throughput genomic data, the multiple comparison problem is most often addressed through 
estimation of the false discovery rate (FDR). To control for multiple hypothesis testing, the p-values were 
subsequently used in estimating FDR using the q-value method166.  More specifically, when testing m null 
hypotheses, we may want to control the number of rejected null hypotheses that are truly null (F) among 
all those null hypotheses that are rejected (S). The q-value is such a method that for a particular feature is 
defined to be the expected proportion of false positives among all features as or more extreme than the 
one observed166. For a given p-value threshold t where 0 ≤ t ≤ 1, we want to estimate FDR(t) = E (F(t)/S 
(t)) ≈ E(F(t))/E(S (t)). F(t) represents the number of false discoveries at threshold t while S (t) represents 
the number of null hypotheses considered significant at threshold t. Formally, FDR(t) is estimated as 
, ,i pre eclampsia i normalβ β− =
, ,i pre eclampsia i normalβ β− ≠
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where π0 represents the proportion of hypotheses for which the null is true and  is 1 if the p-
value for the gth CpG site is less than or equal to the threshold t. For application datasets, π0 is typically 
unknown and so is estimated using the distribution of raw p-values using either a smoothing or bootstrap 
method. In this study CpG sites with a FDR < 10% were considered significant. 
 For CpG sites identified as significant, the CpG sites were mapped to Gene Ontology terms 
(molecular function (MF), biological process (BP)) and a hypergeometric test was performed to determine 
whether any term was over-represented among those CpG sites identified as significant compared to the 
number of CpG sites mapping to that term on the entire array. For MF and BP terms, a p-value < 0.05 was 
considered significant.  
 
5. Canonical pathway and network identification 
 
Genes with statistically differentially methylated CpG sites were imported into Ingenuity 
Pathways Analysis software (IPA, v9; Ingenuity systems, Redwood City, CA) to identify canonical 
pathways and gene-to-gene interaction networks within our dataset. Canonical pathways and gene 
networks were algorithmically constructed based on published literature in the Ingenuity Knowledge 
Base, where each relation was supported by at least one reference.  
 
D. Results 
 
( )gI p t≤
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Due to the role of methylation in X-chromosome inactivation, differential methylation patterns 
between males and females have been observed for CpG sites of genes located on the X chromosome, and 
are used as quality control checks182. Therefore, the quality of the hybridizations was examined by 
plotting the proportion methylated for the six X-linked genes (EFNB1, ELK1, FMR1, G6PD, GPC3, 
GLA), which are expected to show hemi-methylation for females as an indication of good quality183. 
Based upon this examination, there were no quality concerns for the twelve samples included in this study 
(Figure 1). As an additional validation, COBRA quantification of methylation was used for the -1538 
CpG site in the matrix metalloproteinase-1 (MMP1) promoter, which we previously showed to have 
reduced methylation associated with increased expression of MMP-1 in amnions of patients with preterm 
premature rupture of the membranes164. COBRA quantification was similar to the BeadChip assay. 
Methylation by COBRA of an omental artery from a normal pregnant woman was 63% and methylation 
of an omental artery from a preeclamptic woman was 52% for a Δβ of -0.11. This compared favorably 
with the BeadChip analysis of the -1298 CpG site for MMP1 of 81.6% for normal pregnancy versus 
73.6% for preeclamptic pregnancy for a Δβ of -0.08 (p = 0.016, FDR = 0.1069). Although the methylation 
percentage of the -1538 CpG site varied from that of the -1298 CpG site, this is not unexpected because 
methylation percentage varies for CpG sites in the MMP1 promoter164.  
Unsupervised hierarchical clustering using Euclidean distance and Ward’s method was applied to 
determine whether the samples naturally clustered by diagnosis. The methylation matrix was filtered to 
include CpG sites having a mean β >0.15 and a standard deviation among the top 90% of standard 
deviations, leaving 1,233 CpG sites. Unsupervised hierarchical clustering (Figure 2) revealed natural 
clustering of the samples by diagnosis, normal pregnant versus preeclamptic and natural clustering of the 
CpG sites by methylation status, reduced methylated versus relatively more methylated.  
Statistical analysis revealed 4,184 CpG sites, corresponding to 3,736 genes, with significant 
differential methylation when comparing between normal pregnant and preeclamptic omental arteries at 
P-value of less than 0.05. This is considerably greater than what is expected by chance alone. Of these 
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CpG sites, 1,771 CpG sites, mapped to 1,685 genes, had a FDR of less than 10% (Table 4) and 237 CpG 
sites, representing 236 genes, had a FDR of less than 5%. Interestingly, many of these genes were related 
to inflammation. Of the 237 CpG sites, 155 CpG sites (~65%) had reduced methylation in preeclamptic 
omental arteries. For each CpG detected in the BeadChip, the distance from the transcription start site 
(TSS), and whether it was located within a CpG island, was provided by Illumina. Transcription factor 
binding sites are often located within the nucleosome free region of the gene promoter184. The position of 
the CpG sites relative to nucleosomes was not provided in this assay. However, one could infer that the 
nucleosome free region is most likely 200 base pairs upstream of the TSS185. The median distance from 
TSS for the 237 CpG sites was -299. Also, of these CpG sites, 112 CpG sites (~47%) were located within 
CpG islands. Interestingly, 67% of CpG sites that had significantly reduced methylation were not located 
in CpG islands whereas 91% of CpG sites that were significantly more methylated were located in CpG 
islands. When data were analyzed more stringently to a FDR of less than 5% and difference in 
methylation of more than 0.10, 65 genes were identified, all of which were less methylated in 
preeclamptic women.  
To visualize the distribution of the CpG sites based on their biological and statistical significance, 
a volcano plot was created by plotting the difference between average proportion methylated for normal 
pregnant and preeclamptic women for all 27,578 CpG sites analyzed by the BeadChip on the X axes, and 
the negative log10 transformed P-values from the two class comparison analysis performed for each CpG 
site on the Y axis. The plot was divided into four quadrants by the line X=0 which divided the CpG sites 
into CpG sites that are less methylated in preeclamptic omental arteries compared to normal pregnant 
counterparts on the left and CpG sites that were more methylated in preeclamptic omental arteries on the 
right, and the line Y= -log10 (P-value equivalent to FDR of 10%) which divided the CpG sites that were 
significantly differentially methylated above that line and CpG site with no significant difference in 
methylation below the line (Figure 3). The larger population of CpG sites that was observed in the upper 
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left quadrant of the plot indicated preeclamptic samples had a significant decrease in their DNA 
methylation compared to normal pregnant.  
When genes with differentially methylated CpG sites at FDR cut-off of 0.05 were mapped to 
Gene Ontology for Molecular Functions (MF) and Biological Processes (BP), 75 MFs and 149 BPs were 
over-represented in the preeclamptic vessels (p < 0.05), many of which were pertinent to the 
pathophysiology of preeclampsia (Table 5).  
Genes with differentially methylated CpG sites at FDR cut-off of 0.1 were analyzed with IPA 
software to assess the interconnectivity between these genes and other related genes within a canonical 
pathway or a gene-to-gene interaction network which may indicate functional importance of these genes 
in the biology of the disease. Twenty-five significant canonical pathways (p < 0.05) were identified 
(Table 6). Some of these pathways were associated with inflammation, such as retinoid X receptor (RXR) 
inhibition, peroxisome proliferator-activated receptor (PPAR) signaling and high mobility group box 
chromosomal protein 1 (HMGB1) signaling. Using IPA network analysis, 50 gene-to-gene interaction 
networks were identified. Four of them included inflammatory response, hematological disease, 
inflammatory disease and/or cardiovascular disease among their top three associated biological functions 
(p < 0.005). A network is shown in Figure 4 for inflammatory genes. 
 
E. Discussion  
 
In this study, we used a high throughput assay to investigate the global DNA methylation profiles 
in omental arteries from normal pregnant women and women with severe preeclampsia. We identified 
3,736 genes with significantly differentially methylated CpG sites between the two groups, which is 
significantly greater than expected by chance alone. Unsupervised hierarchical clustering revealed natural 
clustering by diagnosis demonstrating that DNA methylation profiles distinguished each group. Volcano 
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plot demonstrated that the most significant differences in DNA methylation of CpG sites were 
“hypomethylated” genes in preeclamptic women. Of genes with significant methylation differences, 236 
were significant at a FDR of less than 5%. When data were analyzed more stringently to FDR of 5% and 
difference in methylation of more than 0.10, 65 genes were identified, all of which had lower levels of 
methylation in preeclampsia.     
DNA methylation is maintained by the action of DNA methyltransferases, which use S- 
adenosylmethionine as a donor of methyl group in their reactions131. When the methyl group is 
transferred, S-adenosylmethionine is converted to S-adenosylhomocysteine, which is hydrolyzed under 
physiological conditions to homocysteine and adenosine. The equilibrium of this reversible reaction 
strongly favors S-adenosylhomocysteine synthesis rather than hydrolysis and an increase in intracellular 
homocysteine levels can increase S-adenosylhomocysteine levels 132. S-adenosylhomocysteine has a 
higher affinity to DNA methyltransferases than S-adenosylmethionine does, which makes it a potent 
inhibitor of DNA methylation reactions133. A number of studies reported that plasma levels of 
homocysteine and S-adenosylhomocysteine are significantly elevated in preeclamptic women as 
compared to normal pregnant women135-137. The relationship between hyperhomocysteinemia and DNA 
methylation has been studied in cardiovascular diseases such as atherosclerosis. For example, increased 
plasma levels of total homocysteine and S-adenosylhomocysteine were correlated with decreased global 
DNA methylation in white blood cells of patients with advance atherosclerosis134. 
Methylenetetrahydrofolate reductase is the enzyme that catalyzes the conversion of 5,10-
methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is required for the re-methylation 
homocysteine to methionine. A study using methylenetetrahydrofolate reductase knockout mice found 
that decreased S-adenosylmethionine levels or significantly increased S-adenosylhomocysteine levels, or 
both, correlated with global DNA hypomethylation138. Knockout mice also showed abnormal aortic lipid 
deposition similar to those observed in early atherosclerosis. Our study showed that preeclampsia is 
associated with changes in DNA methylation patterns in maternal systemic vasculature. Preeclampsia is 
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associated with increased risk of cardiovascular diseases, such as hypertension, atherosclerosis, ischemic 
heart disease and stroke later in life186. The exact role of DNA methylation in the etiology of these 
diseases with respect to preeclampsia remains to be determined.  
The thromboxane synthase gene (TBXAS1) was the most hypomethylated gene in preeclamptic 
women. TBXAS1 encodes an enzyme that catalyzes the isomerization of prostaglandin H2 into 
thromboxane94. Preeclampsia is associated with an imbalance of increased thromboxane and decreased 
prostacyclin, which was first described in placenta95 and later confirmed for maternal blood96 and 
maternal urine97. This imbalance can provide a plausible explanation for hypertension, reduced 
uteroplacental blood flow and hypercoagulopathy observed in women with preeclampsia because 
thromboxane is a potent vasoconstrictor and platelet activator, whereas prostacyclin is a potent 
vasodilator and inhibitor of platelet activation27. Our findings suggest an epigenetic regulation of the 
TBXAS1 gene because we found that its reduced methylation is associated with its increased expression in 
omental arteries of preeclamptic women187.   
Another gene that was significantly less methylated in our analysis was MMP1 (p = 0.016, FDR = 
0.1069, Δβ = 0.08). This gene also appears to be epigenetically regulated because its reduced methylation 
is associated with its increased expression in omental arteries of preeclamptic women 159 and 
experimentally induced hypomethylation results in its increased expression in human vascular smooth 
muscle cells in culture188. Interestingly, increased expression of MMP-1 is also associated with reduced 
DNA methylation in amnion of patients with preterm premature rupture of the membranes 164. 
Normal pregnancy is associated with mild systemic inflammatory changes which increase as 
pregnancy progresses82. These changes include increased plasma levels of fibrinogen101, plasminogen 
activator inhibitor type 1102 ceruloplasmin103, interleukin-6104, and tumor necrosis factor-α105,106. They also 
include leukocytosis189, leukocyte activation38,190,191, increased circulating markers of oxidative stress such 
as lipid hydroperoxides and malondialdehyde192, and hypertriglyceridemia108. All these inflammatory 
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changes are exacerbated in preeclampsia109. The differences between normal pregnancy 
and preeclampsia in terms of systemic inflammation are less striking than those between normal 
pregnancy and the nonpregnant state82. This suggests that preeclampsia may arise due to an inability of 
maternal homeostasis to adapt to a pregnancy induced systemic inflammation. In our study, many 
inflammation-related genes were significantly hypomethylated in preeclamptic women as compared to 
normal pregnant women. DNA hypomethylation is generally associated with increased gene expression, 
so reduced methylation may place a woman in a more responsive state to inflammatory stimuli.  
Ingenuity pathway analysis (IPA) demonstrated that genes with significant changes in 
methylation in preeclamptic women were associated with multiple canonical pathways related to 
inflammation and immune response. These pathways included inhibition of RXR function and PPAR 
signaling. PPARs and RXRs help regulate inflammatory responses in endothelial and vascular smooth 
muscle cells. Activation of these receptors results in the formation of PPAR/RXR heterodimers which 
exert anti-inflammatory effects in these cells193. Preeclampsia is associated with inflammation and 
dysfunction of maternal systemic endothelial and vascular smooth muscle cells62, so the inhibition of 
these pathways may contribute to the pathophysiology of preeclampsia. HMGB1 signaling is another 
canonical pathway identified by IPA software in our dataset. HMGB1 is a nuclear transcription factor 
which possesses potent cytokine activity when released from innate immune cells, mediating the late 
response to inflammation194 through toll-like receptors 4 and 2195. HMGB1 is also released from cultured 
human vascular smooth muscle cells in response to C-reactive protein196, which is elevated in 
preeclampsia197,198. HMGB1 causes increased expression of intercellular adhesion molecule-1 (ICAM-1) 
and interleukin-8 (IL-8) in cultured human endothelial cells199 and increases expression of C-reactive 
protein, MMP-2 and MMP-9 in cultured human vascular smooth muscles196. These changes are similar to 
what is found in preeclampsia where the expression of ICAM-1 and IL-8 are increased in endothelial cells 
of maternal systemic blood vessels61, and levels of C-reactive protein197,198, MMP-2200 and MMP-9201 are 
elevated in the plasma. This suggests that hypomethylation related to HMGB1 signaling may be involved 
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in the pathophysiology of preeclampsia. IPA analysis also indicated that genes in our dataset were 
involved in gene-to-gene interaction networks, which had inflammatory response, inflammatory disease 
and cardiovascular disease among their top associated biological functions. These relationships suggest 
that DNA methylation may contribute to preeclampsia by influencing multiple pathways and gene-to-
gene networks related to inflammation in a woman’s systemic blood vessels.   
When genes with an FDR of less than 5% were mapped for Molecular Functions and Biological 
Processes, 75 Molecular Functions and 149 Biological Process were over-represented in preeclampsia 
representing functions and pathways pertinent to pathophysiology. These included smooth muscle 
contraction, thrombosis, inflammation, redox homeostasis, sugar metabolism and amino acid metabolism. 
These are particularly relevant to preeclampsia because it is associated with increased vascular resistance, 
increased arterial pressure202, reduced uteroplacental blood flow203, hypercoagulopathy204, 
inflammation109, oxidative stress89 and altered carbohydrate and amino acid  metabolism205.   
Our study had some methodological limitations. The number of samples analyzed was limited 
due to the difficulty in obtaining omental arterial samples. In addition, although the Illumina Human 
Methylation27 platform is a reliable way to assess the methylation status of large numbers of CpG sites in 
the promoter region of genes183, it does not cover all CpG sites in the human genome. Methylation of 
CpG sites outside of the gene promoter regions are also likely important. Consequently, some important 
epigenetic alterations may have been overlooked in our analysis. Another limitation is the cellular 
heterogeneity of omental arteries, which did not allow us to specify the cell type where methylation 
changes were occurring. Because of the extensive infiltration of neutrophils into the mother’s blood 
vessels in preeclampsia61-63, neutrophils are just as likely to be the source of the DNA methylation 
changes as are endothelial or vascular smooth muscle cells.  
Our study is the first to compare DNA methylation profiles in systemic blood vessels of normal 
pregnant and preeclamptic women. Reduced methylation of inflammatory genes was prominent in 
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omental arteries of preeclamptic women. Genes with significant differential methylation were involved in 
multiple pathways and gene-to-gene networks pertinent to the clinical features of preeclampsia. We 
speculate that reduced methylation prior to pregnancy may increase the risk of getting preeclampsia, 
whereas reduced methylation caused by oxidative stress during preeclampsia may contribute to increasing 
the risk of cardiovascular disease later in life186. 
Our study may have clinical implications for the treatment of preeclampsia. Folate is an essential 
vitamin for the synthesis of methyl donors utilized by methyltransferases to methylate DNA. Therefore, 
dietary supplementation with folate might restore reduced methylation in inflammatory genes, and protect 
against development of preeclampsia. In this regard, a large study of almost 3,000 pregnant women found 
supplementation with multivitamins containing folic acid was associated with reduced risk of 
preeclampsia206.  
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Table 3: Clinical Characteristics of Patient Groups. 
Variable 
Normal Pregnant 
(n = 5) 
Preeclamptic 
(n = 7) 
Maternal age (y) 23.0 ± 1.7 24.9 ± 1.4 
Pre-pregnancy BMI (kg/m2) 24.4 ± 1.5 29.9 ± 2.9 
Systolic blood pressure (mmHg) 115.0 ± 3.2 168.0 ± 2.8* 
Diastolic blood pressure (mmHg) 69.6 ± 1.3 91.1 ± 3.9** 
Proteinuria (mg/24 h) ND 307.8 ± 26.7 (n = 4) 
Dipstick ND 2.3 ± 0.9 (n = 3) 
Parity 
Primiparous 
Multiparous 
 
2 
3 
 
2 
5 
Gestational age (wk) 39.2 ± 0.2 34.1 ± 1.7* 
Infant birth weight (g) 3424 ± 110 2304 ± 393 
Values are presented as mean ± SEM.  
*p < 0.05, **p < 0.01, *** p < 0.001 by t-test. 
 ND, not detectable.   
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Table 4: List of differentially methylated CpG sites at false discovery rate (FDR) < 10%. NP = normal 
pregnant, PE = preeclamptic, β = methylation values where 0≤ β≤1, 0 = no methylation and 1 = full 
methylation.  ∆β = difference in methylation. Minus values indicate less methylation and positive values 
more methylation in preeclamptic arteries as compared to normal pregnant arteries.  
Symbol Gene ID Gene Description Mean β PE 
Mean β 
NP ∆β FDR 
A2ML1 144568 alpha-2-macroglobulin-like 1 0.68 0.83 -0.15 0.042 
A4GNT 51146 alpha-1,4-N-acetylglucosaminyltransferase 0.71 0.84 -0.13 0.063 
AAAS 8086 achalasia, adrenocortical insufficiency, alacrimia (Allgrove, triple-A) 0.20 0.14 0.06 0.080 
AANAT 15 arylalkylamine N-acetyltransferase 0.94 0.91 0.03 0.065 
ABCA4 24 ATP-binding cassette, sub-family A (ABC1), member 4 0.71 0.80 -0.09 0.080 
ABCB4 5244 ATP-binding cassette, sub-family B (MDR/TAP), member 4 0.83 0.79 0.04 0.089 
ABCC5 10057 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 0.02 0.01 0.01 0.086 
ABCG1 9619 ATP-binding cassette, sub-family G (WHITE), member 1 0.68 0.79 -0.11 0.047 
ABCG5 64240 ATP-binding cassette, sub-family G (WHITE), member 5 0.81 0.89 -0.08 0.066 
ABHD2 11057 abhydrolase domain containing 2 0.08 0.05 0.03 0.080 
ABO 28 
ABO blood group (transferase A, 
alpha 1-3-N-
acetylgalactosaminyltransferase; 
transferase B, alpha 1-3-
galactosyltransferase) 
0.94 0.89 0.04 0.087 
ABR 29 active BCR-related gene 0.02 0.01 0.01 0.073 
ACAT2 39 acetyl-Coenzyme A acetyltransferase 2 0.40 0.19 0.21 0.067 
ACO1 48 aconitase 1, soluble 0.02 0.01 0.01 0.079 
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Symbol Gene ID Gene Description Mean β PE 
Mean β 
NP ∆β FDR 
ACRBP 84519 acrosin binding protein 0.72 0.80 -0.08 0.099 
ACSBG2 81616 acyl-CoA synthetase bubblegum family member 2 0.85 0.89 -0.05 0.051 
ACSL4 2182 acyl-CoA synthetase long-chain family member 4 0.73 0.83 -0.10 0.061 
ACSL5 51703 acyl-CoA synthetase long-chain family member 5 0.66 0.75 -0.10 0.069 
ACSL5 51703 acyl-CoA synthetase long-chain family member 5 0.84 0.92 -0.08 0.085 
ACTL7A 10881 actin-like 7A 0.73 0.79 -0.06 0.074 
ACTL7B 10880 actin-like 7B 0.94 0.96 -0.02 0.089 
ACTR1B 10120 ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 0.04 0.02 0.02 0.090 
ACTRT1 139741 actin-related protein T1 0.69 0.60 0.09 0.072 
ACY1 95 aminoacylase 1 0.91 0.96 -0.05 0.089 
ADA 100 adenosine deaminase 0.80 0.69 0.11 0.073 
ADAMTS6 11174 ADAM metallopeptidase with thrombospondin type 1 motif, 6 0.04 0.02 0.02 0.067 
ADAMTS9 56999 ADAM metallopeptidase with thrombospondin type 1 motif, 9 0.02 0.01 0.00 0.065 
ADAMTSL3 57188 ADAMTS-like 3 0.03 0.02 0.01 0.061 
ADC 113451 arginine decarboxylase 0.05 0.03 0.01 0.086 
ADH1A 124 alcohol dehydrogenase 1A (class I), alpha polypeptide 0.23 0.31 -0.08 0.099 
ADORA2B 136 adenosine A2b receptor 0.61 0.78 -0.16 0.053 
AES 166 amino-terminal enhancer of split 0.12 0.19 -0.07 0.084 
AFF2 2334 AF4/FMR2 family, member 2 0.87 0.90 -0.04 0.042 
AFF2 2334 AF4/FMR2 family, member 2 0.70 0.82 -0.12 0.080 
AFM 173 afamin 0.46 0.58 -0.12 0.084 
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AGBL2 79841 ATP/GTP binding protein-like 2 0.28 0.35 -0.08 0.066 
AGTR1 185 angiotensin II receptor, type 1 0.05 0.03 0.02 0.047 
AGTRAP 57085 angiotensin II receptor-associated protein 0.05 0.03 0.02 0.078 
AKAP5 9495 A kinase (PRKA) anchor protein 5 0.13 0.09 0.04 0.099 
AKT3 10000 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) 0.94 0.97 -0.03 0.075 
ALDH1A3 220 aldehyde dehydrogenase 1 family, member A3 0.60 0.72 -0.12 0.094 
ALDH3A1 218 aldehyde dehydrogenase 3 family, memberA1 0.37 0.30 0.07 0.059 
ALDOB 229 aldolase B, fructose-bisphosphate 0.79 0.87 -0.08 0.064 
ALG1 56052 
asparagine-linked glycosylation 1, 
beta-1,4-mannosyltransferase homolog 
(S. cerevisiae) 
0.18 0.10 0.08 0.077 
ALG5 29880 
asparagine-linked glycosylation 5, 
dolichyl-phosphate beta-
glucosyltransferase homolog (S. 
cerevisiae) 
0.05 0.03 0.02 0.094 
ALPK1 80216 alpha-kinase 1 0.95 0.98 -0.02 0.086 
ALS2CR12 130540 
amyotrophic lateral sclerosis 2 
(juvenile) chromosome region, 
candidate 12 
0.85 0.91 -0.05 0.053 
ALX4 60529 ALX homeobox 4 0.76 0.70 0.07 0.088 
AMBP 259 alpha-1-microglobulin/bikunin precursor 0.81 0.90 -0.09 0.054 
AMDHD1 144193 amidohydrolase domain containing 1 0.84 0.91 -0.08 0.039 
AMHR2 269 anti-Mullerian hormone receptor, type II 0.88 0.93 -0.05 0.083 
AMY2B 280 amylase, alpha 2B (pancreatic) 0.29 0.35 -0.06 0.076 
ANK1 286 ankyrin 1, erythrocytic 0.73 0.85 -0.11 0.063 
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ANKRD10 55608 ankyrin repeat domain 10 0.07 0.05 0.03 0.074 
ANKRD35 148741 ankyrin repeat domain 35 0.02 0.01 0.01 0.077 
ANKRD37 353322 ankyrin repeat domain 37 0.02 0.01 0.01 0.090 
ANKRD38 163782 KN motif and ankyrin repeat domains 4 0.96 0.98 -0.01 0.053 
ANKRD7 56311 ankyrin repeat domain 7 0.81 0.88 -0.07 0.064 
ANPEP 290 alanyl (membrane) aminopeptidase 0.81 0.90 -0.09 0.047 
ANXA8 244 annexin A8-like 2 0.60 0.72 -0.13 0.085 
AP2S1 1175 adaptor-related protein complex 2, sigma 1 subunit 0.55 0.69 -0.14 0.074 
APC 324 adenomatous polyposis coli 0.04 0.03 0.01 0.044 
APEH 327 N-acylaminoacyl-peptide hydrolase 0.09 0.05 0.04 0.098 
API5 8539 API5-like 1; apoptosis inhibitor 5 0.15 0.11 0.04 0.057 
APLP2 334 amyloid beta (A4) precursor-like protein 2 0.09 0.07 0.03 0.076 
APOBEC1 339 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 0.75 0.85 -0.10 0.055 
APOBEC4 403314 
apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 4 
(putative) 
0.64 0.73 -0.09 0.080 
APOC4 346 apolipoprotein C-IV 0.33 0.52 -0.19 0.053 
APOD 347 apolipoprotein D 0.67 0.77 -0.11 0.080 
APOH 350 apolipoprotein H (beta-2-glycoprotein I) 0.44 0.57 -0.13 0.074 
APOL1 8542 apolipoprotein L, 1 0.92 0.90 0.02 0.086 
APOL3 80833 apolipoprotein L, 3 0.20 0.31 -0.12 0.042 
AQP8 343 aquaporin 8 0.50 0.62 -0.12 0.083 
ARD1A 8260 ARD1 homolog A, N-acetyltransferase (S. cerevisiae) 0.97 0.98 -0.01 0.087 
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ARF3 377 ADP-ribosylation factor 3 0.05 0.02 0.02 0.088 
ARFRP1 10139 ADP-ribosylation factor related protein 1 0.90 0.95 -0.05 0.073 
ARHGAP9 64333 Rho GTPase activating protein 9 0.91 0.87 0.04 0.073 
ARHGEF16 27237 Rho guanine exchange factor (GEF) 16 0.88 0.83 0.05 0.077 
ARID1A 8289 AT rich interactive domain 1A (SWI-like) 0.02 0.01 0.01 0.077 
ARIH2 10425 ariadne homolog 2 (Drosophila) 0.62 0.75 -0.13 0.053 
ARL11 115761 ADP-ribosylation factor-like 11 0.83 0.90 -0.07 0.042 
ARL13B 200894 ADP-ribosylation factor-like 13B 0.04 0.02 0.02 0.039 
ARL13B 200894 ADP-ribosylation factor-like 13B 0.87 0.92 -0.06 0.053 
ARL2 402 ADP-ribosylation factor-like 2 0.04 0.02 0.02 0.090 
ARL6 84100 ADP-ribosylation factor-like 6 0.05 0.03 0.02 0.070 
ARMC2 84071 armadillo repeat containing 2 0.67 0.79 -0.11 0.063 
ARP10 164668 apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3H 0.84 0.88 -0.05 0.091 
ASAH1 427 N-acylsphingosine amidohydrolase (acid ceramidase) 1 0.02 0.01 0.01 0.053 
ASB14 142686 ankyrin repeat and SOCS box-containing 14 0.81 0.90 -0.08 0.042 
ASB2 51676 ankyrin repeat and SOCS box-containing 2 0.69 0.80 -0.12 0.053 
ASB3 51130 ankyrin repeat and SOCS box-containing 3 0.13 0.08 0.04 0.055 
ASB4 51666 ankyrin repeat and SOCS box-containing 4 0.72 0.79 -0.07 0.055 
ASB5 140458 ankyrin repeat and SOCS box-containing 5 0.88 0.92 -0.04 0.089 
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ASB8 140461 ankyrin repeat and SOCS box-containing 8 0.04 0.03 0.01 0.077 
ASCL3 56676 achaete-scute complex homolog 3 (Drosophila) 0.86 0.93 -0.06 0.059 
ASPA 443 aspartoacylase (Canavan disease) 0.49 0.63 -0.14 0.082 
ASZ1 136991 ankyrin repeat, SAM and basic leucine zipper domain containing 1 0.90 0.94 -0.04 0.090 
ATF7 11016 activating transcription factor 7 0.05 0.03 0.01 0.094 
ATF7IP2 80063 activating transcription factor 7 interacting protein 2 0.45 0.62 -0.17 0.060 
ATG10 83734 ATG10 autophagy related 10 homolog (S. cerevisiae) 0.04 0.02 0.01 0.094 
ATG7 10533 ATG7 autophagy related 7 homolog (S. cerevisiae) 0.39 0.48 -0.09 0.099 
ATP10A 57194 ATPase, class V, type 10A 0.50 0.68 -0.17 0.042 
ATP10A 57194 ATPase, class V, type 10A 0.86 0.93 -0.07 0.047 
ATP10A 57194 ATPase, class V, type 10A 0.74 0.83 -0.09 0.064 
ATP10A 57194 ATPase, class V, type 10A 0.88 0.92 -0.05 0.082 
ATP2B1 490 ATPase, Ca++ transporting, plasma membrane 1 0.86 0.91 -0.05 0.067 
ATP6V0D1 9114 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 0.02 0.01 0.00 0.094 
ATP6V1A 523 ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 0.09 0.05 0.04 0.064 
ATP6V1C2 245973 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C2 0.04 0.02 0.02 0.093 
ATP6V1F 9296 ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F 0.04 0.02 0.02 0.074 
ATP9A 10079 ATPase, class II, type 9A 0.79 0.89 -0.10 0.047 
ATP9B 374868 ATPase, class II, type 9B 0.02 0.01 0.01 0.047 
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ATPBD1C 51184 GPN-loop GTPase 3 0.06 0.03 0.03 0.057 
AVPR1A 552 arginine vasopressin receptor 1A 0.72 0.80 -0.08 0.096 
AVPR2 554 arginine vasopressin receptor 2 0.84 0.78 0.06 0.076 
B3GALT1 8708 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 0.86 0.92 -0.06 0.080 
B3GALT7 374907 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 0.49 0.62 -0.13 0.093 
B3GNT1 10678 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 0.80 0.91 -0.11 0.046 
BANF1 8815 barrier to autointegration factor 1 0.74 0.68 0.06 0.073 
BAPX1 579 NK3 homeobox 2 0.03 0.02 0.01 0.090 
BASP1 10409 brain abundant, membrane attached signal protein 1 0.04 0.02 0.02 0.086 
BAT2D1 23215 BAT2 domain containing 1 0.05 0.03 0.02 0.062 
BAZ2B 29994 bromodomain adjacent to zinc finger domain, 2B 0.77 0.86 -0.08 0.066 
BCAS2 10286 breast carcinoma amplified sequence 2 0.04 0.02 0.02 0.094 
BCL10 8915 B-cell CLL/lymphoma 10 0.80 0.73 0.06 0.090 
BCL2A1 597 BCL2-related protein A1 0.38 0.49 -0.12 0.056 
BCL2L13 23786 BCL2-like 13 (apoptosis facilitator) 0.03 0.02 0.02 0.066 
BFSP2 8419 beaded filament structural protein 2, phakinin 0.56 0.65 -0.08 0.089 
BIRC8 112401 baculoviral IAP repeat-containing 8 0.69 0.79 -0.10 0.094 
BLOC1S2 282991 biogenesis of lysosomal organelles complex-1, subunit 2 0.07 0.04 0.02 0.066 
BNIPL 149428 BCL2/adenovirus E1B 19kD interacting protein like 0.51 0.63 -0.12 0.066 
BRCA1 672 breast cancer 1, early onset 0.73 0.83 -0.10 0.059 
BRCA1 672 breast cancer 1, early onset 0.85 0.91 -0.06 0.073 
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BRCA1 672 breast cancer 1, early onset 0.25 0.35 -0.09 0.077 
BRIP1 83990 BRCA1 interacting protein C-terminal helicase 1 0.08 0.05 0.03 0.024 
BRSK1 84446 BR serine/threonine kinase 1 0.93 0.95 -0.03 0.055 
BRWD1 54014 bromodomain and WD repeat domain containing 1 0.04 0.01 0.03 0.083 
BTN2A1 11120 butyrophilin, subfamily 2, member A1 0.87 0.91 -0.05 0.056 
BTNL8 79908 butyrophilin-like 8 0.68 0.76 -0.08 0.095 
BXDC1 84154 ribosome production factor 2 homolog (S. cerevisiae) 0.04 0.02 0.02 0.073 
C10orf10 11067 chromosome 10 open reading frame 10 0.64 0.75 -0.11 0.071 
C10orf111 221060 chromosome 10 open reading frame 111 0.65 0.81 -0.16 0.047 
C10orf32 119032 chromosome 10 open reading frame 32 0.03 0.02 0.01 0.094 
C10orf63 219670 enkurin, TRPC channel interacting protein 0.05 0.03 0.02 0.087 
C10orf70 55847 CDGSH iron sulfur domain 1 0.03 0.02 0.01 0.073 
C11orf30 56946 chromosome 11 open reading frame 30 0.03 0.02 0.01 0.066 
C11orf44 283171 chromosome 11 open reading frame 44 0.87 0.84 0.04 0.082 
C11orf49 79096 chromosome 11 open reading frame 49 0.06 0.04 0.02 0.084 
C11orf54 28970 chromosome 11 open reading frame 54 0.03 0.02 0.01 0.063 
C12orf30 80018 chromosome 12 open reading frame 30 0.03 0.02 0.01 0.065 
C12orf31 84298 LLP homolog, long-term synaptic facilitation (Aplysia) 0.05 0.04 0.02 0.050 
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C12orf36 283422 chromosome 12 open reading frame 36 0.85 0.91 -0.06 0.081 
C12orf47 51275 chromosome 12 open reading frame 47 0.03 0.02 0.01 0.088 
C14orf112 51241 COX16 cytochrome c oxidase assembly homolog (S. cerevisiae) 0.05 0.03 0.02 0.080 
C14orf166B 145497 chromosome 14 open reading frame 166B 0.09 0.10 -0.02 0.094 
C14orf29 145447 abhydrolase domain containing 12B 0.67 0.80 -0.14 0.042 
C14orf48 256369 chromosome 14 open reading frame 48 0.79 0.89 -0.10 0.040 
C14orf68 283600 chromosome 14 open reading frame 68 0.97 0.98 -0.01 0.094 
C14orf8 122664 tubulin polymerization-promoting protein family member 2 0.61 0.71 -0.10 0.089 
C15orf15 51187 ribosomal L24 domain containing 1 0.01 0.01 0.00 0.052 
C15orf24 56851 chromosome 15 open reading frame 24 0.65 0.76 -0.11 0.076 
C15orf24 56851 chromosome 15 open reading frame 24 0.91 0.94 -0.03 0.087 
C15orf27 123591 chromosome 15 open reading frame 27 0.05 0.03 0.02 0.070 
C15orf32 145858 chromosome 15 open reading frame 32 0.78 0.83 -0.05 0.068 
C16orf34 90861 hematological and neurological expressed 1-like 0.03 0.02 0.01 0.053 
C16orf46 123775 chromosome 16 open reading frame 46 0.08 0.04 0.04 0.074 
C16orf47 388289 chromosome 16 open reading frame 47 0.63 0.75 -0.11 0.077 
C16orf60 55839 centromere protein N 0.03 0.02 0.01 0.062 
 
 
81 
 
Symbol Gene ID Gene Description Mean β PE 
Mean β 
NP ∆β FDR 
C16orf61 56942 chromosome 16 open reading frame 61 0.10 0.08 0.03 0.086 
C17orf61 254863 chromosome 17 open reading frame 61 0.02 0.01 0.01 0.065 
C18orf1 753 chromosome 18 open reading frame 1 0.02 0.01 0.01 0.042 
C18orf20 221241 chromosome 18 open reading frame 20 0.67 0.81 -0.13 0.038 
C18orf20 221241 chromosome 18 open reading frame 20 0.77 0.86 -0.10 0.052 
C18orf45 85019 chromosome 18 open reading frame 45 0.05 0.03 0.02 0.084 
C19orf12 83636 chromosome 19 open reading frame 12 0.05 0.03 0.02 0.090 
C19orf18 147685 chromosome 19 open reading frame 18 0.64 0.76 -0.13 0.068 
C19orf6 91304 chromosome 19 open reading frame 6 0.05 0.03 0.02 0.081 
C1orf105 92346 chromosome 1 open reading frame 105 0.80 0.88 -0.07 0.065 
C1orf107 27042 chromosome 1 open reading frame 107 0.11 0.04 0.06 0.085 
C1orf128 57095 chromosome 1 open reading frame 128 0.03 0.02 0.01 0.081 
C1orf128 57095 chromosome 1 open reading frame 128 0.04 0.03 0.01 0.094 
C1orf150 148823 chromosome 1 open reading frame 150 0.73 0.81 -0.07 0.080 
C1orf162 128346 chromosome 1 open reading frame 162 0.74 0.83 -0.09 0.039 
C1orf188 148646 chromosome 1 open reading frame 188 0.74 0.80 -0.06 0.081 
C1orf198 84886 chromosome 1 open reading frame 198 0.13 0.07 0.06 0.074 
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C1orf201 90529 chromosome 1 open reading frame 201 0.89 0.94 -0.05 0.065 
C1orf59 113802 chromosome 1 open reading frame 59 0.06 0.03 0.03 0.077 
C1orf62 254268 chromosome 1 open reading frame 62 0.62 0.79 -0.17 0.038 
C1orf62 254268 chromosome 1 open reading frame 62 0.62 0.75 -0.13 0.054 
C1orf74 148304 chromosome 1 open reading frame 74 0.03 0.03 0.01 0.065 
C1orf83 127428 chromosome 1 open reading frame 83 0.04 0.02 0.02 0.038 
C1QTNF4 114900 C1q and tumor necrosis factor related protein 4 0.49 0.65 -0.16 0.073 
C1RL 51279 complement component 1, r subcomponent-like 0.03 0.02 0.01 0.053 
C1S 716 complement component 1, s subcomponent 0.41 0.34 0.07 0.092 
C20orf114 92747 chromosome 20 open reading frame 114 0.83 0.77 0.05 0.090 
C20orf116 65992 DDRGK domain containing 1 0.87 0.93 -0.06 0.053 
C20orf135 140701 chromosome 20 open reading frame 135 0.64 0.77 -0.13 0.085 
C20orf173 140873 chromosome 20 open reading frame 173 0.80 0.86 -0.06 0.080 
C20orf179 140836 barrier to autointegration factor 2 0.75 0.82 -0.07 0.074 
C20orf20 55257 chromosome 20 open reading frame 20 0.07 0.03 0.03 0.086 
C20orf31 55741 ER degradation enhancer, mannosidase alpha-like 2 0.04 0.02 0.02 0.076 
C20orf38 55304 serine palmitoyltransferase, long chain base subunit 3 0.11 0.07 0.03 0.086 
C20orf52 140823 reactive oxygen species modulator 1 0.06 0.03 0.03 0.050 
C20orf54 113278 chromosome 20 open reading frame 54 0.74 0.84 -0.09 0.093 
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C20orf70 140683 chromosome 20 open reading frame 70 0.52 0.64 -0.12 0.058 
C20orf79 140856 chromosome 20 open reading frame 79 0.71 0.85 -0.14 0.083 
C21orf6 10069 RWD domain containing 2B 0.06 0.14 -0.08 0.050 
C21orf77 55264 chromosome 21 open reading frame 77 0.70 0.74 -0.04 0.086 
C21orf99 149992 chromosome 21 open reading frame 99 0.28 0.19 0.09 0.060 
C22orf18 79019 centromere protein M 0.03 0.01 0.01 0.098 
C2orf7 84279 chromosome 2 open reading frame 7 0.92 0.94 -0.02 0.082 
C3orf24 115795 chromosome 3 open reading frame 24 0.87 0.94 -0.07 0.047 
C3orf45 132228 chromosome 3 open reading frame 45 0.77 0.90 -0.13 0.024 
C5orf20 140947 chromosome 5 open reading frame 20 0.56 0.67 -0.11 0.065 
C5orf3 10827 family with sequence similarity 114, member A2 0.02 0.01 0.01 0.059 
C6orf108 10591 chromosome 6 open reading frame 108 0.08 0.04 0.03 0.080 
C6orf111 25957 splicing factor, arginine/serine-rich 18 0.63 0.77 -0.13 0.053 
C6orf141 135398 chromosome 6 open reading frame 141 0.15 0.10 0.06 0.050 
C6orf15 29113 chromosome 6 open reading frame 15 0.76 0.85 -0.09 0.045 
C6orf151 154007 small nuclear ribonucleoprotein 48kDa (U11/U12) 0.05 0.03 0.02 0.076 
C6orf204 387119 chromosome 6 open reading frame 204 0.52 0.64 -0.13 0.074 
C6orf32 9750 family with sequence similarity 65, member B 0.88 0.83 0.05 0.046 
C6orf72 116254 chromosome 6 open reading frame 72 0.02 0.01 0.01 0.066 
C6orf81 221481 chromosome 6 open reading frame 81 0.69 0.77 -0.08 0.081 
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C6orf89 221477 chromosome 6 open reading frame 89 0.08 0.05 0.03 0.081 
C7orf16 10842 chromosome 7 open reading frame 16 0.62 0.76 -0.14 0.063 
C7orf23 79161 chromosome 7 open reading frame 23 0.05 0.03 0.02 0.050 
C7orf33 202865 chromosome 7 open reading frame 33 0.75 0.87 -0.12 0.090 
C7orf9 64111 neuropeptide VF precursor 0.77 0.85 -0.08 0.090 
C8A 731 complement component 8, alpha polypeptide 0.82 0.91 -0.09 0.053 
C8B 732 complement component 8, beta polypeptide 0.66 0.77 -0.11 0.047 
C8orf17 56988 chromosome 8 open reading frame 17 0.92 0.96 -0.04 0.038 
C8ORFK32 51059 family with sequence similarity 135, member B 0.62 0.70 -0.08 0.093 
C9orf10 23196 family with sequence similarity 120A 0.03 0.02 0.01 0.056 
C9orf138 158297 family with sequence similarity 154, member A 0.86 0.79 0.07 0.083 
C9orf23 138716 chromosome 9 open reading frame 23 0.06 0.05 0.02 0.085 
C9orf24 84688 chromosome 9 open reading frame 24 0.73 0.82 -0.09 0.047 
C9orf40 55071 chromosome 9 open reading frame 40 0.07 0.04 0.03 0.047 
C9orf45 81571 chromosome 9 open reading frame 45 0.76 0.89 -0.12 0.038 
C9orf48 347240 kinesin family member 24 0.76 0.84 -0.08 0.075 
C9orf48 347240 kinesin family member 24 0.81 0.86 -0.05 0.078 
C9orf64 84267 chromosome 9 open reading frame 64 0.46 0.36 0.10 0.080 
C9orf72 203228 chromosome 9 open reading frame 72 0.03 0.02 0.01 0.085 
CA4 762 carbonic anhydrase IV 0.06 0.02 0.04 0.090 
CA6 765 carbonic anhydrase VI 0.81 0.93 -0.12 0.074 
CABYR 26256 calcium binding tyrosine-(Y)-phosphorylation regulated 0.04 0.02 0.02 0.045 
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CACNG1 786 calcium channel, voltage-dependent, gamma subunit 1 0.09 0.13 -0.04 0.093 
CALCA 796 calcitonin-related polypeptide alpha 0.08 0.05 0.03 0.077 
CAMK2A 815 calcium/calmodulin-dependent protein kinase II alpha 0.58 0.75 -0.18 0.052 
CAMSAP1 157922 calmodulin regulated spectrin-associated protein 1 0.61 0.68 -0.07 0.063 
CAMSAP1 157922 calmodulin regulated spectrin-associated protein 1 0.50 0.63 -0.13 0.085 
CANT1 124583 calcium activated nucleotidase 1 0.03 0.02 0.01 0.063 
CAPN6 827 calpain 6 0.14 0.10 0.05 0.100 
CAPS 828 calcyphosine 0.84 0.88 -0.04 0.090 
CASC3 22794 cancer susceptibility candidate 3 0.05 0.03 0.02 0.079 
CASP3 836 caspase 3, apoptosis-related cysteine peptidase 0.87 0.92 -0.05 0.080 
CASP8AP2 9994 caspase 8 associated protein 2 0.03 0.02 0.01 0.086 
CASQ1 844 calsequestrin 1 (fast-twitch, skeletal muscle) 0.91 0.95 -0.04 0.081 
CASZ1 54897 castor zinc finger 1 0.03 0.02 0.01 0.099 
CATSPER1 117144 cation channel, sperm associated 1 0.72 0.83 -0.11 0.066 
CATSPER2 117155 cation channel, sperm associated 2 0.66 0.79 -0.13 0.063 
CBWD1 55871 COBW domain containing 1 0.05 0.03 0.02 0.099 
CCAR1 55749 cell division cycle and apoptosis regulator 1 0.03 0.02 0.01 0.087 
CCBP2 1238 chemokine binding protein 2 0.93 0.95 -0.03 0.084 
CCDC17 149483 coiled-coil domain containing 17 0.62 0.71 -0.09 0.064 
CCDC41 51134 coiled-coil domain containing 41 0.04 0.02 0.02 0.075 
CCDC48 79825 coiled-coil domain containing 48 0.84 0.90 -0.06 0.083 
CCDC55 84081 coiled-coil domain containing 55 0.90 0.93 -0.03 0.074 
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CCKAR 886 cholecystokinin A receptor 0.47 0.57 -0.11 0.081 
CCL1 6346 chemokine (C-C motif) ligand 1 0.77 0.85 -0.08 0.069 
CCL13 6357 chemokine (C-C motif) ligand 13 0.89 0.93 -0.05 0.062 
CCL21 6366 chemokine (C-C motif) ligand 21 0.72 0.80 -0.08 0.065 
CCL22 6367 chemokine (C-C motif) ligand 22 0.86 0.93 -0.07 0.046 
CCL23 6368 chemokine (C-C motif) ligand 23 0.46 0.61 -0.15 0.052 
CCL5 6352 chemokine (C-C motif) ligand 5 0.70 0.82 -0.12 0.087 
CCNC 892 cyclin C 0.03 0.01 0.01 0.081 
CCND1 595 cyclin D1 0.81 0.88 -0.07 0.070 
CCND2 894 cyclin D2 0.16 0.08 0.08 0.055 
CCND2 894 cyclin D2 0.19 0.11 0.08 0.073 
CCNL1 57018 cyclin L1 0.06 0.04 0.02 0.100 
CCR8 1237 chemokine (C-C motif) receptor 8 0.88 0.92 -0.04 0.081 
CD160 11126 CD160 molecule 0.92 0.95 -0.03 0.074 
CD2BP2 10421 CD2 (cytoplasmic tail) binding protein 2 0.05 0.02 0.03 0.058 
CD300LG 146894 CD300 molecule-like family member g 0.86 0.77 0.09 0.089 
CD38 952 CD38 molecule 0.67 0.80 -0.12 0.043 
CD3D 915 CD3d molecule, delta (CD3-TCR complex) 0.91 0.88 0.03 0.053 
CD3G 917 CD3g molecule, gamma (CD3-TCR complex) 0.78 0.85 -0.07 0.080 
CD99L2 83692 CD99 molecule-like 2 0.74 0.87 -0.13 0.042 
CDC14A 8556 CDC14 cell division cycle 14 homolog A (S. cerevisiae) 0.02 0.01 0.01 0.047 
CDCA1 83540 NUF2, NDC80 kinetochore complex component, homolog (S. cerevisiae) 0.01 0.02 -0.01 0.090 
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CDCA8 55143 cell division cycle associated 8 0.05 0.02 0.03 0.088 
CDH1 999 cadherin 1, type 1, E-cadherin (epithelial) 0.44 0.61 -0.16 0.039 
CDH26 60437 cadherin-like 26 0.67 0.80 -0.12 0.046 
CDH3 1001 cadherin 3, type 1, P-cadherin (placental) 0.90 0.94 -0.04 0.099 
CDK2 1017 cyclin-dependent kinase 2 0.04 0.02 0.02 0.073 
CDK2AP1 8099 cyclin-dependent kinase 2 associated protein 1 0.03 0.02 0.01 0.077 
CDK3 1018 cyclin-dependent kinase 3 0.04 0.07 -0.03 0.081 
CDR1 1038 cerebellar degeneration-related protein 1, 34kDa 0.74 0.85 -0.11 0.042 
CDS2 8760 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 0.36 0.47 -0.11 0.079 
CDSN 1041 corneodesmosin 0.93 0.97 -0.04 0.063 
CDX1 1044 caudal type homeobox 1 0.93 0.96 -0.03 0.097 
CEACAM19 56971 carcinoembryonic antigen-related cell adhesion molecule 19 0.67 0.77 -0.11 0.065 
CEACAM7 1087 carcinoembryonic antigen-related cell adhesion molecule 7 0.84 0.91 -0.07 0.073 
CEACAM8 1088 carcinoembryonic antigen-related cell adhesion molecule 8 0.27 0.37 -0.10 0.038 
CEBPZ 10153 CCAAT/enhancer binding protein (C/EBP), zeta 0.03 0.02 0.01 0.080 
CECR5 27440 cat eye syndrome chromosome region, candidate 5 0.64 0.75 -0.11 0.041 
CECR5 27440 cat eye syndrome chromosome region, candidate 5 0.70 0.83 -0.14 0.053 
CEL 1056 carboxyl ester lipase (bile salt-stimulated lipase) 0.90 0.95 -0.04 0.065 
CEP350 9857 centrosomal protein 350kDa 0.04 0.03 0.01 0.074 
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CEPT1 10390 choline/ethanolamine phosphotransferase 1 0.05 0.03 0.02 0.063 
CHCHD8 51287 coiled-coil-helix-coiled-coil-helix domain containing 8 0.03 0.02 0.01 0.094 
CHD2 1106 chromodomain helicase DNA binding protein 2 0.92 0.95 -0.03 0.074 
CHFR 55743 checkpoint with forkhead and ring finger domains 0.77 0.86 -0.09 0.053 
CHKA 1119 choline kinase alpha 0.07 0.03 0.04 0.073 
CHMP4B 128866 chromatin modifying protein 4B 0.83 0.90 -0.07 0.054 
CHMP5 51510 chromatin modifying protein 5 0.07 0.05 0.02 0.055 
CHN1 1123 chimerin (chimaerin) 1 0.05 0.03 0.02 0.074 
CHRM5 1133 cholinergic receptor, muscarinic 5 0.54 0.68 -0.14 0.055 
CHRNA1 1134 cholinergic receptor, nicotinic, alpha 1 (muscle) 0.88 0.93 -0.05 0.077 
CHRNA3 1136 cholinergic receptor, nicotinic, alpha 3 0.13 0.22 -0.09 0.082 
CHRNA4 1137 cholinergic receptor, nicotinic, alpha 4 0.19 0.29 -0.10 0.074 
CHRNA9 55584 cholinergic receptor, nicotinic, alpha 9 0.85 0.90 -0.05 0.080 
CHRND 1144 cholinergic receptor, nicotinic, delta 0.86 0.81 0.04 0.089 
CHST10 9486 carbohydrate sulfotransferase 10 0.08 0.05 0.03 0.087 
CHST11 50515 carbohydrate (chondroitin 4) sulfotransferase 11 0.55 0.76 -0.21 0.093 
CHST12 55501 carbohydrate (chondroitin 4) sulfotransferase 12 0.64 0.73 -0.09 0.099 
CIB3 117286 calcium and integrin binding family member 3 0.82 0.89 -0.07 0.040 
CIDEC 63924 cell death-inducing DFFA-like effector c 0.85 0.81 0.04 0.085 
CINP 51550 cyclin-dependent kinase 2-interacting protein 0.02 0.01 0.01 0.067 
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CIP29 84324 SAP domain containing ribonucleoprotein 0.03 0.02 0.01 0.089 
CIR 9541 corepressor interacting with RBPJ 0.51 0.69 -0.19 0.056 
CLC 1178 Charcot-Leyden crystal protein 0.81 0.88 -0.07 0.059 
CLCA2 9635 chloride channel accessory 2 0.74 0.82 -0.08 0.093 
CLCN3 1182 chloride channel 3 0.05 0.03 0.02 0.099 
CLDN10 9071 claudin 10 0.78 0.88 -0.10 0.076 
CLDN18 51208 claudin 18 0.63 0.77 -0.14 0.074 
CLDN18 51208 claudin 18 0.64 0.82 -0.18 0.077 
CLDN20 49861 claudin 20 0.71 0.82 -0.10 0.084 
CLDN8 9073 claudin 8 0.80 0.90 -0.10 0.042 
CLEC2D 29121 C-type lectin domain family 2, member D 0.75 0.81 -0.06 0.090 
CLMN 79789 calmin (calponin-like, transmembrane) 0.04 0.03 0.01 0.099 
CLPX 10845 ClpX caseinolytic peptidase X homolog (E. coli) 0.05 0.03 0.02 0.085 
CLTA 1211 clathrin, light chain (Lca) 0.05 0.02 0.03 0.066 
CLUL1 27098 clusterin-like 1 (retinal) 0.08 0.05 0.03 0.046 
CMTM5 116173 CKLF-like MARVEL transmembrane domain containing 5 0.93 0.96 -0.03 0.066 
CNN1 1264 calponin 1, basic, smooth muscle 0.37 0.54 -0.17 0.053 
CNOT8 9337 CCR4-NOT transcription complex, subunit 8 0.05 0.04 0.01 0.088 
CNR1 1268 cannabinoid receptor 1 (brain) 0.69 0.80 -0.12 0.074 
COCH 1690 coagulation factor C homolog, cochlin (Limulus polyphemus) 0.07 0.04 0.02 0.072 
COL11A2 1302 collagen, type XI, alpha 2 0.08 0.05 0.03 0.094 
COMMD2 51122 COMM domain containing 2 0.03 0.02 0.01 0.066 
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COPS5 10987 COP9 constitutive photomorphogenic homolog subunit 5 (Arabidopsis) 0.03 0.02 0.01 0.069 
COPS6 10980 COP9 constitutive photomorphogenic homolog subunit 6 (Arabidopsis) 0.04 0.03 0.02 0.098 
COPS7B 64708 COP9 constitutive photomorphogenic homolog subunit 7B (Arabidopsis) 0.22 0.13 0.09 0.065 
CORO1C 23603 coronin, actin binding protein, 1C 0.06 0.04 0.02 0.055 
CORO2B 10391 coronin, actin binding protein, 2B 0.89 0.92 -0.03 0.075 
CP110 9738 CP110 protein 0.06 0.04 0.02 0.094 
CPA2 1358 carboxypeptidase A2 (pancreatic) 0.63 0.72 -0.09 0.080 
CPA2 1358 carboxypeptidase A2 (pancreatic) 0.54 0.69 -0.14 0.080 
CPA4 51200 carboxypeptidase A4 0.88 0.91 -0.03 0.054 
CPB2 1361 carboxypeptidase B2 (plasma) 0.89 0.92 -0.03 0.083 
CPNE4 131034 copine IV 0.74 0.85 -0.11 0.024 
CPO 130749 carboxypeptidase O 0.72 0.82 -0.10 0.053 
CPO 130749 carboxypeptidase O 0.85 0.92 -0.07 0.054 
CREBL1 1388 activating transcription factor 6 beta 0.03 0.02 0.02 0.063 
CRH 1392 corticotropin releasing hormone 0.51 0.67 -0.17 0.042 
CRMP1 1400 collapsin response mediator protein 1 0.07 0.06 0.02 0.090 
CRSP6 9440 mediator complex subunit 17 0.02 0.01 0.01 0.096 
CRTAM 56253 cytotoxic and regulatory T cell molecule 0.50 0.67 -0.17 0.046 
CRYBA1 1411 crystallin, beta A1 0.77 0.86 -0.09 0.063 
CRYBA1 1411 crystallin, beta A1 0.91 0.95 -0.05 0.073 
CRYGC 1420 crystallin, gamma C 0.73 0.88 -0.14 0.074 
CSH2 1443 chorionic somatomammotropin hormone 2 0.94 0.91 0.03 0.053 
CST4 1472 cystatin S 0.82 0.91 -0.08 0.042 
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CST8 10047 cystatin 8 (cystatin-related epididymal specific) 0.72 0.82 -0.10 0.059 
CTCF 10664 CCCTC-binding factor (zinc finger protein) 0.03 0.02 0.01 0.070 
CTNNA3 29119 catenin (cadherin-associated protein), alpha 3 0.14 0.10 0.04 0.091 
CTPS 1503 CTP synthase 0.87 0.92 -0.05 0.065 
CTSE 1510 cathepsin E 0.75 0.88 -0.13 0.054 
CTTNBP2NL 55917 CTTNBP2 N-terminal like 0.10 0.04 0.06 0.055 
CTXN1 404217 cortexin 1 0.75 0.66 0.09 0.073 
CUEDC1 404093 CUE domain containing 1 0.60 0.69 -0.09 0.081 
CUL5 8065 cullin 5 0.08 0.05 0.04 0.064 
CUZD1 50624 CUB and zona pellucida-like domains 1 0.27 0.36 -0.09 0.063 
CWF19L2 143884 CWF19-like 2, cell cycle control (S. pombe) 0.83 0.90 -0.07 0.053 
CX62 84694 gap junction protein, alpha 10, 62kDa 0.76 0.84 -0.08 0.086 
CXCL16 58191 chemokine (C-X-C motif) ligand 16 0.97 0.98 -0.01 0.099 
CXCR3 2833 chemokine (C-X-C motif) receptor 3 0.52 0.61 -0.09 0.040 
CXorf15 55787 chromosome X open reading frame 15 0.05 0.02 0.03 0.047 
CXorf20 139105 BEN domain containing 2 0.53 0.66 -0.13 0.088 
CXorf45 79868 asparagine-linked glycosylation 13 homolog (S. cerevisiae) 0.54 0.67 -0.12 0.099 
CXorf9 54440 SAM and SH3 domain containing 3 0.63 0.70 -0.07 0.085 
CYCS 54205 cytochrome c, somatic 0.06 0.04 0.02 0.089 
CYP17A1 1586 cytochrome P450, family 17, subfamily A, polypeptide 1 0.60 0.71 -0.11 0.055 
CYP19A1 1588 cytochrome P450, family 19, subfamily A, polypeptide 1 0.82 0.90 -0.08 0.063 
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CYP2R1 120227 cytochrome P450, family 2, subfamily R, polypeptide 1 0.04 0.02 0.01 0.050 
CYP3A7 1551 cytochrome P450, family 3, subfamily A, polypeptide 7 0.73 0.81 -0.08 0.094 
CYP4F2 8529 cytochrome P450, family 4, subfamily F, polypeptide 2 0.63 0.74 -0.11 0.087 
CYP4Z1 199974 cytochrome P450, family 4, subfamily Z, polypeptide 1 0.56 0.66 -0.09 0.079 
CYP7B1 9420 cytochrome P450, family 7, subfamily B, polypeptide 1 0.71 0.85 -0.14 0.041 
CYSLTR2 57105 cysteinyl leukotriene receptor 2 0.78 0.87 -0.09 0.061 
DAO 1610 D-amino-acid oxidase 0.88 0.92 -0.04 0.050 
DAPK1 1612 death-associated protein kinase 1 0.59 0.73 -0.14 0.074 
DAPK3 1613 death-associated protein kinase 3 0.03 0.02 0.01 0.089 
DBT 1629 dihydrolipoamide branched chain transacylase E2 0.04 0.02 0.02 0.081 
DCAKD 79877 dephospho-CoA kinase domain containing 0.82 0.87 -0.06 0.065 
DCC 1630 deleted in colorectal carcinoma 0.09 0.06 0.04 0.038 
DCHS1 8642 dachsous 1 (Drosophila) 0.82 0.78 0.05 0.065 
DCLRE1C 64421 DNA cross-link repair 1C (PSO2 homolog, S. cerevisiae) 0.01 0.01 0.01 0.087 
DCST1 149095 DC-STAMP domain containing 1 0.84 0.91 -0.07 0.074 
DCST1 149095 DC-STAMP domain containing 1 0.15 0.20 -0.05 0.090 
DCTN4 51164 dynactin 4 (p62) 0.03 0.02 0.01 0.079 
DDX10 1662 DEAD (Asp-Glu-Ala-Asp) box polypeptide 10 0.05 0.03 0.01 0.094 
DDX19A 55308 DEAD (Asp-Glu-Ala-As) box polypeptide 19A 0.03 0.02 0.01 0.089 
 
 
93 
 
Symbol Gene ID Gene Description Mean β PE 
Mean β 
NP ∆β FDR 
DDX6 1656 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 0.09 0.06 0.02 0.084 
DEFA1 1667 defensin, alpha 1 0.58 0.69 -0.11 0.065 
DEFB1 1672 defensin, beta 1 0.62 0.53 0.09 0.089 
DEFB125 245938 defensin, beta 125 0.67 0.76 -0.09 0.067 
DEFB129 140881 defensin, beta 129 0.71 0.80 -0.09 0.074 
DENND2C 163259 DENN/MADD domain containing 2C 0.03 0.01 0.01 0.065 
DENND4C 55667 DENN/MADD domain containing 4C 0.55 0.68 -0.14 0.075 
DEPDC2 80243 
phosphatidylinositol-3,4,5-
trisphosphate-dependent Rac exchange 
factor 2 
0.05 0.04 0.01 0.087 
DERL1 79139 Der1-like domain family, member 1 0.04 0.02 0.01 0.080 
DHDH 27294 dihydrodiol dehydrogenase (dimeric) 0.77 0.88 -0.12 0.052 
DHRS8 51170 hydroxysteroid (17-beta) dehydrogenase 11 0.05 0.03 0.02 0.087 
DHTKD1 55526 dehydrogenase E1 and transketolase domain containing 1 0.07 0.04 0.03 0.100 
DHX16 8449 DEAH (Asp-Glu-Ala-His) box polypeptide 16 0.04 0.02 0.02 0.097 
DHX37 57647 DEAH (Asp-Glu-Ala-His) box polypeptide 37 0.83 0.92 -0.09 0.065 
DHX57 90957 DEAH (Asp-Glu-Ala-Asp/His) box polypeptide 57 0.36 0.49 -0.12 0.066 
DIPA 11007 coiled-coil domain containing 85B 0.05 0.03 0.02 0.063 
DIRAS3 9077 DIRAS family, GTP-binding RAS-like 3 0.27 0.42 -0.14 0.074 
DKFZp434N
035 84222 transmembrane protein 191A 0.84 0.92 -0.08 0.047 
DKFZp434O
0527 255101 coiled-coil domain containing 108 0.86 0.78 0.08 0.064 
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DKFZp727G
131 221786 chromosome 7 open reading frame 38 0.07 0.04 0.03 0.090 
DLK1 8788 delta-like 1 homolog (Drosophila) 0.04 0.02 0.01 0.066 
DLX5 1749 distal-less homeobox 5 0.07 0.03 0.04 0.046 
DLX5 1749 distal-less homeobox 5 0.03 0.02 0.01 0.097 
DMBX1 127343 diencephalon/mesencephalon homeobox 1 0.40 0.55 -0.16 0.088 
DNAH10 196385 dynein, axonemal, heavy chain 10 0.82 0.89 -0.07 0.065 
DNAH5 1767 dynein, axonemal, heavy chain 5 0.78 0.87 -0.09 0.042 
DNAH8 1769 dynein, axonemal, heavy chain 8 0.78 0.86 -0.07 0.080 
DNAHL1 284176 dynein, axonemal, heavy chain like 1 0.90 0.94 -0.04 0.063 
DNAI2 64446 dynein, axonemal, intermediate chain 2 0.83 0.92 -0.09 0.042 
DNAJA4 55466 DnaJ (Hsp40) homolog, subfamily A, member 4 0.81 0.89 -0.08 0.066 
DNAJC11 55735 DnaJ (Hsp40) homolog, subfamily C, member 11 0.71 0.80 -0.09 0.084 
DNAJC12 56521 DnaJ (Hsp40) homolog, subfamily C, member 12 0.85 0.89 -0.04 0.080 
DNAJC5G 285126 DnaJ (Hsp40) homolog, subfamily C, member 5 gamma 0.73 0.82 -0.09 0.099 
DNASE1 1773 deoxyribonuclease I 0.87 0.93 -0.06 0.053 
DNM1L 10059 dynamin 1-like 0.87 0.92 -0.05 0.063 
DNMBP 23268 dynamin binding protein 0.73 0.82 -0.09 0.098 
DNTT 1791 deoxynucleotidyltransferase, terminal 0.56 0.71 -0.15 0.038 
DNTT 1791 deoxynucleotidyltransferase, terminal 0.61 0.70 -0.09 0.099 
DOCK1 1793 dedicator of cytokinesis 1 0.93 0.91 0.02 0.047 
DOM3Z 1797 dom-3 homolog Z (C. elegans) 0.87 0.92 -0.05 0.080 
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DPF1 8193 D4, zinc and double PHD fingers family 1 0.11 0.06 0.04 0.065 
DPF1 8193 D4, zinc and double PHD fingers family 1 0.16 0.09 0.07 0.073 
DPM2 8818 
dolichyl-phosphate 
mannosyltransferase polypeptide 2, 
regulatory subunit 
0.03 0.02 0.01 0.065 
DPP6 1804 dipeptidyl-peptidase 6 0.77 0.84 -0.07 0.098 
DQX1 165545 DEAQ box RNA-dependent ATPase 1 0.06 0.08 -0.02 0.076 
DQX1 165545 DEAQ box RNA-dependent ATPase 1 0.79 0.87 -0.08 0.093 
DRD2 1813 dopamine receptor D2 0.91 0.94 -0.03 0.075 
DRP2 1821 dystrophin related protein 2 0.52 0.61 -0.10 0.073 
DSCR10 259234 Down syndrome critical region gene 10 0.85 0.91 -0.06 0.052 
DSU 55686 melanoregulin 0.05 0.02 0.03 0.094 
DTNBP1 84062 dystrobrevin binding protein 1 0.72 0.84 -0.11 0.052 
DUS2L 54920 dihydrouridine synthase 2-like, SMM1 homolog (S. cerevisiae) 0.02 0.01 0.01 0.068 
DUSP13 51207 dual specificity phosphatase 13 0.31 0.42 -0.11 0.065 
DUSP3 1845 dual specificity phosphatase 3 0.03 0.02 0.01 0.065 
DUSP4 1846 dual specificity phosphatase 4 0.04 0.03 0.01 0.075 
DYNC1LI2 1783 dynein, cytoplasmic 1, light intermediate chain 2 0.02 0.01 0.01 0.081 
DYNLT1 6993 dynein, light chain, Tctex-type 1 0.07 0.04 0.02 0.067 
DYRK4 8798 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 0.79 0.85 -0.06 0.067 
E2F5 1875 E2F transcription factor 5, p130-binding 0.03 0.02 0.01 0.090 
EAF2 55840 ELL associated factor 2 0.02 0.01 0.01 0.084 
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EBNA1BP2 10969 EBNA1 binding protein 2 0.05 0.03 0.02 0.071 
ECH1 1891 enoyl Coenzyme A hydratase 1, peroxisomal 0.03 0.01 0.01 0.059 
EDG7 23566 lysophosphatidic acid receptor 3 0.64 0.76 -0.12 0.099 
EDG8 53637 sphingosine-1-phosphate receptor 5 0.05 0.04 0.02 0.098 
EDN1 1906 endothelin 1 0.04 0.03 0.01 0.040 
EDNRB 1910 endothelin receptor type B 0.42 0.53 -0.11 0.100 
EEF1G 1937 eukaryotic translation elongation factor 1 gamma 0.03 0.02 0.01 0.080 
EFCAB1 79645 EF-hand calcium binding domain 1 0.83 0.89 -0.06 0.066 
EFHD1 80303 EF-hand domain family, member D1 0.11 0.07 0.04 0.090 
EFNB1 1947 ephrin-B1 0.22 0.31 -0.10 0.090 
EGFL7 51162 EGF-like-domain, multiple 7 0.45 0.60 -0.15 0.065 
EI24 9538 etoposide induced 2.4 mRNA 0.16 0.06 0.11 0.067 
EIF2AK1 27102 eukaryotic translation initiation factor 2-alpha kinase 1 0.03 0.02 0.01 0.074 
EIF2B3 8891 eukaryotic translation initiation factor 2B, subunit 3 gamma, 58kDa 0.02 0.01 0.01 0.065 
ELA2 1991 elastase, neutrophil expressed 0.56 0.68 -0.11 0.042 
ELAC1 55520 elaC homolog 1 (E. coli) 0.72 0.82 -0.10 0.082 
ELOF1 84337 elongation factor 1 homolog (S. cerevisiae) 0.76 0.86 -0.09 0.069 
ENDOGL1 9941 endo/exonuclease (5'-3'), endonuclease G-like 0.60 0.73 -0.14 0.047 
ENPP3 5169 ectonucleotide pyrophosphatase/phosphodiesterase 3 0.70 0.79 -0.09 0.065 
ENPP5 59084 
ectonucleotide 
pyrophosphatase/phosphodiesterase 5 
(putative function) 
0.04 0.03 0.01 0.074 
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ENTPD4 9583 ectonucleoside triphosphate diphosphohydrolase 4 0.82 0.86 -0.05 0.094 
ENTPD7 57089 ectonucleoside triphosphate diphosphohydrolase 7 0.05 0.03 0.02 0.099 
ENY2 56943 enhancer of yellow 2 homolog (Drosophila) 0.02 0.01 0.01 0.095 
EPB49 2039 erythrocyte membrane protein band 4.9 (dematin) 0.68 0.78 -0.09 0.065 
EPPB9 27077 B9 protein domain 1 0.64 0.76 -0.12 0.082 
EPS8L1 54869 EPS8-like 1 0.83 0.89 -0.06 0.070 
EPS8L3 79574 EPS8-like 3 0.20 0.27 -0.06 0.066 
EPS8L3 79574 EPS8-like 3 0.90 0.87 0.03 0.094 
ERAF 51327 erythroid associated factor 0.70 0.77 -0.07 0.074 
ERBB2 2064 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
0.08 0.06 0.02 0.065 
ERBB2 2064 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
0.04 0.02 0.01 0.081 
ERBB2IP 55914 erbb2 interacting protein 0.07 0.04 0.03 0.063 
ERCC1 2067 
excision repair cross-complementing 
rodent repair deficiency, 
complementation group 1 (includes 
overlapping antisense sequence) 
0.15 0.11 0.05 0.099 
ERCC6 2074 
excision repair cross-complementing 
rodent repair deficiency, 
complementation group 6 
0.03 0.02 0.01 0.070 
ERH 2079 enhancer of rudimentary homolog (Drosophila) 0.03 0.02 0.01 0.065 
ERMAP 114625 erythroblast membrane-associated protein (Scianna blood group) 0.04 0.02 0.02 0.025 
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ERV3 2086 
endogenous retroviral sequence 3 
(includes zinc finger protein H-
plk/HPF9) 
0.89 0.93 -0.04 0.039 
ERVWE1 30816 endogenous retroviral family W, env(C7), member 1 0.73 0.85 -0.12 0.047 
ETS1 2113 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 0.03 0.02 0.02 0.066 
ETS1 2113 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 0.03 0.02 0.01 0.067 
EVI5 7813 ecotropic viral integration site 5 0.87 0.92 -0.05 0.068 
EVPL 2125 envoplakin 0.06 0.10 -0.04 0.064 
EWSR1 2130 Ewing sarcoma breakpoint region 1 0.03 0.01 0.01 0.087 
EXOC1 55763 exocyst complex component 1 0.02 0.01 0.01 0.079 
EXOSC6 118460 exosome component 6 0.71 0.82 -0.11 0.042 
EXOSC9 5393 exosome component 9 0.04 0.02 0.02 0.046 
F12 2161 coagulation factor XII (Hageman factor) 0.86 0.91 -0.04 0.063 
F2 2147 coagulation factor II (thrombin) 0.82 0.87 -0.06 0.061 
F8A1 8263 coagulation factor VIII-associated (intronic transcript) 1 0.79 0.72 0.07 0.084 
FABP1 2168 fatty acid binding protein 1, liver 0.60 0.71 -0.11 0.047 
FABP4 2167 fatty acid binding protein 4, adipocyte 0.41 0.58 -0.16 0.050 
FAIM2 23017 Fas apoptotic inhibitory molecule 2 0.87 0.94 -0.07 0.042 
FALZ 2186 bromodomain PHD finger transcription factor 0.03 0.01 0.02 0.099 
FAM113A 64773 family with sequence similarity 113, member A 0.84 0.92 -0.09 0.045 
FAM71B 153745 family with sequence similarity 71, member B 0.66 0.80 -0.15 0.065 
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FAM76A 199870 family with sequence similarity 76, member A 0.03 0.01 0.01 0.094 
FAM83A 84985 family with sequence similarity 83, member A 0.54 0.67 -0.14 0.053 
FAM86A 196483 family with sequence similarity 86, member A 0.02 0.01 0.01 0.078 
FAM9A 171482 family with sequence similarity 9, member A 0.92 0.94 -0.02 0.065 
FBLN1 2192 fibulin 1 0.82 0.86 -0.04 0.088 
FBP1 2203 fructose-1,6-bisphosphatase 1 0.11 0.07 0.04 0.074 
FBXL19 54620 F-box and leucine-rich repeat protein 19 0.82 0.87 -0.06 0.074 
FBXO15 201456 F-box protein 15 0.09 0.05 0.05 0.071 
FBXO28 23219 F-box protein 28 0.02 0.01 0.01 0.066 
FBXO28 23219 F-box protein 28 0.04 0.02 0.02 0.074 
FBXO44 93611 F-box protein 44 0.84 0.89 -0.05 0.080 
FBXO5 26271 F-box protein 5 0.03 0.01 0.01 0.085 
FCGR2A 2212 Fc fragment of IgG, low affinity IIa, receptor (CD32) 0.86 0.91 -0.06 0.053 
FCN3 8547 ficolin (collagen/fibrinogen domain containing) 3 (Hakata antigen) 0.92 0.89 0.03 0.088 
FCRL3 115352 Fc receptor-like 3 0.57 0.69 -0.12 0.086 
FDPS 2224 
farnesyl diphosphate synthase 
(farnesyl pyrophosphate synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase) 
0.03 0.02 0.01 0.074 
FECH 2235 ferrochelatase (protoporphyria) 0.07 0.03 0.04 0.074 
FEN1 2237 flap structure-specific endonuclease 1 0.03 0.02 0.01 0.065 
FEN1 2237 flap structure-specific endonuclease 1 0.06 0.02 0.04 0.074 
FERD3L 222894 Fer3-like (Drosophila) 0.07 0.04 0.03 0.080 
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FGF19 9965 fibroblast growth factor 19 0.55 0.45 0.09 0.090 
FGF21 26291 fibroblast growth factor 21 0.90 0.86 0.04 0.074 
FHIT 2272 fragile histidine triad gene 0.29 0.21 0.08 0.063 
FHL1 2273 four and a half LIM domains 1 0.75 0.85 -0.10 0.065 
FHL3 2275 four and a half LIM domains 3 0.06 0.03 0.04 0.098 
FKBP4 2288 FK506 binding protein 4, 59kDa 0.85 0.91 -0.06 0.056 
FKBP5 2289 FK506 binding protein 5 0.67 0.75 -0.08 0.042 
FKSG2 59347 apoptosis inhibitor 0.89 0.92 -0.04 0.094 
FLJ10379 55133 S1 RNA binding domain 1 0.73 0.81 -0.08 0.089 
FLJ10916 55258 threonine synthase-like 2 (S. cerevisiae) 0.64 0.79 -0.15 0.066 
FLJ13614 84142 family with sequence similarity 175, member A 0.05 0.03 0.02 0.081 
FLJ14437 84665 myopalladin 0.76 0.85 -0.09 0.067 
FLJ14437 84665 myopalladin 0.59 0.74 -0.15 0.074 
FLJ20130 54830 nucleoporin 62kDa C-terminal like 0.75 0.65 0.10 0.065 
FLJ20364 54908 coiled-coil domain containing 99 0.04 0.03 0.02 0.074 
FLJ20718 55027 HEAT repeat containing 3 0.83 0.89 -0.06 0.073 
FLJ21103 79607 family with sequence similarity 118, member B 0.71 0.80 -0.10 0.074 
FLJ21736 79984 esterase 31 0.58 0.68 -0.10 0.074 
FLJ21827 56912 chromosome 11 open reading frame 60 0.07 0.03 0.03 0.047 
FLJ21908 79657 RNA polymerase II associated protein 3 0.07 0.04 0.02 0.094 
FLJ22222 79701 chromosome 17 open reading frame 101 0.07 0.04 0.02 0.080 
FLJ22555 79568 chromosome 2 open reading frame 47 0.84 0.89 -0.05 0.073 
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FLJ22624 79866 chromosome 13 open reading frame 34 0.05 0.03 0.03 0.081 
FLJ23322 80020 FAD-dependent oxidoreductase domain containing 2 0.77 0.87 -0.10 0.075 
FLJ23356 84197 protein kinase-like protein SgK196 0.03 0.02 0.02 0.086 
FLJ25006 124923 uncharacterized serine/threonine-protein kinase SgK494 0.61 0.75 -0.13 0.094 
FLJ25067 149840 chromosome 20 open reading frame 196 0.15 0.12 0.04 0.067 
FLJ25084 151516 aspartic peptidase, retroviral-like 1 0.61 0.70 -0.09 0.068 
FLJ25369 200523 chromosome 2 open reading frame 51 0.78 0.85 -0.07 0.065 
FLJ25530 220296 hepatic and glial cell adhesion molecule 0.69 0.81 -0.12 0.047 
FLJ25976 283579 chromosome 14 open reading frame 178 0.51 0.65 -0.14 0.082 
FLJ30294 130827 transmembrane protein 182 0.65 0.74 -0.09 0.047 
FLJ32028 201799 transmembrane protein 154 0.63 0.77 -0.15 0.053 
FLJ32065 201283 hypothetical protein FLJ32065 0.03 0.02 0.01 0.054 
FLJ32065 201283 hypothetical protein FLJ32065 0.81 0.91 -0.10 0.065 
FLJ32206 149421 chromosome 1 open reading frame 215 0.58 0.73 -0.15 0.081 
FLJ32894 144360 chromosome 12 open reading frame 67 0.77 0.85 -0.08 0.088 
FLJ33534 285150 hypothetical LOC285150 0.52 0.67 -0.15 0.067 
FLJ33790 283212 kelch-like 35 (Drosophila) 0.04 0.03 0.02 0.048 
FLJ35784 374877 chromosome 19 open reading frame 45 0.78 0.85 -0.07 0.043 
FLJ35785 283796 golgin A8 family, member I, pseudogene 0.74 0.80 -0.06 0.090 
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FLJ35801 150291 chromosome 22 open reading frame 27 0.64 0.52 0.12 0.081 
FLJ35894 283847 coiled-coil domain containing 79 0.90 0.94 -0.04 0.073 
FLJ37078 222183 hypothetical protein FLJ37078 0.47 0.57 -0.10 0.088 
FLJ37587 283446 myosin IH 0.74 0.83 -0.09 0.042 
FLJ37587 283446 myosin IH 0.77 0.71 0.06 0.053 
FLJ38379 285097 hypothetical FLJ38379 0.47 0.62 -0.14 0.047 
FLJ38451 126375 zinc finger protein 792 0.86 0.93 -0.07 0.053 
FLJ40142 400073 chromosome 12 open reading frame 76 0.93 0.96 -0.03 0.054 
FLJ40288 286023 hypothetical FLJ40288 0.53 0.74 -0.21 0.086 
FLJ40919 144809 chromosome 13 open reading frame 30 0.70 0.78 -0.08 0.079 
FLJ41131 284325 chromosome 19 open reading frame 54 0.03 0.02 0.01 0.086 
FLJ42291 346547 hypothetical LOC346547 0.49 0.61 -0.12 0.073 
FLJ43582 389649 chromosome 8 open reading frame 86 0.95 0.97 -0.02 0.056 
FLJ44186 346689 killer cell lectin-like receptor subfamily G, member 2 0.67 0.79 -0.12 0.038 
FLJ44691 345193 leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 0.71 0.85 -0.13 0.057 
FLJ45909 126432 Ras and Rab interactor-like 0.67 0.79 -0.12 0.072 
FLJ90650 206338 laeverin 0.74 0.83 -0.09 0.050 
FLJ90805 284339 transmembrane protein 145 0.10 0.07 0.03 0.094 
FLT3LG 2323 fms-related tyrosine kinase 3 ligand 0.05 0.02 0.02 0.094 
FMO1 2326 flavin containing monooxygenase 1 0.66 0.72 -0.07 0.080 
FMO3 2328 flavin containing monooxygenase 3 0.87 0.91 -0.05 0.080 
FMO5 2330 flavin containing monooxygenase 5 0.07 0.04 0.03 0.090 
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FNDC3B 64778 fibronectin type III domain containing 3B 0.88 0.93 -0.05 0.065 
FNDC3B 64778 fibronectin type III domain containing 3B 0.81 0.93 -0.12 0.065 
FNDC8 54752 fibronectin type III domain containing 8 0.73 0.81 -0.08 0.050 
FNDC8 54752 fibronectin type III domain containing 8 0.15 0.10 0.06 0.089 
FNTB 2342 farnesyltransferase, CAAX box, beta 0.06 0.03 0.03 0.066 
FOLR2 2350 folate receptor 2 (fetal) 0.80 0.88 -0.08 0.073 
FOS 2353 v-fos FBJ murine osteosarcoma viral oncogene homolog 0.01 0.01 0.01 0.074 
FOXD4L4 349334 forkhead box D4-like 4 0.04 0.06 -0.02 0.062 
FOXN1 8456 forkhead box N1 0.85 0.94 -0.09 0.025 
FRMD4A 55691 FERM domain containing 4A 0.69 0.58 0.12 0.077 
FSIP1 161835 fibrous sheath interacting protein 1 0.07 0.04 0.03 0.070 
FTMT 94033 ferritin mitochondrial 0.80 0.91 -0.12 0.066 
FURIN 5045 furin (paired basic amino acid cleaving enzyme) 0.33 0.39 -0.06 0.099 
FUT5 2527 fucosyltransferase 5 (alpha (1,3) fucosyltransferase) 0.67 0.77 -0.10 0.065 
FXC1 26515 fracture callus 1 homolog (rat) 0.80 0.91 -0.11 0.042 
FYTTD1 84248 forty-two-three domain containing 1 0.05 0.03 0.02 0.046 
FZD4 8322 frizzled homolog 4 (Drosophila) 0.03 0.02 0.01 0.089 
G1P2 9636 ISG15 ubiquitin-like modifier 0.04 0.02 0.02 0.094 
GABPA 2551 GA binding protein transcription factor, alpha subunit 60kDa 0.05 0.02 0.03 0.065 
GABRA5 2558 gamma-aminobutyric acid (GABA) A receptor, alpha 5 0.20 0.30 -0.11 0.042 
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GALNT13 114805 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 13 
(GalNAc-T13) 
0.32 0.51 -0.19 0.054 
GALNT6 11226 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 
(GalNAc-T6) 
0.81 0.88 -0.07 0.042 
GAP43 2596 growth associated protein 43 0.03 0.02 0.01 0.065 
GAS7 8522 growth arrest-specific 7 0.06 0.04 0.02 0.075 
GAS8 2622 growth arrest-specific 8 0.02 0.02 0.01 0.074 
GATA1 2623 GATA binding protein 1 (globin transcription factor 1) 0.65 0.78 -0.13 0.047 
GATA5 140628 GATA binding protein 5 0.90 0.86 0.04 0.094 
GCA 25801 grancalcin, EF-hand calcium binding protein 0.06 0.04 0.03 0.086 
GCDH 2639 glutaryl-Coenzyme A dehydrogenase 0.03 0.02 0.01 0.050 
GCK 2645 glucokinase (hexokinase 4) 0.85 0.91 -0.06 0.087 
GCNT2 2651 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) 0.67 0.76 -0.09 0.065 
Gcom1 145781 GRINL1A complex locus 0.10 0.15 -0.05 0.088 
GFRA2 2675 GDNF family receptor alpha 2 0.90 0.96 -0.06 0.074 
GGA2 23062 golgi associated, gamma adaptin ear containing, ARF binding protein 2 0.05 0.03 0.02 0.065 
GGPS1 9453 geranylgeranyl diphosphate synthase 1 0.10 0.06 0.04 0.065 
GIMAP7 168537 GTPase, IMAP family member 7 0.78 0.86 -0.08 0.064 
GIPR 2696 gastric inhibitory polypeptide receptor 0.65 0.78 -0.12 0.056 
GJB1 2705 gap junction protein, beta 1, 32kDa 0.86 0.90 -0.05 0.053 
GJB6 10804 gap junction protein, beta 6, 30kDa 0.71 0.81 -0.10 0.081 
GK 2710 glycerol kinase 0.73 0.80 -0.06 0.089 
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GLI3 2737 GLI family zinc finger 3 0.03 0.02 0.01 0.064 
GLO1 2739 glyoxalase I 0.03 0.02 0.01 0.047 
GLT28D1 55849 asparagine-linked glycosylation 13 homolog (S. cerevisiae) 0.89 0.92 -0.03 0.081 
GLTSCR1 29998 glioma tumor suppressor candidate region gene 1 0.76 0.85 -0.09 0.050 
GLTSCR1 29998 glioma tumor suppressor candidate region gene 1 0.74 0.82 -0.08 0.096 
GLULD1 51557 lengsin, lens protein with glutamine synthetase domain 0.89 0.93 -0.04 0.050 
GMCL1L 64396 germ cell-less homolog 1 (Drosophila) 0.81 0.89 -0.07 0.050 
GNAO1 2775 
guanine nucleotide binding protein (G 
protein), alpha activating activity 
polypeptide O 
0.03 0.02 0.01 0.089 
GNAS 2778 GNAS complex locus 0.25 0.36 -0.11 0.048 
GNAS 2778 GNAS complex locus 0.46 0.56 -0.11 0.093 
GNB1L 54584 guanine nucleotide binding protein (G protein), beta polypeptide 1-like 0.02 0.01 0.01 0.074 
GNG4 2786 guanine nucleotide binding protein (G protein), gamma 4 0.10 0.05 0.05 0.067 
GNG7 2788 guanine nucleotide binding protein (G protein), gamma 7 0.53 0.67 -0.14 0.056 
GOLGA2L1 55592 golgi autoantigen, golgin subfamily a, 2-like 1 0.91 0.94 -0.03 0.085 
GOLPH2 51280 golgi membrane protein 1 0.10 0.05 0.05 0.099 
GORASP1 64689 golgi reassembly stacking protein 1, 65kDa 0.08 0.04 0.04 0.065 
GOSR2 9570 golgi SNAP receptor complex member 2 0.06 0.04 0.03 0.064 
GOSR2 9570 golgi SNAP receptor complex member 2 0.02 0.01 0.01 0.093 
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GP1BA 2811 glycoprotein Ib (platelet), alpha polypeptide 0.69 0.81 -0.12 0.063 
GP2 2813 glycoprotein 2 (zymogen granule membrane) 0.62 0.73 -0.11 0.094 
GP5 2814 glycoprotein V (platelet) 0.82 0.89 -0.07 0.063 
GPAA1 8733 glycosylphosphatidylinositol anchor attachment protein 1 homolog (yeast) 0.04 0.02 0.02 0.064 
GPATC2 55105 G patch domain containing 2 0.60 0.74 -0.14 0.052 
GPC4 2239 glypican 4 0.85 0.91 -0.06 0.076 
GPR1 2825 G protein-coupled receptor 1 0.65 0.79 -0.14 0.042 
GPR115 221393 G protein-coupled receptor 115 0.17 0.29 -0.11 0.094 
GPR12 2835 G protein-coupled receptor 12 0.59 0.70 -0.10 0.074 
GPR137B 7107 G protein-coupled receptor 137B 0.02 0.01 0.01 0.093 
GPR15 2838 G protein-coupled receptor 15 0.78 0.87 -0.09 0.082 
GPR156 165829 G protein-coupled receptor 156 0.23 0.34 -0.11 0.055 
GPR173 54328 G protein-coupled receptor 173 0.89 0.94 -0.05 0.050 
GPR175 131601 G protein-coupled receptor 175 0.91 0.95 -0.03 0.068 
GPR3 2827 G protein-coupled receptor 3 0.05 0.03 0.02 0.095 
GPR31 2853 G protein-coupled receptor 31 0.89 0.92 -0.03 0.074 
GPR37L1 9283 G protein-coupled receptor 37 like 1 0.81 0.86 -0.05 0.089 
GPR61 83873 G protein-coupled receptor 61 0.80 0.87 -0.08 0.064 
GPRC5D 55507 G protein-coupled receptor, family C, group 5, member D 0.55 0.67 -0.12 0.097 
GPSM1 26086 G-protein signaling modulator 1 (AGS3-like, C. elegans) 0.21 0.28 -0.07 0.046 
GPSM1 26086 G-protein signaling modulator 1 (AGS3-like, C. elegans) 0.79 0.88 -0.09 0.046 
GPSN2 9524 glycoprotein, synaptic 2 0.13 0.09 0.04 0.042 
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GPSN2 9524 glycoprotein, synaptic 2 0.08 0.05 0.02 0.079 
GPT 2875 glutamic-pyruvate transaminase (alanine aminotransferase) 0.04 0.05 -0.01 0.097 
GRLF1 2909 glucocorticoid receptor DNA binding factor 1 0.93 0.96 -0.03 0.095 
GRTP1 79774 growth hormone regulated TBC protein 1 0.93 0.97 -0.04 0.067 
GSG1 83445 germ cell associated 1 0.89 0.94 -0.05 0.053 
GSTM4 2948 glutathione S-transferase mu 4 0.89 0.94 -0.05 0.038 
GSTP1 2950 glutathione S-transferase pi 1 0.85 0.91 -0.06 0.067 
GUCY2C 2984 guanylate cyclase 2C (heat stable enterotoxin receptor) 0.64 0.76 -0.12 0.050 
GYG1 2992 glycogenin 1 0.06 0.03 0.03 0.099 
GYPA 2993 glycophorin A (MNS blood group) 0.90 0.88 0.02 0.065 
GYS2 2998 glycogen synthase 2 (liver) 0.80 0.90 -0.10 0.038 
H19 283120 H19, imprinted maternally expressed transcript (non-protein coding) 0.87 0.81 0.06 0.071 
H19 283120 H19, imprinted maternally expressed transcript (non-protein coding) 0.89 0.85 0.04 0.088 
H1F0 3005 H1 histone family, member 0 0.76 0.85 -0.09 0.074 
H1T2 341567 H1 histone family, member N, testis-specific 0.22 0.28 -0.06 0.070 
HAL 3034 histidine ammonia-lyase 0.83 0.90 -0.07 0.053 
HAO1 54363 hydroxyacid oxidase (glycolate oxidase) 1 0.56 0.66 -0.10 0.074 
HAPLN2 60484 hyaluronan and proteoglycan link protein 2 0.49 0.39 0.10 0.078 
HBB 3043 hemoglobin, beta 0.68 0.79 -0.11 0.053 
HBII-437 338427 small nucleolar RNA, C/D box 108 0.79 0.87 -0.08 0.067 
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HCLS1 3059 hematopoietic cell-specific Lyn substrate 1 0.59 0.70 -0.11 0.080 
HCRTR1 3061 hypocretin (orexin) receptor 1 0.67 0.82 -0.15 0.052 
HDAC9 9734 histone deacetylase 9 0.07 0.05 0.02 0.086 
HES1 3280 hairy and enhancer of split 1, (Drosophila) 0.03 0.02 0.01 0.050 
HGFAC 3083 HGF activator 0.45 0.57 -0.13 0.065 
HHLA1 10086 HERV-H LTR-associating 1 0.90 0.82 0.08 0.025 
HHLA3 11147 HERV-H LTR-associating 3 0.04 0.02 0.02 0.053 
HINT1 3094 histidine triad nucleotide binding protein 1 0.06 0.04 0.02 0.062 
HINT2 84681 histidine triad nucleotide binding protein 2 0.03 0.01 0.01 0.066 
HIPK4 147746 homeodomain interacting protein kinase 4 0.76 0.72 0.04 0.093 
HIST1H2AH 85235 histone cluster 1, H2a 0.04 0.02 0.02 0.087 
HIST1H2AM 8336 histone cluster 1, H2am 0.03 0.02 0.01 0.086 
HIST1H2BD 3017 histone cluster 1, H2bd 0.06 0.04 0.02 0.065 
HIST1H3B 8358 histone cluster 1, H3b 0.02 0.02 0.01 0.063 
HIST1H3H 8357 histone cluster 1, H4d 0.08 0.05 0.04 0.040 
HIST1H4D 8360 histone cluster 1, H3h 0.05 0.03 0.02 0.075 
HK1 3098 hexokinase 1 0.63 0.71 -0.07 0.073 
HKR1 284459 GLI-Kruppel family member HKR1 0.94 0.96 -0.02 0.055 
HMG20B 10362 high-mobility group 20B 0.97 0.98 -0.01 0.080 
HMGCL 3155 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 0.95 0.97 -0.02 0.085 
HMP19 51617 HMP19 protein 0.01 0.01 0.00 0.062 
HNF4A 3172 hepatocyte nuclear factor 4, alpha 0.90 0.87 0.04 0.060 
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HNRPA3 220988 heterogeneous nuclear ribonucleoprotein A3 0.03 0.02 0.01 0.057 
HNRPC 3183 heterogeneous nuclear ribonucleoprotein C (C1/C2) 0.04 0.02 0.02 0.040 
HNRPLL 92906 heterogeneous nuclear ribonucleoprotein L-like 0.04 0.03 0.01 0.095 
HNRPM 4670 heterogeneous nuclear ribonucleoprotein M 0.05 0.03 0.03 0.063 
HOMER3 9454 homer homolog 3 (Drosophila) 0.77 0.71 0.05 0.094 
HOXA2 3199 homeobox A2 0.44 0.33 0.11 0.090 
HOXD10 3236 homeobox D10 0.33 0.24 0.09 0.084 
H-plk 51351 zinc finger protein 117 0.61 0.71 -0.10 0.086 
HPR 3250 haptoglobin-related protein 0.77 0.85 -0.08 0.090 
HPS3 84343 Hermansky-Pudlak syndrome 3 0.04 0.01 0.02 0.087 
HPSE2 60495 heparanase 2 0.07 0.03 0.04 0.038 
HRASLS2 54979 HRAS-like suppressor 2 0.42 0.54 -0.12 0.044 
HRB2 11103 
KRR1, small subunit (SSU) 
processome component, homolog 
(yeast) 
0.05 0.02 0.02 0.063 
HSD17B1 3292 hydroxysteroid (17-beta) dehydrogenase 1 0.68 0.81 -0.14 0.044 
HSD17B1 3292 hydroxysteroid (17-beta) dehydrogenase 1 0.67 0.74 -0.08 0.085 
HSP90B1 7184 heat shock protein 90kDa beta (Grp94), member 1 0.05 0.03 0.02 0.067 
HSPA2 3306 heat shock 70kDa protein 2 0.91 0.95 -0.04 0.047 
HSPA2 3306 heat shock 70kDa protein 2 0.91 0.96 -0.05 0.065 
HSPA2 3306 heat shock 70kDa protein 2 0.78 0.88 -0.09 0.081 
HSPB6 126393 heat shock protein, alpha-crystallin-related, B6 0.91 0.96 -0.05 0.077 
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HSPBAP1 79663 HSPB (heat shock 27kDa) associated protein 1 0.04 0.03 0.02 0.090 
HTR3C 170572 5-hydroxytryptamine (serotonin) receptor 3, family member C 0.53 0.64 -0.11 0.065 
HTR3D 200909 5-hydroxytryptamine (serotonin) receptor 3 family member D 0.85 0.78 0.07 0.056 
HTR7 3363 5-hydroxytryptamine (serotonin) receptor 7 (adenylate cyclase-coupled) 0.05 0.03 0.02 0.089 
HYMAI 57061 hydatidiform mole associated and imprinted (non-protein coding) 0.62 0.73 -0.11 0.059 
HYPK 25764 chromosome 15 open reading frame 63 0.11 0.07 0.04 0.087 
IARS 3376 isoleucyl-tRNA synthetase 0.05 0.04 0.01 0.072 
IBRDC1 154214 ring finger protein 217 0.88 0.92 -0.04 0.075 
IDH3B 3420 isocitrate dehydrogenase 3 (NAD+) beta 0.03 0.02 0.01 0.089 
IFIT1 3434 interferon-induced protein with tetratricopeptide repeats 1 0.08 0.06 0.02 0.091 
IFITM1 8519 interferon induced transmembrane protein 1 (9-27) 0.67 0.75 -0.08 0.063 
IFITM2 10581 interferon induced transmembrane protein 2 (1-8D) 0.97 0.98 -0.01 0.089 
IFNA16 3449 interferon, alpha 16 0.61 0.73 -0.12 0.073 
IFNA21 3452 interferon, alpha 21 0.65 0.76 -0.11 0.080 
IFT57 55081 intraflagellar transport 57 homolog (Chlamydomonas) 0.04 0.03 0.01 0.095 
IGFBP7 3490 insulin-like growth factor binding protein 7 0.06 0.04 0.02 0.089 
IGSF10 285313 immunoglobulin superfamily, member 10 0.83 0.90 -0.07 0.063 
IGSF6 10261 immunoglobulin superfamily, member 6 0.81 0.89 -0.08 0.047 
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IL10 3586 interleukin 10 0.78 0.88 -0.10 0.086 
IL17 3605 interleukin 17A 0.59 0.70 -0.11 0.074 
IL17E 64806 interleukin 25 0.42 0.55 -0.14 0.042 
IL18RAP 8807 interleukin 18 receptor accessory protein 0.17 0.22 -0.05 0.094 
IL1A 3552 interleukin 1, alpha 0.75 0.84 -0.09 0.040 
IL1F10 84639 interleukin 1 family, member 10 (theta) 0.67 0.77 -0.10 0.070 
IL1F9 56300 interleukin 1 family, member 9 0.78 0.87 -0.10 0.042 
IL1RAP 3556 interleukin 1 receptor accessory protein 0.03 0.01 0.01 0.087 
IL1RL1 9173 interleukin 1 receptor-like 1 0.81 0.88 -0.07 0.039 
IL1RL1 9173 interleukin 1 receptor-like 1 0.57 0.69 -0.12 0.053 
IL20RA 53832 interleukin 20 receptor, alpha 0.93 0.96 -0.04 0.076 
IL24 11009 interleukin 24 0.91 0.96 -0.05 0.074 
IL27 246778 interleukin 27 0.65 0.78 -0.13 0.065 
IL2RB 3560 interleukin 2 receptor, beta 0.84 0.89 -0.06 0.065 
IL4 3565 interleukin 4 0.91 0.96 -0.04 0.050 
IL5 3567 interleukin 5 (colony-stimulating factor, eosinophil) 0.53 0.68 -0.15 0.065 
IL7 3574 interleukin 7 0.04 0.02 0.02 0.074 
IMPACT 55364 Impact homolog (mouse) 0.96 0.98 -0.02 0.094 
INGX 27160 inhibitor of growth family, X-linked, pseudogene 0.71 0.82 -0.11 0.078 
INPP5F 22876 inositol polyphosphate-5-phosphatase F 0.06 0.04 0.02 0.090 
INSIG2 51141 insulin induced gene 2 0.04 0.03 0.02 0.066 
INSL4 3641 insulin-like 4 (placenta) 0.79 0.87 -0.09 0.067 
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IQCF1 132141 IQ motif containing F1 0.72 0.84 -0.12 0.044 
IQCG 84223 IQ motif containing G 0.07 0.04 0.02 0.064 
IQCH 64799 IQ motif containing H 0.58 0.69 -0.11 0.086 
ISG20L1 64782 apoptosis enhancing nuclease 0.03 0.02 0.01 0.042 
ITGA11 22801 integrin, alpha 11 0.04 0.02 0.01 0.095 
ITGA8 8516 integrin, alpha 8 0.92 0.95 -0.03 0.087 
ITGAE 3682 
integrin, alpha E (antigen CD103, 
human mucosal lymphocyte antigen 1; 
alpha polypeptide) 
0.56 0.65 -0.09 0.083 
ITGB4BP 3692 eukaryotic translation initiation factor 6 0.06 0.03 0.02 0.053 
ITK 3702 IL2-inducible T-cell kinase 0.79 0.87 -0.09 0.049 
ITSN1 6453 intersectin 1 (SH3 domain protein) 0.04 0.02 0.02 0.074 
ITSN2 50618 intersectin 2 0.08 0.04 0.04 0.050 
IVL 3713 involucrin 0.80 0.88 -0.08 0.065 
IZUMO1 284359 izumo sperm-egg fusion 1 0.04 0.03 0.01 0.094 
JMJD2A 9682 lysine (K)-specific demethylase 4A 0.12 0.07 0.04 0.083 
JMY 133746 junction mediating and regulatory protein, p53 cofactor 0.66 0.80 -0.13 0.047 
JOSD3 79101 
TATA box binding protein (TBP)-
associated factor, RNA polymerase I, 
D, 41kDa 
0.73 0.83 -0.10 0.089 
JTV1 7965 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 0.61 0.73 -0.12 0.075 
KCNE1L 23630 KCNE1-like 0.54 0.68 -0.14 0.073 
KCNJ11 3767 potassium inwardly-rectifying channel, subfamily J, member 11 0.06 0.03 0.03 0.097 
KCNQ1 3784 potassium voltage-gated channel, KQT-like subfamily, member 1 0.81 0.86 -0.05 0.070 
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KCNS1 3787 
potassium voltage-gated channel, 
delayed-rectifier, subfamily S, 
member 1 
0.30 0.22 0.08 0.042 
KCNT2 343450 potassium channel, subfamily T, member 2 0.08 0.06 0.02 0.073 
KCNV2 169522 potassium channel, subfamily V, member 2 0.52 0.67 -0.15 0.074 
KIAA0141 9812 KIAA0141 0.89 0.94 -0.05 0.076 
KIAA0174 9798 KIAA0174 0.03 0.01 0.01 0.054 
KIAA0179 23076 ribosomal RNA processing 1 homolog B (S. cerevisiae) 0.79 0.86 -0.07 0.087 
KIAA0247 9766 KIAA0247 0.06 0.03 0.03 0.053 
KIAA0652 9776 KIAA0652 0.56 0.70 -0.14 0.068 
KIAA0676 23061 TBC1 domain family, member 9B (with GRAM domain) 0.93 0.97 -0.04 0.042 
KIAA0703 9914 ATPase, Ca++ transporting, type 2C, member 2 0.97 0.98 -0.01 0.086 
KIAA0738 9747 family with sequence similarity 115, member A 0.87 0.92 -0.06 0.070 
KIAA0889 25781 KIAA0889 0.86 0.91 -0.06 0.038 
KIAA1008 22894 DIS3 mitotic control homolog (S. cerevisiae) 0.02 0.01 0.01 0.085 
KIAA1128 54462 KIAA1128 0.64 0.75 -0.11 0.095 
KIAA1143 57456 KIAA1143 0.06 0.03 0.02 0.063 
KIAA1244 57221 KIAA1244 0.63 0.76 -0.13 0.071 
KIAA1704 55425 KIAA1704 0.74 0.87 -0.12 0.065 
KIAA1754 85450 inositol 1,4,5-triphosphate receptor interacting protein 0.59 0.71 -0.12 0.064 
KIF22 3835 kinesin family member 22 0.05 0.02 0.03 0.095 
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KIR3DL2 3812 
killer cell immunoglobulin-like 
receptor, three domains, long 
cytoplasmic tail, 2 
0.52 0.63 -0.11 0.065 
KLB 152831 klotho beta 0.70 0.79 -0.09 0.094 
KLC4 89953 kinesin light chain 4 0.92 0.96 -0.04 0.047 
KLF12 11278 Kruppel-like factor 12 0.03 0.01 0.01 0.073 
KLHDC4 54758 kelch domain containing 4 0.04 0.02 0.02 0.099 
KLHL20 27252 kelch-like 20 (Drosophila) 0.03 0.01 0.01 0.055 
KLHL3 26249 kelch-like 3 (Drosophila) 0.11 0.08 0.04 0.041 
KLHL8 57563 kelch-like 8 (Drosophila) 0.01 0.01 0.01 0.065 
KLK11 11012 kallikrein-related peptidase 11 0.85 0.88 -0.03 0.077 
KLK14 43847 kallikrein-related peptidase 14 0.83 0.91 -0.07 0.040 
KLRG1 10219 killer cell lectin-like receptor subfamily G, member 1 0.66 0.78 -0.12 0.075 
KRT10 3858 keratin 10 0.87 0.93 -0.06 0.096 
KRT24 192666 keratin 24 0.28 0.46 -0.18 0.063 
KRT25C 342574 keratin 27 0.72 0.81 -0.09 0.082 
KRT2A 3849 keratin 2 0.63 0.72 -0.09 0.080 
KRTAP1-1 81851 keratin associated protein 1-1 0.64 0.79 -0.15 0.050 
KRTAP13-4 284827 keratin associated protein 13-4 0.80 0.87 -0.07 0.076 
KRTAP17-1 83902 keratin associated protein 17-1 0.80 0.90 -0.09 0.025 
KRTAP19-2 337969 keratin associated protein 19-2 0.56 0.67 -0.12 0.065 
KRTAP19-3 337970 keratin associated protein 19-3 0.63 0.73 -0.10 0.070 
KRTAP4-4 84616 keratin associated protein 4-4 0.78 0.88 -0.09 0.065 
KRTAP6-2 337967 keratin associated protein 6-2 0.89 0.92 -0.03 0.099 
KRTAP9-3 83900 keratin associated protein 9-3 0.82 0.88 -0.07 0.042 
KRTCAP2 200185 keratinocyte associated protein 2 0.06 0.04 0.02 0.078 
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KRTHA3A 3883 keratin 33A 0.79 0.84 -0.06 0.086 
KRTHA4 3885 keratin 34 0.73 0.81 -0.08 0.082 
KRTHA4 3885 keratin 34 0.86 0.93 -0.07 0.090 
KRTHA5 3886 keratin 35 0.81 0.87 -0.06 0.065 
KRTHA8 8687 keratin 38 0.47 0.60 -0.13 0.077 
KRTHB2 3888 keratin 82 0.74 0.83 -0.10 0.042 
KSP37 83888 fibroblast growth factor binding protein 2 0.49 0.64 -0.15 0.049 
KTN1 3895 kinectin 1 (kinesin receptor) 0.08 0.04 0.04 0.075 
LACE1 246269 lactation elevated 1 0.02 0.01 0.01 0.070 
LAG3 3902 lymphocyte-activation gene 3 0.47 0.56 -0.09 0.047 
LAIR2 3904 leukocyte-associated immunoglobulin-like receptor 2 0.95 0.98 -0.02 0.080 
LAMP1 3916 lysosomal-associated membrane protein 1 0.10 0.05 0.05 0.094 
LANCL1 10314 LanC lantibiotic synthetase component C-like 1 (bacterial) 0.03 0.02 0.01 0.088 
LASS2 29956 LAG1 homolog, ceramide synthase 2 0.03 0.02 0.01 0.075 
LATS1 9113 LATS, large tumor suppressor, homolog 1 (Drosophila) 0.02 0.01 0.01 0.100 
LCN6 158062 lipocalin 6 0.75 0.83 -0.08 0.073 
LCT 3938 lactase 0.81 0.89 -0.08 0.046 
LEMD3 23592 LEM domain containing 3 0.06 0.03 0.03 0.082 
LETM2 137994 leucine zipper-EF-hand containing transmembrane protein 2 0.07 0.04 0.03 0.061 
LGALS2 3957 lectin, galactoside-binding, soluble, 2 0.33 0.44 -0.11 0.055 
LGALS4 3960 lectin, galactoside-binding, soluble, 4 0.27 0.34 -0.07 0.053 
LHFP 10186 lipoma HMGIC fusion partner 0.02 0.01 0.01 0.047 
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LIG4 3981 ligase IV, DNA, ATP-dependent 0.03 0.02 0.01 0.081 
LILRB2 10288 
leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and 
ITIM domains), member 2 
0.67 0.79 -0.12 0.054 
LILRB2 10288 
leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and 
ITIM domains), member 2 
0.78 0.87 -0.10 0.088 
LILRB4 11006 
leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and 
ITIM domains), member 4 
0.51 0.62 -0.11 0.075 
LIN10 80262 chromosome 16 open reading frame 70 0.02 0.01 0.01 0.050 
LIPH 200879 lipase, member H 0.70 0.78 -0.08 0.080 
LMAN2L 81562 lectin, mannose-binding 2-like 0.07 0.04 0.03 0.038 
LMX1A 4009 LIM homeobox transcription factor 1, alpha 0.91 0.94 -0.03 0.084 
LOC112714 112714 tubulin, alpha 3e 0.88 0.93 -0.05 0.063 
LOC120379 120379 PIH1 domain containing 2 0.52 0.68 -0.16 0.074 
LOC122258 122258 chromosome 13 open reading frame 28 0.62 0.71 -0.09 0.056 
LOC133957 133957 coiled-coil domain containing 127 0.05 0.03 0.02 0.084 
LOC196549 196549 eukaryotic translation elongation factor 1 delta pseudogene 3 0.56 0.70 -0.14 0.056 
LOC202459 202459 oligosaccharyltransferase complex subunit-like 0.81 0.88 -0.07 0.050 
LOC253012 253012 HEPACAM family member 2 0.88 0.92 -0.05 0.089 
LOC283377 283377 SPRY domain containing 4 0.05 0.03 0.02 0.072 
LOC284361 284361 chromosome 19 open reading frame 63 0.82 0.91 -0.09 0.044 
LOC339524 339524 hypothetical LOC339524 0.07 0.05 0.02 0.086 
LOC339789 339789 chromosome 2 open reading frame 46 0.78 0.87 -0.08 0.038 
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LOC340061 340061 transmembrane protein 173 0.05 0.03 0.02 0.099 
LOC346673 346673 stimulated by retinoic acid gene 8 homolog (mouse) 0.70 0.80 -0.10 0.043 
LOC346673 346673 stimulated by retinoic acid gene 8 homolog (mouse) 0.80 0.89 -0.09 0.047 
LOC51136 51136 ring finger protein, transmembrane 1 0.04 0.02 0.02 0.058 
LOC54103 54103 pigeon homolog (Drosophila) 0.79 0.90 -0.11 0.066 
LOC57146 57146 transmembrane protein 159 0.02 0.01 0.01 0.038 
LOC57146 57146 transmembrane protein 159 0.04 0.02 0.02 0.087 
LOC81691 81691 exonuclease NEF-sp 0.61 0.73 -0.12 0.085 
LOC84661 84661 dpy-30 homolog (C. elegans) 0.03 0.02 0.01 0.067 
LOC90580 90580 chromosome 19 open reading frame 52 0.83 0.89 -0.06 0.074 
LOC90826 90826 protein arginine methyltransferase 10 (putative) 0.04 0.03 0.01 0.075 
LPAL2 80350 lipoprotein, Lp(a)-like 2 0.32 0.40 -0.08 0.089 
LPPR4 9890 plasticity related gene 1 0.08 0.05 0.03 0.059 
LPXN 9404 leupaxin 0.80 0.89 -0.09 0.081 
LRP2 4036 low density lipoprotein-related protein 2 0.06 0.03 0.03 0.056 
LRP3 4037 low density lipoprotein receptor-related protein 3 0.80 0.86 -0.07 0.086 
LRRC25 126364 leucine rich repeat containing 25 0.83 0.90 -0.07 0.048 
LRRC44 127255 leucine-rich repeats and IQ motif containing 3 0.12 0.09 0.03 0.091 
LRRC8B 23507 leucine rich repeat containing 8 family, member B 0.07 0.10 -0.04 0.038 
LSP1 4046 lymphocyte-specific protein 1 0.39 0.52 -0.13 0.074 
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LTA 4049 lymphotoxin alpha (TNF superfamily, member 1) 0.33 0.49 -0.16 0.046 
LTB 4050 lymphotoxin beta (TNF superfamily, member 3) 0.92 0.95 -0.03 0.078 
LTBP4 8425 latent transforming growth factor beta binding protein 4 0.66 0.75 -0.09 0.050 
LTK 4058 leukocyte receptor tyrosine kinase 0.76 0.86 -0.10 0.076 
LY6E 4061 lymphocyte antigen 6 complex, locus E 0.05 0.02 0.02 0.099 
LY6G6C 80740 lymphocyte antigen 6 complex, locus G6C 0.89 0.85 0.04 0.094 
LYNX1 66004 Ly6/neurotoxin 1 0.04 0.03 0.02 0.087 
LYSMD4 145748 LysM, putative peptidoglycan-binding, domain containing 4 0.91 0.87 0.04 0.053 
LYZL2 119180 lysozyme-like 2 0.77 0.85 -0.07 0.086 
MAGEA10 4109 melanoma antigen family A, 10 0.19 0.26 -0.07 0.065 
MAGEA2B 266740 melanoma antigen family A, 2B 0.74 0.84 -0.10 0.038 
MAGEA4 4103 melanoma antigen family A, 4 0.48 0.56 -0.08 0.087 
MAGEC2 51438 melanoma antigen family C, 2 0.83 0.77 0.06 0.094 
MAK 4117 male germ cell-associated kinase 0.09 0.14 -0.05 0.093 
MAK 4117 male germ cell-associated kinase 0.85 0.88 -0.03 0.093 
MAP1LC3A 84557 microtubule-associated protein 1 light chain 3 alpha 0.60 0.71 -0.11 0.066 
MAP2K5 5607 mitogen-activated protein kinase kinase 5 0.03 0.02 0.02 0.080 
MAP3K11 4296 mitogen-activated protein kinase kinase kinase 11 0.07 0.04 0.03 0.065 
MAP3K14 9020 mitogen-activated protein kinase kinase kinase 14 0.94 0.91 0.03 0.082 
MAPK13 5603 mitogen-activated protein kinase 13 0.50 0.61 -0.11 0.094 
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MAPK4 5596 mitogen-activated protein kinase 4 0.93 0.95 -0.02 0.080 
MAPRE1 22919 microtubule-associated protein, RP/EB family, member 1 0.07 0.04 0.03 0.080 
MARCH8 220972 membrane-associated ring finger (C3HC4) 8 0.08 0.05 0.03 0.066 
MARK3 4140 MAP/microtubule affinity-regulating kinase 3 0.02 0.01 0.01 0.053 
MAS1L 116511 MAS1 oncogene-like 0.61 0.74 -0.12 0.073 
MASTL 84930 microtubule associated serine/threonine kinase-like 0.04 0.02 0.02 0.047 
MASTL 84930 microtubule associated serine/threonine kinase-like 0.03 0.02 0.01 0.086 
MBTD1 54799 mbt domain containing 1 0.37 0.50 -0.13 0.063 
MC2R 4158 melanocortin 2 receptor (adrenocorticotropic hormone) 0.77 0.85 -0.08 0.050 
MCFD2 90411 multiple coagulation factor deficiency 2 0.11 0.06 0.05 0.088 
MCM4 4173 minichromosome maintenance complex component 4 0.05 0.03 0.02 0.100 
MCM5 4174 minichromosome maintenance complex component 5 0.12 0.15 -0.03 0.080 
MCTS1 28985 malignant T cell amplified sequence 1 0.75 0.84 -0.09 0.067 
MECP2 4204 methyl CpG binding protein 2 (Rett syndrome) 0.56 0.71 -0.15 0.061 
METAP1 23173 methionyl aminopeptidase 1 0.88 0.92 -0.04 0.080 
MFAP3 4238 microfibrillar-associated protein 3 0.70 0.78 -0.08 0.086 
MFAP4 4239 microfibrillar-associated protein 4 0.22 0.32 -0.10 0.066 
MFN1 55669 mitofusin 1 0.02 0.01 0.01 0.053 
MFSD2 84879 major facilitator superfamily domain containing 2 0.05 0.02 0.02 0.094 
 
 
120 
 
Symbol Gene ID Gene Description Mean β PE 
Mean β 
NP ∆β FDR 
MGC11257 84310 chromosome 7 open reading frame 50 0.93 0.96 -0.03 0.090 
MGC11266 79172 centromere protein O 0.03 0.01 0.01 0.046 
MGC13024 93129 ORAI calcium release-activated calcium modulator 3 0.02 0.01 0.01 0.062 
MGC13034 134288 transmembrane protein 174 0.82 0.88 -0.07 0.079 
MGC13096 84306 programmed cell death 2-like 0.02 0.01 0.01 0.098 
MGC16169 93627 TBC domain-containing protein kinase-like 0.05 0.03 0.02 0.047 
MGC16943 112479 exoribonuclease 2 0.03 0.02 0.01 0.074 
MGC17330 113791 phosphoinositide-3-kinase interacting protein 1 0.03 0.02 0.01 0.094 
MGC22001 197196 transmembrane protein 148 0.77 0.84 -0.08 0.097 
MGC2463 79037 poliovirus receptor related immunoglobulin domain containing 0.84 0.81 0.03 0.087 
MGC32020 91442 chromosome 19 open reading frame 40 0.04 0.02 0.02 0.083 
MGC3265 78991 prenylcysteine oxidase 1 like 0.02 0.01 0.01 0.064 
MGC33302 256471 major facilitator superfamily domain containing 8 0.09 0.05 0.05 0.075 
MGC33530 222008 V-set and transmembrane domain containing 2A 0.05 0.03 0.02 0.085 
MGC33839 125875 claudin domain containing 2 0.80 0.87 -0.07 0.073 
MGC34646 157807 retinaldehyde binding protein 1-like 1 0.07 0.04 0.03 0.050 
MGC34830 120196 chromosome 11 open reading frame 69 0.51 0.65 -0.14 0.065 
MGC34830 120196 chromosome 11 open reading frame 69 0.73 0.80 -0.07 0.077 
MGC35043 255119 chromosome 4 open reading frame 22 0.03 0.01 0.01 0.045 
MGC35048 124152 IQ motif containing K 0.80 0.84 -0.04 0.057 
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MGC35154 165100 chromosome 2 open reading frame 57 0.90 0.85 0.05 0.039 
MGC35169 121793 chromosome 13 open reading frame 16 0.55 0.66 -0.12 0.053 
MGC35308 285800 proline rich 18 0.77 0.82 -0.05 0.084 
MGC4618 84286 transmembrane protein 175 0.68 0.63 0.05 0.089 
MGC48595 399671 HEAT repeat containing 4 0.60 0.75 -0.14 0.053 
MGC50372 253143 chromosome 22 open reading frame 30 0.87 0.91 -0.04 0.074 
MGC7036 196383 Rab interacting lysosomal protein-like 2 0.03 0.02 0.01 0.065 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.90 0.95 -0.05 0.042 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.93 0.97 -0.04 0.042 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.88 0.95 -0.07 0.055 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.80 0.86 -0.05 0.073 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.77 0.84 -0.07 0.074 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.09 0.14 -0.05 0.084 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.78 0.86 -0.08 0.089 
MGMT 4255 O-6-methylguanine-DNA methyltransferase 0.91 0.93 -0.02 0.099 
MGST3 4259 microsomal glutathione S-transferase 3 0.02 0.01 0.01 0.073 
MINPP1 9562 multiple inositol polyphosphate histidine phosphatase, 1 0.04 0.02 0.02 0.070 
MIP 4284 major intrinsic protein of lens fiber 0.80 0.88 -0.08 0.041 
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MKRN1 23608 makorin ring finger protein 1 0.12 0.09 0.03 0.085 
MKRN3 7681 makorin ring finger protein 3 0.61 0.78 -0.16 0.080 
MLANA 2315 melan-A 0.65 0.78 -0.13 0.079 
MLH1 4292 mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) 0.04 0.03 0.01 0.063 
MLL4 9757 myeloid/lymphoid or mixed-lineage leukemia 4 0.03 0.02 0.01 0.055 
MLSTD1 55711 fatty acyl CoA reductase 2 0.77 0.86 -0.09 0.066 
MME 4311 membrane metallo-endopeptidase 0.04 0.02 0.02 0.085 
MMS19L 64210 MMS19 nucleotide excision repair homolog (S. cerevisiae) 0.06 0.04 0.02 0.073 
MON1B 22879 MON1 homolog B (yeast) 0.03 0.02 0.01 0.079 
MORC1 27136 MORC family CW-type zinc finger 1 0.85 0.92 -0.07 0.080 
MORF4L1 10933 mortality factor 4 like 1 0.81 0.88 -0.07 0.053 
MPDZ 8777 multiple PDZ domain protein 0.92 0.95 -0.04 0.055 
MPI 4351 mannose phosphate isomerase 0.92 0.94 -0.02 0.074 
MPL 4352 myeloproliferative leukemia virus oncogene 0.84 0.88 -0.04 0.077 
MPPED1 758 metallophosphoesterase domain containing 1 0.74 0.85 -0.10 0.059 
MPPED2 744 metallophosphoesterase domain containing 2 0.92 0.97 -0.04 0.067 
MPZL1 9019 myelin protein zero-like 1 0.83 0.91 -0.08 0.046 
MPZL1 9019 myelin protein zero-like 1 0.07 0.04 0.03 0.084 
MRPL15 29088 mitochondrial ribosomal protein L15 0.03 0.02 0.01 0.056 
MRPL35 51318 mitochondrial ribosomal protein L35 0.02 0.01 0.01 0.091 
MRPL4 51073 mitochondrial ribosomal protein L4 0.03 0.02 0.01 0.077 
MRPL44 65080 mitochondrial ribosomal protein L44 0.04 0.03 0.02 0.090 
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MRPL51 51258 mitochondrial ribosomal protein L51 0.06 0.04 0.02 0.083 
MRPS10 55173 mitochondrial ribosomal protein S10 0.02 0.01 0.01 0.066 
MRPS22 56945 mitochondrial ribosomal protein S22 0.02 0.01 0.01 0.061 
MRPS34 65993 mitochondrial ribosomal protein S34 0.04 0.02 0.02 0.062 
MRRF 92399 mitochondrial ribosome recycling factor 0.03 0.01 0.01 0.087 
MRS2L 57380 MRS2 magnesium homeostasis factor homolog (S. cerevisiae) 0.03 0.01 0.02 0.061 
MS4A10 341116 membrane-spanning 4-domains, subfamily A, member 10 0.61 0.73 -0.12 0.087 
MSH6 2956 mutS homolog 6 (E. coli) 0.04 0.02 0.02 0.069 
MSMB 4477 microseminoprotein, beta- 0.62 0.77 -0.15 0.061 
MSN 4478 moesin 0.78 0.87 -0.09 0.042 
MSR1 4481 macrophage scavenger receptor 1 0.88 0.93 -0.05 0.065 
MT 27349 malonyl CoA:ACP acyltransferase (mitochondrial) 0.02 0.01 0.01 0.084 
MT1B 4490 metallothionein 1B 0.81 0.89 -0.08 0.044 
MTAP 4507 methylthioadenosine phosphorylase 0.18 0.12 0.06 0.095 
MTCP1 4515 mature T-cell proliferation 1 0.54 0.67 -0.13 0.070 
MTMR1 8776 myotubularin related protein 1 0.75 0.82 -0.07 0.094 
MUC1 4582 mucin 1, cell surface associated 0.70 0.81 -0.11 0.044 
MUC13 56667 mucin 13, cell surface associated 0.81 0.86 -0.05 0.094 
MYBPC1 4604 myosin binding protein C, slow type 0.77 0.85 -0.07 0.078 
MYBPC2 4606 myosin binding protein C, fast type 0.76 0.85 -0.09 0.047 
MYBPC3 4607 myosin binding protein C, cardiac 0.58 0.66 -0.08 0.053 
MYBPC3 4607 myosin binding protein C, cardiac 0.91 0.89 0.02 0.073 
MYBPH 4608 myosin binding protein H 0.77 0.85 -0.09 0.054 
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MYBPH 4608 myosin binding protein H 0.43 0.59 -0.17 0.093 
MYCBP 26292 c-myc binding protein 0.05 0.03 0.02 0.089 
MYD88 4615 myeloid differentiation primary response gene (88) 0.04 0.03 0.02 0.063 
MYH4 4622 myosin, heavy chain 4, skeletal muscle 0.78 0.85 -0.07 0.089 
MYLPF 29895 myosin light chain, phosphorylatable, fast skeletal muscle 0.63 0.74 -0.11 0.086 
MYO18B 84700 myosin XVIIIB 0.87 0.93 -0.05 0.099 
MYO1F 4542 myosin IF 0.09 0.05 0.04 0.099 
MYO5A 4644 myosin VA (heavy chain 12, myoxin) 0.02 0.01 0.01 0.061 
MYO5A 4644 myosin VA (heavy chain 12, myoxin) 0.03 0.02 0.01 0.097 
MYO9B 4650 myosin IXB 0.05 0.07 -0.02 0.086 
MYOM2 9172 myomesin (M-protein) 2, 165kDa 0.17 0.11 0.06 0.080 
MYST4 23522 MYST histone acetyltransferase (monocytic leukemia) 4 0.90 0.95 -0.05 0.038 
MYST4 23522 MYST histone acetyltransferase (monocytic leukemia) 4 0.69 0.78 -0.09 0.071 
N4BP2 55728 NEDD4 binding protein 2 0.93 0.90 0.03 0.074 
NALP4 147945 NLR family, pyrin domain containing 4 0.89 0.93 -0.04 0.094 
NALP5 126206 NLR family, pyrin domain containing 5 0.76 0.84 -0.08 0.077 
NALP7 199713 NLR family, pyrin domain containing 7 0.66 0.75 -0.08 0.094 
NALP8 126205 NLR family, pyrin domain containing 8 0.71 0.83 -0.12 0.064 
NAPRT1 93100 nicotinate phosphoribosyltransferase domain containing 1 0.89 0.93 -0.04 0.065 
NARG2 79664 NMDA receptor regulated 2 0.03 0.02 0.01 0.083 
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NARS 4677 asparaginyl-tRNA synthetase 0.81 0.89 -0.08 0.042 
NAT5 51126 N-acetyltransferase 5 (GCN5-related, putative) 0.03 0.02 0.01 0.088 
NBL1 4681 neuroblastoma, suppression of tumorigenicity 1 0.75 0.88 -0.13 0.099 
NBPF3 84224 neuroblastoma breakpoint family, member 3 0.02 0.02 0.01 0.081 
NCL 4691 nucleolin 0.94 0.92 0.02 0.084 
NDRG3 57446 NDRG family member 3 0.05 0.03 0.02 0.065 
NDUFA13 51079 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 0.83 0.90 -0.07 0.089 
NDUFA3 4696 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa 0.05 0.02 0.03 0.076 
NDUFA4 4697 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa 0.03 0.02 0.01 0.061 
NDUFA4 4697 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa 0.04 0.02 0.02 0.080 
NDUFB6 4712 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa 0.04 0.02 0.02 0.055 
NDUFC1 4717 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 0.03 0.02 0.01 0.052 
NECAP1 25977 NECAP endocytosis associated 1 0.82 0.91 -0.08 0.044 
NEFL 4747 neurofilament, light polypeptide 0.06 0.04 0.02 0.076 
NEK10 152110 NIMA (never in mitosis gene a)- related kinase 10 0.92 0.96 -0.04 0.070 
NEU2 4759 sialidase 2 (cytosolic sialidase) 0.13 0.16 -0.04 0.086 
NEURL 9148 neuralized homolog (Drosophila) 0.69 0.59 0.10 0.067 
NEUROD2 4761 neurogenic differentiation 2 0.91 0.96 -0.05 0.078 
NEUROD4 58158 neurogenic differentiation 4 0.08 0.05 0.03 0.067 
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NFKB2 4791 
nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 2 
(p49/p100) 
0.03 0.02 0.01 0.075 
NFKBIE 4794 
nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 
inhibitor, epsilon 
0.59 0.72 -0.13 0.063 
NFRKB 4798 nuclear factor related to kappaB binding protein 0.91 0.94 -0.03 0.087 
NMNAT2 23057 nicotinamide nucleotide adenylyltransferase 2 0.02 0.01 0.01 0.086 
NNAT 4826 neuronatin 0.89 0.93 -0.04 0.090 
NOLA3 55505 NOP10 ribonucleoprotein homolog (yeast) 0.05 0.03 0.02 0.067 
NOPE 57722 immunoglobulin superfamily, DCC subclass, member 4 0.14 0.09 0.05 0.063 
NOS3 4846 nitric oxide synthase 3 (endothelial cell) 0.79 0.86 -0.07 0.066 
NPBWR1 2831 neuropeptides B/W receptor 1 0.04 0.02 0.02 0.038 
NPFF 8620 neuropeptide FF-amide peptide precursor 0.90 0.93 -0.03 0.099 
NPFFR2 10886 neuropeptide FF receptor 2 0.66 0.77 -0.11 0.053 
NPM3 10360 nucleophosmin/nucleoplasmin, 3 0.06 0.04 0.02 0.070 
NQO2 4835 NAD(P)H dehydrogenase, quinone 2 0.02 0.02 0.01 0.085 
NR0B1 190 nuclear receptor subfamily 0, group B, member 1 0.66 0.75 -0.09 0.087 
NR0B2 8431 nuclear receptor subfamily 0, group B, member 2 0.95 0.97 -0.02 0.055 
NR0B2 8431 nuclear receptor subfamily 0, group B, member 2 0.85 0.92 -0.08 0.055 
NR1D1 9572 nuclear receptor subfamily 1, group D, member 1 0.08 0.04 0.03 0.077 
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NR1H2 7376 nuclear receptor subfamily 1, group H, member 2 0.04 0.03 0.01 0.075 
NR1I2 8856 nuclear receptor subfamily 1, group I, member 2 0.58 0.67 -0.09 0.094 
NRAP 4892 nebulin-related anchoring protein 0.86 0.89 -0.04 0.045 
NRTN 4902 neurturin 0.81 0.75 0.06 0.064 
NSDHL 50814 NAD(P) dependent steroid dehydrogenase-like 0.78 0.85 -0.07 0.039 
NSUN5C 260294 NOL1/NOP2/Sun domain family, member 5C 0.87 0.93 -0.06 0.042 
NSUN6 221078 NOL1/NOP2/Sun domain family, member 6 0.03 0.02 0.01 0.074 
NT5C3L 115024 5'-nucleotidase, cytosolic III-like 0.65 0.76 -0.11 0.061 
NUDT1 4521 nudix (nucleoside diphosphate linked moiety X)-type motif 1 0.88 0.93 -0.05 0.051 
NUMB 8650 numb homolog (Drosophila) 0.09 0.05 0.04 0.065 
NUP93 9688 nucleoporin 93kDa 0.87 0.92 -0.04 0.088 
NUT 256646 chromosome 15 open reading frame 55 0.77 0.88 -0.11 0.061 
NXF3 56000 nuclear RNA export factor 3 0.36 0.43 -0.06 0.086 
NYD-SP18 84691 family with sequence similarity 71, member F1 0.85 0.89 -0.04 0.067 
OACT5 10162 lysophosphatidylcholine acyltransferase 3 0.03 0.01 0.02 0.073 
OBP2B 29989 odorant binding protein 2B 0.89 0.95 -0.05 0.044 
OCM 4951 oncomodulin 2 0.72 0.82 -0.10 0.053 
OKL38 29948 oxidative stress induced growth inhibitor 1 0.79 0.87 -0.08 0.042 
OLFM1 10439 olfactomedin 1 0.66 0.77 -0.10 0.064 
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OPA3 80207 optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) 0.02 0.01 0.01 0.070 
OR1A1 8383 olfactory receptor, family 1, subfamily A, member 1 0.56 0.72 -0.16 0.042 
OR1D2 4991 olfactory receptor, family 1, subfamily D, member 2 0.32 0.46 -0.14 0.053 
OR1F1 4992 olfactory receptor, family 1, subfamily F, member 1 0.39 0.46 -0.08 0.090 
OR2F1 26211 olfactory receptor, family 2, subfamily F, member 1 0.72 0.79 -0.06 0.058 
OR2K2 26248 olfactory receptor, family 2, subfamily K, member 2 0.84 0.91 -0.07 0.061 
OR2V2 285659 olfactory receptor, family 2, subfamily V, member 2 0.83 0.88 -0.05 0.065 
OR3A1 4994 olfactory receptor, family 3, subfamily A, member 1 0.94 0.91 0.03 0.065 
OR3A1 4994 olfactory receptor, family 3, subfamily A, member 1 0.02 0.03 -0.01 0.085 
OR7A17 26333 olfactory receptor, family 7, subfamily A, member 17 0.45 0.63 -0.18 0.046 
OSBPL5 114879 oxysterol binding protein-like 5 0.22 0.30 -0.08 0.070 
OSBPL5 114879 oxysterol binding protein-like 5 0.22 0.28 -0.06 0.075 
OTUD4 54726 OTU domain containing 4 0.80 0.86 -0.06 0.084 
OTUD6B 51633 OTU domain containing 6B 0.03 0.02 0.02 0.042 
OTUD7 161725 OTU domain containing 7A 0.79 0.88 -0.09 0.063 
OXA1L 5018 oxidase (cytochrome c) assembly 1-like 0.06 0.04 0.03 0.100 
OXSM 54995 3-oxoacyl-ACP synthase, mitochondrial 0.02 0.01 0.01 0.093 
OXT 5020 oxytocin, prepropeptide 0.17 0.26 -0.09 0.047 
OXT 5020 oxytocin, prepropeptide 0.80 0.86 -0.05 0.064 
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P11 8909 26 serine protease 0.69 0.83 -0.14 0.044 
P2RX4 5025 purinergic receptor P2X, ligand-gated ion channel, 4 0.85 0.92 -0.08 0.065 
P2RXL1 9127 purinergic receptor P2X, ligand-gated ion channel, 6 0.80 0.90 -0.10 0.064 
P2RY11 5032 purinergic receptor P2Y, G-protein coupled, 11 0.63 0.75 -0.12 0.090 
P2RY2 5029 purinergic receptor P2Y, G-protein coupled, 2 0.11 0.05 0.05 0.065 
P2RY6 5031 pyrimidinergic receptor P2Y, G-protein coupled, 6 0.76 0.84 -0.08 0.094 
PAGE1 8712 P antigen family, member 1 (prostate associated) 0.57 0.68 -0.11 0.074 
PAIP2 51247 poly(A) binding protein interacting protein 2 0.02 0.01 0.01 0.039 
PAIP2 51247 poly(A) binding protein interacting protein 2 0.08 0.06 0.02 0.095 
PAK6 56924 p21 protein (Cdc42/Rac)-activated kinase 6 0.67 0.78 -0.11 0.055 
PAK6 56924 p21 protein (Cdc42/Rac)-activated kinase 6 0.02 0.01 0.01 0.073 
PANX1 24145 pannexin 1 0.17 0.12 0.05 0.095 
PAQR5 54852 progestin and adipoQ receptor family member V 0.87 0.93 -0.05 0.065 
PAQR8 85315 progestin and adipoQ receptor family member VIII 0.06 0.03 0.03 0.068 
PARK7 11315 Parkinson disease (autosomal recessive, early onset) 7 0.08 0.06 0.03 0.071 
PARP16 54956 poly (ADP-ribose) polymerase family, member 16 0.07 0.04 0.03 0.085 
PARP4 143 poly (ADP-ribose) polymerase family, member 4 0.01 0.01 0.01 0.090 
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PARP9 83666 poly (ADP-ribose) polymerase family, member 9 0.83 0.90 -0.07 0.067 
PARS2 25973 prolyl-tRNA synthetase 2, mitochondrial (putative) 0.01 0.01 0.01 0.098 
PARVB 29780 parvin, beta 0.83 0.90 -0.07 0.073 
PC 5091 pyruvate carboxylase 0.76 0.83 -0.07 0.099 
PCAF 8850 K(lysine) acetyltransferase 2B 0.08 0.05 0.03 0.095 
PCBP3 54039 poly(rC) binding protein 3 0.76 0.85 -0.09 0.063 
PCDH20 64881 protocadherin 20 0.05 0.04 0.01 0.082 
PCDHB2 56133 protocadherin beta 2 0.07 0.05 0.02 0.098 
PCNA 5111 proliferating cell nuclear antigen 0.05 0.03 0.02 0.082 
PCOLCE 5118 procollagen C-endopeptidase enhancer 0.72 0.83 -0.12 0.065 
PCSK2 5126 proprotein convertase subtilisin/kexin type 2 0.03 0.02 0.01 0.087 
PDCD7 10081 programmed cell death 7 0.04 0.02 0.02 0.047 
PDE4D 5144 
phosphodiesterase 4D, cAMP-specific 
(phosphodiesterase E3 dunce 
homolog, Drosophila) 
0.92 0.94 -0.02 0.094 
PDE6H 5149 phosphodiesterase 6H, cGMP-specific, cone, gamma 0.89 0.94 -0.04 0.087 
PDP2 57546 pyruvate dehyrogenase phosphatase catalytic subunit 2 0.03 0.02 0.01 0.084 
PDXK 8566 pyridoxal (pyridoxine, vitamin B6) kinase 0.81 0.86 -0.05 0.065 
PDZRN4 29951 PDZ domain containing ring finger 4 0.63 0.75 -0.12 0.050 
PEG10 23089 paternally expressed 10 0.49 0.63 -0.14 0.065 
PEG10 23089 paternally expressed 10 0.91 0.95 -0.04 0.073 
PELI1 57162 pellino homolog 1 (Drosophila) 0.41 0.50 -0.09 0.090 
PER2 8864 period homolog 2 (Drosophila) 0.07 0.05 0.03 0.073 
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PER3 8863 period homolog 3 (Drosophila) 0.96 0.94 0.02 0.065 
PERP 64065 PERP, TP53 apoptosis effector 0.05 0.03 0.02 0.086 
PES1 23481 pescadillo homolog 1, containing BRCT domain (zebrafish) 0.03 0.02 0.01 0.065 
PEX11A 8800 peroxisomal biogenesis factor 11 alpha 0.06 0.03 0.03 0.050 
PEX11B 8799 peroxisomal biogenesis factor 11 beta 0.02 0.01 0.01 0.025 
PEX14 5195 peroxisomal biogenesis factor 14 0.05 0.04 0.02 0.065 
PEX19 5824 peroxisomal biogenesis factor 19 0.03 0.02 0.01 0.046 
PEX5L 51555 peroxisomal biogenesis factor 5-like 0.01 0.01 0.00 0.099 
PF4V1 5197 platelet factor 4 variant 1 0.93 0.94 -0.02 0.070 
PFC 5199 complement factor properdin 0.64 0.70 -0.06 0.089 
PFDN4 5203 prefoldin subunit 4 0.04 0.01 0.02 0.071 
PFDN5 5204 prefoldin subunit 5 0.07 0.04 0.03 0.068 
PFKFB2 5208 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 0.03 0.02 0.01 0.075 
PFTK1 5218 PFTAIRE protein kinase 1 0.41 0.61 -0.20 0.025 
PGAM1 5223 phosphoglycerate mutase 1 (brain) 0.03 0.02 0.01 0.047 
PGBD4 161779 piggyBac transposable element derived 4 0.08 0.04 0.04 0.042 
PGBD5 79605 piggyBac transposable element derived 5 0.81 0.88 -0.08 0.090 
PGCP 10404 plasma glutamate carboxypeptidase 0.16 0.10 0.06 0.089 
PGPEP1 54858 pyroglutamyl-peptidase I 0.96 0.98 -0.02 0.074 
PHC2 1912 polyhomeotic homolog 2 (Drosophila) 0.52 0.70 -0.17 0.069 
PHTF1 10745 putative homeodomain transcription factor 1 0.28 0.17 0.12 0.071 
PHYH2 26061 2-hydroxyacyl-CoA lyase 1 0.04 0.03 0.01 0.077 
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PIGF 5281 phosphatidylinositol glycan anchor biosynthesis, class F 0.04 0.02 0.01 0.086 
PIGL 9487 phosphatidylinositol glycan anchor biosynthesis, class L 0.07 0.04 0.03 0.089 
PIGV 55650 phosphatidylinositol glycan anchor biosynthesis, class V 0.04 0.02 0.02 0.098 
PIK4CA 5297 phosphatidylinositol 4-kinase, catalytic, alpha 0.88 0.92 -0.04 0.100 
PIP5K1A 8394 phosphatidylinositol-4-phosphate 5-kinase, type I, alpha 0.02 0.01 0.01 0.065 
PIP5KL1 138429 phosphatidylinositol-4-phosphate 5-kinase-like 1 0.06 0.03 0.03 0.040 
PKD1 5310 polycystic kidney disease 1 (autosomal dominant) 0.90 0.94 -0.04 0.059 
PKHD1 5314 polycystic kidney and hepatic disease 1 (autosomal recessive) 0.56 0.68 -0.12 0.075 
PKIB 5570 protein kinase (cAMP-dependent, catalytic) inhibitor beta 0.04 0.02 0.02 0.073 
PLA1A 51365 phospholipase A1 member A 0.88 0.91 -0.04 0.065 
PLA2G3 50487 phospholipase A2, group III 0.63 0.55 0.08 0.098 
PLA2R1 22925 phospholipase A2 receptor 1, 180kDa 0.03 0.01 0.01 0.038 
PLAC4 191585 placenta-specific 4 0.62 0.71 -0.10 0.085 
PLAGL2 5326 pleiomorphic adenoma gene-like 2 0.03 0.06 -0.03 0.095 
PLCG2 5336 phospholipase C, gamma 2 (phosphatidylinositol-specific) 0.47 0.65 -0.17 0.071 
PLCXD2 257068 
phosphatidylinositol-specific 
phospholipase C, X domain containing 
2 
0.04 0.02 0.02 0.074 
PLEKHA9 51054 
pleckstrin homology domain 
containing, family A 
(phosphoinositide binding specific) 
member 9 
0.05 0.03 0.02 0.073 
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PLEKHH2 130271 
pleckstrin homology domain 
containing, family H (with MyTH4 
domain) member 2 
0.55 0.65 -0.11 0.068 
PLIN 5346 perilipin 0.82 0.92 -0.10 0.039 
PLK2 10769 polo-like kinase 2 (Drosophila) 0.03 0.02 0.02 0.063 
PLSCR1 5359 phospholipid scramblase 1 0.31 0.43 -0.12 0.088 
PLSCR2 57047 phospholipid scramblase 2 0.64 0.71 -0.08 0.063 
PLXNB3 5365 plexin B3 0.73 0.80 -0.07 0.090 
PMCHL2 5370 pro-melanin-concentrating hormone-like 2 0.75 0.86 -0.11 0.038 
PMM2 5373 phosphomannomutase 2 0.84 0.90 -0.06 0.087 
PMM2 5373 phosphomannomutase 2 0.83 0.87 -0.04 0.094 
PNKD 25953 paroxysmal nonkinesigenic dyskinesia 0.52 0.64 -0.12 0.076 
PNLIPRP1 5407 pancreatic lipase-related protein 1 0.55 0.72 -0.18 0.055 
PNLIPRP2 5408 pancreatic lipase-related protein 2 0.82 0.91 -0.09 0.040 
PNN 5411 pinin, desmosome associated protein 0.04 0.02 0.02 0.093 
POLE3 54107 polymerase (DNA directed), epsilon 3 (p17 subunit) 0.75 0.83 -0.08 0.081 
POLN 353497 polymerase (DNA directed) nu 0.58 0.70 -0.12 0.089 
POLR1C 9533 polymerase (RNA) I polypeptide C, 30kDa 0.75 0.85 -0.10 0.087 
POLR1C 9533 polymerase (RNA) I polypeptide C, 30kDa 0.78 0.85 -0.07 0.091 
POLR2B 5431 polymerase (RNA) II (DNA directed) polypeptide B, 140kDa 0.05 0.04 0.02 0.062 
POLR2C 5432 polymerase (RNA) II (DNA directed) polypeptide C, 33kDa 0.03 0.02 0.01 0.073 
POLR3E 55718 polymerase (RNA) III (DNA directed) polypeptide E (80kD) 0.07 0.04 0.03 0.099 
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POLR3H 171568 polymerase (RNA) III (DNA directed) polypeptide H (22.9kD) 0.83 0.90 -0.07 0.055 
POMT1 10585 protein-O-mannosyltransferase 1 0.04 0.02 0.02 0.074 
PON2 5445 paraoxonase 2 0.05 0.03 0.02 0.072 
PPHLN1 51535 periphilin 1 0.05 0.03 0.02 0.067 
PPIE 10450 peptidylprolyl isomerase E (cyclophilin E) 0.05 0.03 0.02 0.087 
PPM1D 8493 protein phosphatase 1D magnesium-dependent, delta isoform 0.03 0.02 0.01 0.063 
PPME1 51400 protein phosphatase methylesterase 1 0.05 0.02 0.02 0.064 
PPME1 51400 protein phosphatase methylesterase 1 0.03 0.02 0.01 0.089 
PPP4C 5531 protein phosphatase 4 (formerly X), catalytic subunit 0.04 0.02 0.02 0.040 
PRAME 23532 preferentially expressed antigen in melanoma 0.71 0.62 0.09 0.055 
PRCP 5547 prolylcarboxypeptidase (angiotensinase C) 0.08 0.05 0.04 0.051 
PRDM2 7799 PR domain containing 2, with ZNF domain 0.64 0.77 -0.13 0.055 
PRH1 5554 proline-rich protein HaeIII subfamily 1 0.38 0.51 -0.14 0.091 
PRH2 5555 proline-rich protein HaeIII subfamily 2 0.83 0.91 -0.08 0.056 
PRH2 5555 proline-rich protein HaeIII subfamily 2 0.73 0.79 -0.05 0.094 
PRKAA2 5563 protein kinase, AMP-activated, alpha 2 catalytic subunit 0.03 0.02 0.01 0.055 
PRKACG 5568 protein kinase, cAMP-dependent, catalytic, gamma 0.89 0.94 -0.05 0.073 
PRKD3 23683 protein kinase D3 0.71 0.80 -0.09 0.080 
PRMT3 10196 protein arginine methyltransferase 3 0.04 0.02 0.02 0.083 
PROC 5624 protein C (inactivator of coagulation factors Va and VIIIa) 0.89 0.93 -0.04 0.078 
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PROC 5624 protein C (inactivator of coagulation factors Va and VIIIa) 0.86 0.90 -0.04 0.086 
PROM1 8842 prominin 1 0.90 0.96 -0.06 0.061 
PRPF3 9129 PRP3 pre-mRNA processing factor 3 homolog (S. cerevisiae) 0.08 0.05 0.03 0.076 
PRPF39 55015 PRP39 pre-mRNA processing factor 39 homolog (S. cerevisiae) 0.11 0.07 0.04 0.065 
PRPF8 10594 PRP8 pre-mRNA processing factor 8 homolog (S. cerevisiae) 0.05 0.03 0.02 0.081 
PRPS1L1 221823 phosphoribosyl pyrophosphate synthetase 1 0.60 0.74 -0.14 0.069 
PRSSL1 400668 protease, serine-like 1 0.91 0.95 -0.04 0.053 
PSCD1 9267 cytohesin 1 0.05 0.02 0.03 0.042 
PSCD4 27128 cytohesin 4 0.90 0.94 -0.04 0.074 
PSEN1 5663 presenilin 1 0.03 0.02 0.01 0.094 
PSF1 9837 GINS complex subunit 1 (Psf1 homolog) 0.91 0.94 -0.03 0.065 
PSMA3 5684 proteasome (prosome, macropain) subunit, alpha type, 3 0.05 0.03 0.02 0.089 
PSMB6 5694 proteasome (prosome, macropain) subunit, beta type, 6 0.06 0.03 0.03 0.046 
PSMB7 5695 proteasome (prosome, macropain) subunit, beta type, 7 0.05 0.02 0.03 0.090 
PSMC2 5701 proteasome (prosome, macropain) 26S subunit, ATPase, 2 0.05 0.03 0.02 0.065 
PSMD14 10213 proteasome (prosome, macropain) 26S subunit, non-ATPase, 14 0.03 0.02 0.01 0.093 
PSMD9 5715 proteasome (prosome, macropain) 26S subunit, non-ATPase, 9 0.03 0.01 0.01 0.063 
PSMF1 9491 proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 0.54 0.72 -0.17 0.089 
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PSRC1 84722 proline/serine-rich coiled-coil 1 0.03 0.02 0.01 0.047 
PTAFR 5724 platelet-activating factor receptor 0.74 0.79 -0.04 0.086 
PTBP2 58155 polypyrimidine tract binding protein 2 0.02 0.01 0.01 0.063 
PTCD2 79810 pentatricopeptide repeat domain 2 0.52 0.68 -0.15 0.053 
PTER 9317 phosphotriesterase related 0.07 0.04 0.03 0.067 
PTGS2 5743 
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and 
cyclooxygenase) 
0.03 0.01 0.02 0.048 
PTK6 5753 PTK6 protein tyrosine kinase 6 0.90 0.85 0.04 0.055 
PTK7 5754 PTK7 protein tyrosine kinase 7 0.03 0.01 0.01 0.066 
PTP4A1 7803 protein tyrosine phosphatase type IVA, member 1 0.03 0.02 0.01 0.053 
PTP4A3 11156 protein tyrosine phosphatase type IVA, member 3 0.55 0.70 -0.16 0.068 
PTPN3 5774 protein tyrosine phosphatase, non-receptor type 3 0.82 0.88 -0.06 0.053 
PTPRD 5789 protein tyrosine phosphatase, receptor type, D 0.92 0.96 -0.03 0.063 
PTPRN2 5799 protein tyrosine phosphatase, receptor type, N polypeptide 2 0.03 0.02 0.02 0.074 
PTTG2 10744 pituitary tumor-transforming 2 0.92 0.94 -0.02 0.066 
PUM2 23369 pumilio homolog 2 (Drosophila) 0.38 0.46 -0.07 0.095 
PUS7L 83448 pseudouridylate synthase 7 homolog (S. cerevisiae)-like 0.88 0.95 -0.07 0.038 
PVRL3 25945 poliovirus receptor-related 3 0.04 0.02 0.01 0.067 
PVT1 5820 Pvt1 oncogene (non-protein coding) 0.91 0.95 -0.03 0.063 
PWCR1 63968 #N/A 0.74 0.83 -0.09 0.088 
PXT1 222659 peroxisomal, testis specific 1 0.76 0.83 -0.08 0.094 
PYGM 5837 phosphorylase, glycogen, muscle 0.92 0.96 -0.04 0.055 
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PYY2 23615 peptide YY, 2 (seminalplasmin) 0.77 0.87 -0.10 0.055 
QARS 5859 glutaminyl-tRNA synthetase 0.04 0.02 0.01 0.071 
QRSL1 55278 glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 0.01 0.01 0.01 0.087 
RAB34 83871 RAB34, member RAS oncogene family 0.94 0.97 -0.02 0.084 
RAB3C 115827 RAB3C, member RAS oncogene family 0.08 0.04 0.04 0.060 
RAB3IL1 5866 RAB3A interacting protein (rabin3)-like 1 0.02 0.01 0.01 0.055 
RAB4A 5867 RAB4A, member RAS oncogene family 0.13 0.09 0.04 0.081 
RAB5A 5868 RAB5A, member RAS oncogene family 0.10 0.06 0.03 0.063 
RAB5B 5869 RAB5B, member RAS oncogene family 0.05 0.02 0.03 0.038 
RAB8A 4218 RAB8A, member RAS oncogene family 0.81 0.72 0.09 0.066 
RABGGTA 5875 Rab geranylgeranyltransferase, alpha subunit 0.87 0.83 0.04 0.086 
RACGAP1 29127 Rac GTPase activating protein 1 0.87 0.92 -0.06 0.099 
RAD23A 5886 RAD23 homolog A (S. cerevisiae) 0.34 0.47 -0.13 0.087 
RAD52 5893 RAD52 homolog (S. cerevisiae) 0.05 0.03 0.03 0.065 
RAI16 64760 family with sequence similarity 160, member B2 0.86 0.92 -0.05 0.063 
RAI17 57178 zinc finger, MIZ-type containing 1 0.80 0.87 -0.07 0.076 
RALBP1 10928 ralA binding protein 1 0.16 0.12 0.04 0.064 
RANBP2 5903 RAN binding protein 2 0.04 0.02 0.02 0.045 
RAPGEF1 2889 Rap guanine nucleotide exchange factor (GEF) 1 0.50 0.61 -0.11 0.042 
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RASA1 5921 RAS p21 protein activator (GTPase activating protein) 1 0.05 0.03 0.02 0.042 
RASGRP3 25780 RAS guanyl releasing protein 3 (calcium and DAG-regulated) 0.43 0.57 -0.14 0.081 
RB1 5925 retinoblastoma 1 0.82 0.74 0.08 0.065 
RB1 5925 retinoblastoma 1 0.94 0.91 0.03 0.083 
RB1 5925 retinoblastoma 1 0.57 0.68 -0.11 0.084 
RBAF600 23352 ubiquitin protein ligase E3 component n-recognin 4 0.03 0.02 0.01 0.070 
RBBP4 5928 retinoblastoma binding protein 4 0.57 0.68 -0.11 0.073 
RBBP7 5931 retinoblastoma binding protein 7 0.85 0.89 -0.05 0.053 
RBKS 64080 ribokinase 0.14 0.09 0.05 0.074 
RBM10 8241 RNA binding motif protein 10 0.69 0.79 -0.11 0.080 
RBM12 10137 RNA binding motif protein 12 0.02 0.01 0.01 0.073 
RBM21 64852 terminal uridylyl transferase 1, U6 snRNA-specific 0.03 0.02 0.02 0.085 
RBP2 5948 retinol binding protein 2, cellular 0.45 0.57 -0.12 0.098 
RC74 55756 integrator complex subunit 9 0.03 0.01 0.01 0.066 
RCD-8 23644 enhancer of mRNA decapping 4 0.04 0.02 0.01 0.076 
RDH11 51109 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 0.02 0.01 0.01 0.067 
RDS 5961 peripherin 2 (retinal degeneration, slow) 0.66 0.77 -0.11 0.085 
REG1A 5967 regenerating islet-derived 1 alpha 0.81 0.89 -0.08 0.065 
REG1A 5967 regenerating islet-derived 1 alpha 0.49 0.62 -0.13 0.070 
REPIN1 29803 replication initiator 1 0.52 0.69 -0.17 0.063 
REXO2 25996 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 0.04 0.02 0.01 0.063 
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RFC1 5981 replication factor C (activator 1) 1, 145kDa 0.05 0.03 0.02 0.059 
Rgr 266747 ral guanine nucleotide dissociation stimulator-like 4 0.77 0.87 -0.10 0.063 
Rgr 266747 ral guanine nucleotide dissociation stimulator-like 4 0.80 0.84 -0.04 0.073 
RGS13 6003 regulator of G-protein signaling 13 0.06 0.11 -0.05 0.063 
RGS3 5998 regulator of G-protein signaling 3 0.80 0.88 -0.07 0.098 
RGS6 9628 regulator of G-protein signaling 6 0.14 0.10 0.04 0.086 
RGSL1 353299 regulator of G-protein signaling like 1 0.81 0.89 -0.08 0.042 
RHO 6010 rhodopsin 0.08 0.10 -0.02 0.094 
RHOBTB3 22836 Rho-related BTB domain containing 3 0.02 0.01 0.01 0.074 
RHOD 29984 ras homolog gene family, member D 0.25 0.16 0.09 0.095 
RIMBP2 23504 RIMS binding protein 2 0.63 0.75 -0.12 0.093 
RIMS3 9783 regulating synaptic membrane exocytosis 3 0.80 0.73 0.07 0.086 
RIOK2 55781 RIO kinase 2 (yeast) 0.06 0.04 0.02 0.098 
RIPK3 11035 receptor-interacting serine-threonine kinase 3 0.50 0.64 -0.14 0.053 
RIT1 6016 Ras-like without CAAX 1 0.06 0.04 0.03 0.087 
RLN3 117579 relaxin 3 0.59 0.74 -0.15 0.055 
RNASEH2A 10535 ribonuclease H2, subunit A 0.83 0.89 -0.07 0.072 
RNASEH2A 10535 ribonuclease H2, subunit A 0.05 0.03 0.02 0.100 
RND3 390 Rho family GTPase 3 0.07 0.04 0.03 0.094 
RNF113A 7737 ring finger protein 113A 0.78 0.86 -0.09 0.094 
RNF14 9604 ring finger protein 14 0.70 0.79 -0.10 0.090 
RNF170 81790 ring finger protein 170 0.08 0.04 0.04 0.053 
RNF185 91445 ring finger protein 185 0.09 0.06 0.04 0.071 
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RNF185 91445 ring finger protein 185 0.07 0.05 0.03 0.072 
RNF2 6045 ring finger protein 2 0.02 0.01 0.01 0.084 
RNF41 10193 ring finger protein 41 0.40 0.46 -0.06 0.086 
RNF41 10193 ring finger protein 41 0.02 0.01 0.01 0.092 
RNGTT 8732 RNA guanylyltransferase and 5'-phosphatase 0.06 0.04 0.02 0.088 
ROR1 4919 receptor tyrosine kinase-like orphan receptor 1 0.05 0.03 0.02 0.087 
RPL18 6141 ribosomal protein L18 0.72 0.80 -0.09 0.076 
RPL18A 6142 ribosomal protein L18a 0.08 0.04 0.04 0.063 
RPL21 6144 ribosomal protein L21 pseudogene 0.04 0.02 0.02 0.070 
RPL22 6146 ribosomal protein L22 0.05 0.03 0.02 0.074 
RPL38 6169 ribosomal protein L38 0.06 0.03 0.03 0.081 
RPL5 6125 ribosomal protein L5 0.04 0.02 0.02 0.055 
RPP21 79897 ribonuclease P/MRP 21kDa subunit 0.90 0.95 -0.05 0.063 
RPP38 10557 ribonuclease P/MRP 38kDa subunit 0.02 0.01 0.01 0.074 
RPS19 6223 ribosomal protein S19 0.02 0.01 0.01 0.077 
RPS24 6229 ribosomal protein S24 0.05 0.03 0.02 0.082 
RPS6KA1 6195 ribosomal protein S6 kinase, 90kDa, polypeptide 1 0.66 0.74 -0.08 0.056 
RPS8 6202 ribosomal protein S8 0.03 0.02 0.01 0.082 
RPS9 6203 ribosomal protein S9 0.05 0.03 0.02 0.039 
RQCD1 9125 RCD1 required for cell differentiation1 homolog (S. pombe) 0.05 0.03 0.02 0.081 
RRAGB 10325 Ras-related GTP binding B 0.68 0.75 -0.07 0.065 
RRAS 6237 related RAS viral (r-ras) oncogene homolog 0.03 0.02 0.01 0.070 
RTBDN 83546 retbindin 0.77 0.87 -0.10 0.047 
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RTN3 10313 reticulon 3 0.03 0.02 0.01 0.070 
RTN4RL2 349667 reticulon 4 receptor-like 2 0.07 0.05 0.03 0.067 
RUNX3 864 runt-related transcription factor 3 0.88 0.92 -0.04 0.070 
RUNX3 864 runt-related transcription factor 3 0.06 0.09 -0.03 0.087 
RUNX3 864 runt-related transcription factor 3 0.81 0.89 -0.08 0.094 
S100A1 6271 S100 calcium binding protein A1 0.87 0.92 -0.04 0.089 
S100A11 6282 S100 calcium binding protein A11 0.03 0.02 0.01 0.065 
S100A16 140576 S100 calcium binding protein A16 0.79 0.84 -0.06 0.090 
S100P 6286 S100 calcium binding protein P 0.59 0.65 -0.07 0.077 
SACS 26278 spastic ataxia of Charlevoix-Saguenay (sacsin) 0.69 0.83 -0.14 0.046 
SAG 6295 retina and pineal gland (arrestin) 0.48 0.60 -0.11 0.055 
SAGE1 55511 sarcoma antigen 1 0.70 0.81 -0.12 0.053 
SAMD12 401474 sterile alpha motif domain containing 12 0.02 0.01 0.01 0.074 
SAP18 10284 Sin3A-associated protein, 18kDa 0.04 0.02 0.02 0.063 
SART3 9733 squamous cell carcinoma antigen recognized by T cells 3 0.02 0.02 0.01 0.100 
SAS10 57050 
UTP3, small subunit (SSU) 
processome component, homolog (S. 
cerevisiae) 
0.04 0.02 0.02 0.080 
SBNO1 55206 strawberry notch homolog 1 (Drosophila) 0.12 0.20 -0.08 0.053 
SBNO1 55206 strawberry notch homolog 1 (Drosophila) 0.84 0.89 -0.05 0.072 
SBP1 90198 chromosome 19 open reading frame 49 0.80 0.91 -0.11 0.050 
SC5DL 6309 
sterol-C5-desaturase (ERG3 delta-5-
desaturase homolog, S. cerevisiae)-
like 
0.05 0.02 0.03 0.058 
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SCAMP2 10066 secretory carrier membrane protein 2 0.04 0.02 0.02 0.074 
SCAMP3 10067 secretory carrier membrane protein 3 0.10 0.07 0.03 0.098 
SCDR10 374875 hydroxysteroid (11-beta) dehydrogenase 1-like 0.04 0.03 0.01 0.087 
SCEL 8796 sciellin 0.66 0.80 -0.14 0.055 
SCML1 6322 sex comb on midleg-like 1 (Drosophila) 0.72 0.83 -0.10 0.055 
SCN7A 6332 sodium channel, voltage-gated, type VII, alpha 0.88 0.92 -0.03 0.065 
SCRN1 9805 secernin 1 0.80 0.88 -0.07 0.098 
SCRN3 79634 secernin 3 0.04 0.02 0.02 0.065 
SCTR 6344 secretin receptor 0.28 0.39 -0.11 0.075 
SCUBE1 80274 signal peptide, CUB domain, EGF-like 1 0.12 0.07 0.06 0.085 
SDCCAG1 9147 serologically defined colon cancer antigen 1 0.04 0.02 0.02 0.068 
SDCCAG33 10194 teashirt zinc finger homeobox 1 0.77 0.87 -0.10 0.085 
SDF2 6388 stromal cell-derived factor 2 0.05 0.04 0.02 0.094 
SDHA 6389 succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 0.87 0.89 -0.03 0.094 
SEC10L1 10640 exocyst complex component 5 0.10 0.06 0.05 0.081 
SEMA6B 10501 
sema domain, transmembrane domain 
(TM), and cytoplasmic domain, 
(semaphorin) 6B 
0.66 0.56 0.10 0.094 
SEPHS1 22929 selenophosphate synthetase 1 0.08 0.05 0.03 0.064 
SEPT2 4735 septin 2 0.04 0.03 0.01 0.074 
SERF2 10169 small EDRK-rich factor 2 0.02 0.01 0.01 0.057 
SERPINA7 6906 
serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), 
member 7 
0.11 0.18 -0.08 0.074 
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SERPINB4 6318 serpin peptidase inhibitor, clade B (ovalbumin), member 4 0.40 0.54 -0.14 0.050 
SERPINB7 8710 serpin peptidase inhibitor, clade B (ovalbumin), member 7 0.58 0.72 -0.14 0.042 
SERPINB7 8710 serpin peptidase inhibitor, clade B (ovalbumin), member 7 0.82 0.90 -0.08 0.053 
SERPINF1 5176 
serpin peptidase inhibitor, clade F 
(alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 
0.81 0.76 0.05 0.094 
SERPINI1 5274 serpin peptidase inhibitor, clade I (neuroserpin), member 1 0.78 0.87 -0.08 0.046 
SERTAD1 29950 SERTA domain containing 1 0.02 0.01 0.01 0.086 
SETBP1 26040 SET binding protein 1 0.85 0.91 -0.06 0.055 
SETBP1 26040 SET binding protein 1 0.09 0.12 -0.04 0.065 
SFRP2 6423 secreted frizzled-related protein 2 0.13 0.09 0.04 0.067 
SFRP5 6425 secreted frizzled-related protein 5 0.14 0.08 0.07 0.064 
SFRS16 11129 splicing factor, arginine/serine-rich 16 0.75 0.86 -0.11 0.080 
SFRS5 6430 splicing factor, arginine/serine-rich 5 0.05 0.02 0.03 0.077 
SFTPB 6439 surfactant protein B 0.82 0.77 0.05 0.099 
SFXN2 118980 sideroflexin 2 0.05 0.03 0.02 0.040 
SH2D4B 387694 SH2 domain containing 4B 0.95 0.97 -0.02 0.086 
SH3KBP1 30011 SH3-domain kinase binding protein 1 0.60 0.73 -0.14 0.089 
SH3RF2 153769 SH3 domain containing ring finger 2 0.09 0.06 0.03 0.098 
SHCBP1 79801 SHC SH2-domain binding protein 1 0.06 0.03 0.02 0.089 
SHFM1 7979 split hand/foot malformation (ectrodactyly) type 1 0.05 0.03 0.02 0.074 
SIAE 54414 sialic acid acetylesterase 0.71 0.81 -0.10 0.041 
SIN3A 25942 SIN3 homolog A, transcription regulator (yeast) 0.04 0.02 0.02 0.091 
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SIRT1 23411 sirtuin (silent mating type information regulation 2 homolog) 1 (S. cerevisiae) 0.88 0.92 -0.04 0.087 
SITPEC 51295 ECSIT homolog (Drosophila) 0.02 0.02 0.01 0.065 
SLAMF8 56833 SLAM family member 8 0.11 0.23 -0.12 0.054 
SLC12A1 6557 
solute carrier family 12 
(sodium/potassium/chloride 
transporters), member 1 
0.91 0.95 -0.04 0.067 
SLC12A3 6559 
solute carrier family 12 
(sodium/chloride transporters), 
member 3 
0.53 0.61 -0.08 0.087 
SLC12A9 56996 
solute carrier family 12 
(potassium/chloride transporters), 
member 9 
0.10 0.05 0.05 0.081 
SLC13A4 26266 
solute carrier family 13 
(sodium/sulfate symporters), member 
4 
0.68 0.75 -0.07 0.076 
SLC14A1 6563 
solute carrier family 14 (urea 
transporter), member 1 (Kidd blood 
group) 
0.39 0.53 -0.13 0.086 
SLC16A6 9120 solute carrier family 16, member 6 (monocarboxylic acid transporter 7) 0.01 0.01 0.00 0.095 
SLC17A2 10246 solute carrier family 17 (sodium phosphate), member 2 0.77 0.84 -0.08 0.087 
SLC17A6 57084 
solute carrier family 17 (sodium-
dependent inorganic phosphate 
cotransporter), member 6 
0.08 0.03 0.05 0.067 
SLC19A3 80704 solute carrier family 19, member 3 0.03 0.02 0.01 0.056 
SLC1A7 6512 solute carrier family 1 (glutamate transporter), member 7 0.91 0.94 -0.03 0.083 
SLC25A12 8604 solute carrier family 25 (mitochondrial carrier, Aralar), member 12 0.06 0.03 0.03 0.099 
SLC25A13 10165 solute carrier family 25, member 13 (citrin) 0.08 0.05 0.02 0.050 
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SLC25A16 8034 
solute carrier family 25 (mitochondrial 
carrier; Graves disease autoantigen), 
member 16 
0.92 0.95 -0.03 0.063 
SLC25A2 83884 
solute carrier family 25 (mitochondrial 
carrier; ornithine transporter) member 
2 
0.80 0.88 -0.08 0.066 
SLC25A20 788 
solute carrier family 25 
(carnitine/acylcarnitine translocase), 
member 20 
0.59 0.73 -0.14 0.063 
SLC25A35 399512 solute carrier family 25, member 35 0.81 0.77 0.05 0.080 
SLC28A2 9153 
solute carrier family 28 (sodium-
coupled nucleoside transporter), 
member 2 
0.67 0.79 -0.13 0.073 
SLC28A2 9153 
solute carrier family 28 (sodium-
coupled nucleoside transporter), 
member 2 
0.81 0.75 0.06 0.075 
SLC29A2 3177 solute carrier family 29 (nucleoside transporters), member 2 0.06 0.04 0.02 0.047 
SLC29A4 222962 solute carrier family 29 (nucleoside transporters), member 4 0.74 0.84 -0.10 0.074 
SLC2A10 81031 solute carrier family 2 (facilitated glucose transporter), member 10 0.86 0.90 -0.04 0.095 
SLC2A7 155184 solute carrier family 2 (facilitated glucose transporter), member 7 0.79 0.87 -0.08 0.073 
SLC2A7 155184 solute carrier family 2 (facilitated glucose transporter), member 7 0.94 0.96 -0.02 0.094 
SLC31A1 1317 solute carrier family 31 (copper transporters), member 1 0.09 0.04 0.05 0.095 
SLC33A1 9197 solute carrier family 33 (acetyl-CoA transporter), member 1 0.04 0.02 0.02 0.078 
SLC34A1 6569 solute carrier family 34 (sodium phosphate), member 1 0.67 0.76 -0.10 0.086 
SLC35C1 55343 solute carrier family 35, member C1 0.68 0.76 -0.08 0.094 
SLC35E3 55508 solute carrier family 35, member E3 0.02 0.01 0.01 0.055 
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SLC35F2 54733 solute carrier family 35, member F2 0.02 0.01 0.01 0.076 
SLC36A3 285641 solute carrier family 36 (proton/amino acid symporter), member 3 0.68 0.77 -0.09 0.067 
SLC39A11 201266 solute carrier family 39 (metal ion transporter), member 11 0.08 0.06 0.03 0.059 
SLC39A12 221074 solute carrier family 39 (zinc transporter), member 12 0.60 0.73 -0.14 0.065 
SLC39A8 64116 solute carrier family 39 (zinc transporter), member 8 0.06 0.04 0.02 0.099 
SLC3A1 6519 
solute carrier family 3 (cystine, dibasic 
and neutral amino acid transporters, 
activator of cystine, dibasic and 
neutral amino acid transport), member 
1 
0.77 0.89 -0.12 0.054 
SLC4A1 6521 
solute carrier family 4, anion 
exchanger, member 1 (erythrocyte 
membrane protein band 3, Diego 
blood group) 
0.62 0.75 -0.12 0.071 
SLC4A5 57835 solute carrier family 4, sodium bicarbonate cotransporter, member 5 0.71 0.85 -0.14 0.063 
SLC4A5 57835 solute carrier family 4, sodium bicarbonate cotransporter, member 5 0.58 0.68 -0.10 0.094 
SLC5A2 6524 
solute carrier family 5 
(sodium/glucose cotransporter), 
member 2 
0.57 0.68 -0.11 0.053 
SLC5A2 6524 
solute carrier family 5 
(sodium/glucose cotransporter), 
member 2 
0.80 0.89 -0.09 0.064 
SLC5A6 8884 
solute carrier family 5 (sodium-
dependent vitamin transporter), 
member 6 
0.07 0.04 0.03 0.056 
SLC5A7 60482 solute carrier family 5 (choline transporter), member 7 0.89 0.86 0.03 0.090 
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SLC7A11 23657 
solute carrier family 7, (cationic amino 
acid transporter, y+ system) member 
11 
0.12 0.17 -0.05 0.077 
SLITRK1 114798 SLIT and NTRK-like family, member 1 0.03 0.02 0.01 0.098 
SLITRK4 139065 SLIT and NTRK-like family, member 4 0.84 0.89 -0.05 0.094 
SLPI 6590 secretory leukocyte peptidase inhibitor 0.90 0.94 -0.04 0.066 
SMAD9 4093 SMAD family member 9 0.92 0.94 -0.02 0.099 
SMARCD3 6604 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily d, member 3 
0.07 0.04 0.03 0.065 
SMARCD3 6604 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily d, member 3 
0.05 0.02 0.03 0.066 
SMC2L1 10592 structural maintenance of chromosomes 2 0.05 0.03 0.02 0.050 
SMCP 4184 sperm mitochondria-associated cysteine-rich protein 0.15 0.24 -0.08 0.065 
SMEK2 57223 SMEK homolog 2, suppressor of mek1 (Dictyostelium) 0.04 0.03 0.01 0.065 
SMNDC1 10285 survival motor neuron domain containing 1 0.04 0.03 0.02 0.092 
SMR3A 26952 submaxillary gland androgen regulated protein 3A 0.74 0.84 -0.10 0.064 
SNAI1 6615 snail homolog 1 (Drosophila) 0.05 0.02 0.03 0.076 
SNAPAP 23557 SNAP-associated protein 0.71 0.82 -0.11 0.067 
SNCA 6622 synuclein, alpha (non A4 component of amyloid precursor) 0.02 0.01 0.01 0.066 
SNF1LK2 23235 salt-inducible kinase 2 0.08 0.05 0.03 0.040 
SNRPA 6626 small nuclear ribonucleoprotein polypeptide A 0.78 0.87 -0.10 0.065 
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SNTA1 6640 
syntrophin, alpha 1 (dystrophin-
associated protein A1, 59kDa, acidic 
component) 
0.06 0.04 0.02 0.064 
SNTB1 6641 
syntrophin, beta 1 (dystrophin-
associated protein A1, 59kDa, basic 
component 1) 
0.87 0.93 -0.06 0.073 
SNURF 8926 SNRPN upstream reading frame 0.67 0.77 -0.10 0.094 
SNX14 57231 sorting nexin 14 0.04 0.02 0.02 0.046 
SOCS2 8835 suppressor of cytokine signaling 2 0.03 0.02 0.01 0.095 
SORBS2 8470 sorbin and SH3 domain containing 2 0.70 0.76 -0.06 0.073 
SOX3 6658 SRY (sex determining region Y)-box 3 0.75 0.85 -0.09 0.086 
SPACA4 171169 sperm acrosome associated 4 0.36 0.49 -0.13 0.053 
SPAG4L 140732 sperm associated antigen 4-like 0.80 0.85 -0.05 0.094 
SPAM1 6677 sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) 0.88 0.94 -0.06 0.046 
SPAM1 6677 sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) 0.85 0.88 -0.03 0.074 
SPAST 6683 spastin 0.03 0.02 0.01 0.055 
SPATA1 64173 spermatogenesis associated 1 0.08 0.03 0.05 0.053 
SPATA3 130560 spermatogenesis associated 3 0.66 0.73 -0.07 0.073 
SPATA8 145946 spermatogenesis associated 8 0.90 0.93 -0.03 0.077 
SPDEF 25803 SAM pointed domain containing ets transcription factor 0.78 0.85 -0.07 0.064 
SPIN 10927 spindlin 1 0.04 0.02 0.02 0.040 
SPIN 10927 spindlin 1 0.02 0.01 0.01 0.098 
SPINLW1 57119 serine peptidase inhibitor-like, with Kunitz and WAP domains 1 (eppin) 0.58 0.70 -0.12 0.094 
SPRR2A 6700 small proline-rich protein 2A 0.51 0.61 -0.10 0.094 
SPTBN2 6712 spectrin, beta, non-erythrocytic 2 0.86 0.92 -0.06 0.055 
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SRC 6714 v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) 0.65 0.74 -0.09 0.077 
SRP54 6729 signal recognition particle 54kDa 0.03 0.01 0.01 0.067 
SRP54 6729 signal recognition particle 54kDa 0.06 0.04 0.03 0.082 
SSNA1 8636 Sjogren syndrome nuclear autoantigen 1 0.93 0.88 0.05 0.064 
SSR2 6746 signal sequence receptor, beta (translocon-associated protein beta) 0.06 0.03 0.02 0.075 
SSX1 6756 synovial sarcoma, X breakpoint 1 0.86 0.79 0.07 0.098 
ST3GAL5 8869 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 0.02 0.01 0.01 0.074 
ST8SIA4 7903 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4 0.05 0.03 0.02 0.075 
STARD6 147323 StAR-related lipid transfer (START) domain containing 6 0.70 0.84 -0.15 0.047 
STCH 6782 heat shock protein 70kDa family, member 13 0.05 0.03 0.02 0.038 
STIM2 57620 stromal interaction molecule 2 0.03 0.02 0.01 0.065 
STIP1 10963 stress-induced-phosphoprotein 1 0.04 0.03 0.02 0.055 
STK31 56164 serine/threonine kinase 31 0.76 0.84 -0.08 0.095 
STOML1 9399 stomatin (EPB72)-like 1 0.06 0.03 0.03 0.067 
STON1 11037 stonin 1 0.92 0.90 0.02 0.086 
STRN 6801 striatin, calmodulin binding protein 0.01 0.01 0.01 0.074 
STX17 55014 syntaxin 17 0.04 0.02 0.02 0.038 
STX17 55014 syntaxin 17 0.03 0.02 0.01 0.078 
STX6 10228 syntaxin 6 0.05 0.03 0.02 0.098 
SULT1A1 6817 sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 0.13 0.03 0.10 0.058 
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SULT1B1 27284 sulfotransferase family, cytosolic, 1B, member 1 0.60 0.71 -0.11 0.066 
SUMO2 6613 SMT3 suppressor of mif two 3 homolog 2 (S. cerevisiae) 0.02 0.01 0.01 0.070 
SUPT5H 6829 suppressor of Ty 5 homolog (S. cerevisiae) 0.07 0.04 0.03 0.067 
SUPV3L1 6832 suppressor of var1, 3-like 1 (S. cerevisiae) 0.01 0.01 0.00 0.090 
SYCP3 50511 synaptonemal complex protein 3 0.97 0.98 -0.01 0.079 
SYT6 148281 synaptotagmin VI 0.02 0.02 0.01 0.095 
TAAR1 134864 trace amine associated receptor 1 0.60 0.71 -0.11 0.070 
TAAR5 9038 trace amine associated receptor 5 0.83 0.69 0.14 0.066 
TACC2 10579 transforming, acidic coiled-coil containing protein 2 0.65 0.74 -0.09 0.089 
TADA1L 117143 transcriptional adaptor 1 (HFI1 homolog, yeast)-like 0.03 0.02 0.01 0.065 
TAF13 6884 
TAF13 RNA polymerase II, TATA 
box binding protein (TBP)-associated 
factor, 18kDa 
0.03 0.01 0.02 0.084 
TAF1B 9014 
TATA box binding protein (TBP)-
associated factor, RNA polymerase I, 
B, 63kDa 
0.04 0.02 0.02 0.047 
TAL2 6887 T-cell acute lymphocytic leukemia 2 0.76 0.85 -0.09 0.074 
TAPBP 6892 TAP binding protein (tapasin) 0.12 0.07 0.04 0.067 
TAS2R48 259294 taste receptor, type 2, member 19 0.48 0.65 -0.17 0.055 
TAS2R5 54429 taste receptor, type 2, member 5 0.49 0.57 -0.08 0.086 
TAS2R5 54429 taste receptor, type 2, member 5 0.20 0.31 -0.11 0.094 
TBC1D10C 374403 TBC1 domain family, member 10C 0.83 0.87 -0.04 0.099 
TBC1D7 51256 TBC1 domain family, member 7 0.67 0.75 -0.08 0.089 
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TBRG4 9238 transforming growth factor beta regulator 4 0.05 0.02 0.03 0.046 
TBXAS1 6916 thromboxane A synthase 1 (platelet) 0.43 0.67 -0.24 0.042 
TCEA1 6917 transcription elongation factor A (SII), 1 0.04 0.02 0.02 0.063 
TCEB3B 51224 transcription elongation factor B polypeptide 3B (elongin A2) 0.62 0.72 -0.10 0.088 
TCEB3C 162699 transcription elongation factor B polypeptide 3C-like 0.79 0.84 -0.05 0.098 
TCIRG1 10312 
T-cell, immune regulator 1, ATPase, 
H+ transporting, lysosomal V0 subunit 
A3 
0.91 0.88 0.03 0.057 
TCP10L 140290 t-complex 10 (mouse)-like 0.54 0.67 -0.12 0.069 
TCP11L1 55346 t-complex 11 (mouse)-like 1 0.08 0.04 0.04 0.038 
TDRD1 56165 tudor domain containing 1 0.65 0.77 -0.12 0.086 
TEAD1 7003 TEA domain family member 1 (SV40 transcriptional enhancer factor) 0.79 0.89 -0.09 0.058 
TEAD2 8463 TEA domain family member 2 0.06 0.04 0.02 0.074 
TEKT2 27285 tektin 2 (testicular) 0.26 0.36 -0.10 0.076 
TENC1 23371 tensin like C1 domain containing phosphatase (tensin 2) 0.02 0.01 0.01 0.069 
TFPI2 7980 tissue factor pathway inhibitor 2 0.03 0.02 0.01 0.065 
TFPT 29844 TCF3 (E2A) fusion partner (in childhood Leukemia) 0.60 0.71 -0.11 0.079 
TG 7038 thyroglobulin 0.59 0.75 -0.17 0.090 
TGM4 7047 transglutaminase 4 (prostate) 0.86 0.91 -0.05 0.098 
THEDC1 55301 oleoyl-ACP hydrolase 0.57 0.68 -0.10 0.085 
THEM5 284486 thioesterase superfamily member 5 0.71 0.81 -0.10 0.047 
THRAP5 10025 mediator complex subunit 16 0.02 0.01 0.01 0.094 
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NP ∆β FDR 
THRSP 7069 thyroid hormone responsive (SPOT14 homolog, rat) 0.41 0.57 -0.15 0.065 
THSD1 55901 thrombospondin, type I, domain containing 1 0.08 0.06 0.02 0.066 
THSD4 79875 thrombospondin, type I, domain containing 4 0.89 0.94 -0.05 0.066 
TIAF1 9220 TGFB1-induced anti-apoptotic factor 1 0.72 0.79 -0.07 0.053 
TICAM1 148022 toll-like receptor adaptor molecule 1 0.87 0.93 -0.05 0.055 
TICAM1 148022 toll-like receptor adaptor molecule 1 0.89 0.96 -0.07 0.089 
TIGD2 166815 tigger transposable element derived 2 0.73 0.86 -0.13 0.025 
TJP3 27134 tight junction protein 3 (zona occludens 3) 0.75 0.68 0.07 0.047 
TJP3 27134 tight junction protein 3 (zona occludens 3) 0.87 0.94 -0.07 0.094 
TLK1 9874 tousled-like kinase 1 0.05 0.03 0.02 0.087 
TLOC1 7095 SEC62 homolog (S. cerevisiae) 0.02 0.01 0.01 0.094 
TLR4 7099 toll-like receptor 4 0.06 0.04 0.02 0.065 
TLR6 10333 toll-like receptor 6 0.74 0.86 -0.12 0.077 
TLX1 3195 T-cell leukemia homeobox 1 0.64 0.80 -0.15 0.055 
TM4SF19 116211 transmembrane 4 L six family member 19 0.90 0.94 -0.03 0.060 
TMC1 117531 transmembrane channel-like 1 0.84 0.89 -0.06 0.074 
TMCC1 23023 transmembrane and coiled-coil domain family 1 0.38 0.49 -0.11 0.068 
TMED6 146456 transmembrane emp24 protein transport domain containing 6 0.56 0.70 -0.13 0.053 
TMEM113 80335 WD repeat domain 82 0.45 0.56 -0.11 0.066 
TMEM125 128218 transmembrane protein 125 0.07 0.04 0.03 0.065 
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TMEM23 259230 sphingomyelin synthase 1 0.07 0.04 0.03 0.038 
TMEM25 84866 transmembrane protein 25 0.05 0.03 0.02 0.066 
TMEM30A 55754 transmembrane protein 30A 0.05 0.04 0.01 0.066 
TMEM39A 55254 transmembrane protein 39A 0.03 0.02 0.01 0.063 
TMEM41A 90407 transmembrane protein 41A 0.84 0.90 -0.06 0.090 
TMEM42 131616 transmembrane protein 42 0.21 0.13 0.08 0.076 
TMEM45A 55076 transmembrane protein 45A 0.04 0.02 0.02 0.045 
TMEM55B 90809 transmembrane protein 55B 0.03 0.02 0.01 0.079 
TMEM66 51669 transmembrane protein 66 0.04 0.03 0.01 0.074 
TMEM81 388730 transmembrane protein 81 0.07 0.13 -0.07 0.047 
TMEM9 252839 transmembrane protein 9 0.03 0.02 0.01 0.066 
TMEM9 252839 transmembrane protein 9 0.04 0.03 0.02 0.086 
TMOD1 7111 tropomodulin 1 0.83 0.89 -0.06 0.095 
TMOD4 29765 tropomodulin 4 (muscle) 0.73 0.84 -0.11 0.039 
TMPRSS11D 9407 transmembrane protease, serine 11D 0.57 0.66 -0.09 0.050 
TMPRSS3 64699 transmembrane protease, serine 3 0.68 0.80 -0.12 0.073 
TMTC4 84899 transmembrane and tetratricopeptide repeat containing 4 0.81 0.89 -0.08 0.067 
TNFAIP8L2 79626 tumor necrosis factor, alpha-induced protein 8-like 2 0.75 0.86 -0.10 0.055 
TNFRSF17 608 tumor necrosis factor receptor superfamily, member 17 0.16 0.23 -0.08 0.089 
TNFRSF25 8718 tumor necrosis factor receptor superfamily, member 25 0.80 0.86 -0.06 0.098 
TNNT2 7139 troponin T type 2 (cardiac) 0.87 0.92 -0.05 0.042 
TNNT3 7140 troponin T type 3 (skeletal, fast) 0.78 0.86 -0.08 0.067 
TOB1 10140 transducer of ERBB2, 1 0.03 0.02 0.01 0.081 
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Mean β 
NP ∆β FDR 
TOR2A 27433 torsin family 2, member A 0.74 0.85 -0.11 0.064 
TP53BP1 7158 tumor protein p53 binding protein 1 0.03 0.01 0.02 0.075 
TP73 7161 tumor protein p73 0.89 0.93 -0.04 0.057 
TP73 7161 tumor protein p73 0.76 0.85 -0.09 0.067 
TP73 7161 tumor protein p73 0.86 0.90 -0.04 0.091 
TRAPPC6B 122553 trafficking protein particle complex 6B 0.03 0.02 0.01 0.053 
TRIAD3 54476 ring finger protein 216 0.87 0.93 -0.05 0.066 
TRIM16 10626 tripartite motif-containing 16 0.65 0.74 -0.10 0.074 
TRIM17 51127 tripartite motif-containing 17 0.13 0.08 0.05 0.047 
TRIM24 8805 tripartite motif-containing 24 0.07 0.04 0.03 0.055 
TRIM29 23650 tripartite motif-containing 29 0.89 0.92 -0.03 0.099 
TRIM41 90933 tripartite motif-containing 41 0.06 0.03 0.02 0.086 
TRIM42 287015 tripartite motif-containing 42 0.88 0.93 -0.05 0.050 
TRIM9 114088 tripartite motif-containing 9 0.05 0.03 0.02 0.038 
TRIP4 9325 thyroid hormone receptor interactor 4 0.04 0.03 0.01 0.084 
TRPC4AP 26133 
transient receptor potential cation 
channel, subfamily C, member 4 
associated protein 
0.06 0.03 0.03 0.066 
TRPM6 140803 transient receptor potential cation channel, subfamily M, member 6 0.86 0.93 -0.07 0.045 
TRPM8 79054 transient receptor potential cation channel, subfamily M, member 8 0.78 0.89 -0.11 0.038 
TRPV6 55503 transient receptor potential cation channel, subfamily V, member 6 0.78 0.86 -0.08 0.074 
TSC2 7249 tuberous sclerosis 2 0.74 0.81 -0.07 0.086 
TSCOT 57864 solute carrier family 46, member 2 0.83 0.89 -0.06 0.086 
TSKS 60385 testis-specific serine kinase substrate 0.87 0.92 -0.05 0.064 
TSPAN15 23555 tetraspanin 15 0.05 0.03 0.02 0.070 
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TSPAN2 10100 tetraspanin 2 0.03 0.01 0.01 0.074 
TSPAN9 10867 tetraspanin 9 0.06 0.02 0.04 0.064 
TSSK2 23617 testis-specific serine kinase 2 0.90 0.93 -0.03 0.094 
TSSK4 283629 testis-specific serine kinase 4 0.78 0.89 -0.11 0.038 
TSSK6 83983 testis-specific serine kinase 6 0.86 0.91 -0.04 0.084 
TTC13 79573 tetratricopeptide repeat domain 13 0.90 0.94 -0.04 0.038 
TTF2 8458 transcription termination factor, RNA polymerase II 0.03 0.02 0.01 0.075 
TTK 7272 TTK protein kinase 0.04 0.02 0.01 0.087 
TTLL2 83887 tubulin tyrosine ligase-like family, member 2 0.51 0.59 -0.08 0.080 
TTLL6 284076 tubulin tyrosine ligase-like family, member 6 0.59 0.73 -0.14 0.045 
TUBB1 81027 tubulin, beta 1 0.60 0.77 -0.17 0.063 
TUG1 55000 taurine upregulated 1 (non-protein coding) 0.06 0.03 0.03 0.063 
TULP1 7287 tubby like protein 1 0.94 0.92 0.02 0.066 
TXNDC2 84203 thioredoxin domain containing 2 (spermatozoa) 0.56 0.65 -0.09 0.063 
TXNDC6 347736 thioredoxin domain containing 6 0.02 0.01 0.01 0.074 
UBADC1 10422 UBA domain containing 1 0.05 0.03 0.02 0.080 
UBD 10537 ubiquitin D 0.71 0.76 -0.06 0.074 
UBE1DC1 79876 ubiquitin-like modifier activating enzyme 5 0.04 0.02 0.02 0.045 
UBE1L2 55236 ubiquitin-like modifier activating enzyme 6 0.02 0.01 0.01 0.071 
UBE2B 7320 ubiquitin-conjugating enzyme E2B (RAD6 homolog) 0.03 0.02 0.01 0.052 
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UBE2B 7320 ubiquitin-conjugating enzyme E2B (RAD6 homolog) 0.05 0.03 0.02 0.081 
UBE2D3 7323 ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 0.02 0.02 0.01 0.098 
UBE2E1 7324 ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast) 0.76 0.84 -0.08 0.047 
UBE2U 148581 ubiquitin-conjugating enzyme E2U (putative) 0.71 0.81 -0.10 0.053 
UBTF 7343 upstream binding transcription factor, RNA polymerase I 0.04 0.03 0.01 0.098 
UCN2 90226 urocortin 2 0.71 0.84 -0.13 0.066 
UGT1A1 54658 UDP glucuronosyltransferase 1 family, polypeptide A1 0.88 0.92 -0.04 0.089 
UGT2A3 79799 UDP glucuronosyltransferase 2 family, polypeptide A3 0.78 0.90 -0.12 0.066 
UGT2B4 7363 UDP glucuronosyltransferase 2 family, polypeptide B4 0.87 0.90 -0.03 0.094 
UNC5CL 222643 unc-5 homolog C (C. elegans)-like 0.81 0.89 -0.08 0.063 
UNQ9391 203074 tryptophan/serine protease 0.90 0.85 0.04 0.080 
UPP2 151531 uridine phosphorylase 2 0.82 0.91 -0.08 0.086 
UQCRH 7388 ubiquinol-cytochrome c reductase hinge protein-like 0.12 0.07 0.06 0.098 
USF2 7392 upstream transcription factor 2, c-fos interacting 0.07 0.04 0.03 0.095 
USP29 57663 ubiquitin specific peptidase 29 0.78 0.88 -0.09 0.065 
USP32 84669 ubiquitin specific peptidase 32 0.05 0.04 0.01 0.088 
USP54 159195 ubiquitin specific peptidase 54 0.76 0.84 -0.08 0.047 
UTP11L 51118 UTP11-like, U3 small nucleolar ribonucleoprotein, (yeast) 0.05 0.03 0.02 0.057 
UVRAG 7405 UV radiation resistance associated gene 0.03 0.02 0.01 0.073 
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VAMP8 8673 vesicle-associated membrane protein 8 (endobrevin) 0.59 0.70 -0.11 0.063 
VAV1 7409 vav 1 guanine nucleotide exchange factor 0.50 0.66 -0.16 0.046 
VBP1 7411 von Hippel-Lindau binding protein 1 0.77 0.85 -0.08 0.065 
VDR 7421 vitamin D (1,25- dihydroxyvitamin D3) receptor 0.08 0.06 0.02 0.066 
VGLL4 9686 vestigial like 4 (Drosophila) 0.06 0.04 0.02 0.042 
VHL 7428 von Hippel-Lindau tumor suppressor 0.66 0.81 -0.15 0.047 
VHL 7428 von Hippel-Lindau tumor suppressor 0.74 0.84 -0.10 0.077 
VNN3 55350 vanin 3 0.40 0.68 -0.28 0.090 
VRK2 7444 vaccinia related kinase 2 0.03 0.02 0.01 0.063 
VRK3 51231 vaccinia related kinase 3 0.06 0.03 0.03 0.040 
WBP2 23558 WW domain binding protein 2 0.02 0.01 0.01 0.070 
WBSCR19 285955 speedy homolog E6 (Xenopus laevis) 0.78 0.68 0.10 0.042 
WDR21A 26094 WD repeat domain 21A 0.50 0.62 -0.12 0.080 
WDR21C 138009 WD repeat domain 21C 0.66 0.81 -0.14 0.047 
WDR34 89891 WD repeat domain 34 0.02 0.01 0.01 0.067 
WDR36 134430 WD repeat domain 36 0.03 0.02 0.01 0.086 
WDR39 9391 cytosolic iron-sulfur protein assembly 1 homolog (S. cerevisiae) 0.94 0.97 -0.03 0.056 
WDR4 10785 WD repeat domain 4 0.02 0.01 0.01 0.064 
WDR40B 139170 WD repeat domain 40B 0.87 0.79 0.08 0.061 
WDR47 22911 WD repeat domain 47 0.12 0.09 0.03 0.079 
WDR65 149465 WD repeat domain 65 0.59 0.70 -0.10 0.100 
WDR7 23335 WD repeat domain 7 0.04 0.02 0.02 0.092 
WDTC1 23038 WD and tetratricopeptide repeats 1 0.09 0.04 0.05 0.096 
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WFDC10B 280664 WAP four-disulfide core domain 10B 0.76 0.86 -0.09 0.057 
WFDC5 149708 WAP four-disulfide core domain 5 0.86 0.81 0.05 0.065 
WFDC6 140870 WAP four-disulfide core domain 6 0.95 0.98 -0.03 0.068 
WFDC8 90199 WAP four-disulfide core domain 8 0.86 0.93 -0.08 0.073 
WHSC1 7468 Wolf-Hirschhorn syndrome candidate 1 0.72 0.85 -0.14 0.075 
WHSC1L1 54904 Wolf-Hirschhorn syndrome candidate 1-like 1 0.03 0.02 0.01 0.073 
WT1 7490 Wilms tumor 1 0.85 0.77 0.07 0.058 
XAGE5 170627 X antigen family, member 5 0.79 0.85 -0.06 0.074 
XCR1 2829 chemokine (C motif) receptor 1 0.52 0.64 -0.12 0.069 
XYLB 9942 xylulokinase homolog (H. influenzae) 0.85 0.92 -0.06 0.075 
YES1 7525 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 0.11 0.07 0.05 0.071 
YIPF5 81555 Yip1 domain family, member 5 0.10 0.06 0.04 0.065 
YY2 404281 YY2 transcription factor 0.66 0.76 -0.09 0.094 
ZBED3 84327 zinc finger, BED-type containing 3 0.03 0.02 0.01 0.063 
ZC3H10 84872 zinc finger CCCH-type containing 10 0.03 0.02 0.01 0.074 
ZD52F10 93099 dermokine 0.76 0.85 -0.09 0.071 
ZD52F10 93099 dermokine 0.88 0.91 -0.03 0.082 
ZDHHC12 84885 zinc finger, DHHC-type containing 12 0.07 0.05 0.02 0.072 
ZFAND2A 90637 zinc finger, AN1-type domain 2A 0.03 0.01 0.01 0.065 
ZFP42 132625 zinc finger protein 42 homolog (mouse) 0.09 0.04 0.05 0.083 
ZFYVE19 84936 zinc finger, FYVE domain containing 19 0.85 0.91 -0.06 0.055 
ZFYVE19 84936 zinc finger, FYVE domain containing 19 0.33 0.47 -0.13 0.065 
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ZFYVE9 9372 zinc finger, FYVE domain containing 9 0.06 0.04 0.02 0.040 
ZHX3 23051 zinc fingers and homeoboxes 3 0.72 0.77 -0.05 0.086 
ZIM2 23619 zinc finger, imprinted 2 0.68 0.63 0.05 0.055 
ZNF114 163071 zinc finger protein 114 0.06 0.04 0.02 0.089 
ZNF157 7712 zinc finger protein 157 0.76 0.86 -0.10 0.062 
ZNF169 169841 zinc finger protein 169 0.62 0.77 -0.14 0.063 
ZNF22 7570 zinc finger protein 22 (KOX 15) 0.84 0.91 -0.06 0.076 
ZNF23 7571 zinc finger protein 23 (KOX 16) 0.07 0.04 0.03 0.075 
ZNF235 9310 zinc finger protein 235 0.08 0.04 0.04 0.094 
ZNF263 10127 zinc finger protein 263 0.02 0.01 0.01 0.065 
ZNF267 10308 zinc finger protein 267 0.06 0.03 0.02 0.055 
ZNF277 11179 zinc finger protein 277 0.97 0.98 -0.01 0.047 
ZNF318 24149 zinc finger protein 318 0.02 0.01 0.01 0.074 
ZNF322B 387328 zinc finger protein 322B 0.87 0.91 -0.05 0.058 
ZNF326 284695 zinc finger protein 326 0.85 0.92 -0.07 0.066 
ZNF331 55422 zinc finger protein 331 0.12 0.07 0.05 0.063 
ZNF333 84449 zinc finger protein 333 0.03 0.02 0.01 0.074 
ZNF385 25946 zinc finger protein 385A 0.82 0.89 -0.07 0.050 
ZNF408 79797 zinc finger protein 408 0.79 0.88 -0.09 0.071 
ZNF436 80818 zinc finger protein 436 0.89 0.94 -0.05 0.052 
ZNF439 90594 zinc finger protein 439 0.70 0.83 -0.13 0.042 
ZNF499 84878 zinc finger and BTB domain containing 45 0.05 0.03 0.02 0.074 
ZNF511 118472 zinc finger protein 511 0.64 0.55 0.09 0.089 
ZNF511 118472 zinc finger protein 511 0.21 0.16 0.06 0.090 
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ZNF512 84450 zinc finger protein 512 0.07 0.04 0.03 0.063 
ZNF512 84450 zinc finger protein 512 0.10 0.04 0.06 0.088 
ZNF512 84450 zinc finger protein 512 0.18 0.14 0.04 0.089 
ZNF558 148156 zinc finger protein 558 0.71 0.79 -0.09 0.060 
ZNF577 84765 zinc finger protein 577 0.11 0.05 0.05 0.043 
ZNF610 162963 zinc finger protein 610 0.70 0.85 -0.15 0.046 
ZNF614 80110 zinc finger protein 614 0.08 0.04 0.04 0.039 
ZNF615 284370 zinc finger protein 615 0.07 0.04 0.03 0.025 
ZNF619 285267 zinc finger protein 619 0.54 0.69 -0.15 0.050 
ZNF623 9831 zinc finger protein 623 0.83 0.88 -0.05 0.046 
ZNF660 285349 zinc finger protein 660 0.02 0.01 0.00 0.069 
ZNF678 339500 zinc finger protein 678 0.04 0.03 0.02 0.074 
ZNF678 339500 zinc finger protein 678 0.76 0.81 -0.05 0.077 
ZNF80 7634 zinc finger protein 80 0.94 0.96 -0.03 0.053 
ZPBP 11055 zona pellucida binding protein 0.08 0.05 0.03 0.093 
ZPLD1 131368 zona pellucida-like domain containing 1 0.16 0.23 -0.08 0.082 
ZZZ3 26009 zinc finger, ZZ-type containing 3 0.03 0.02 0.01 0.065 
SNORD109A 338428 small nucleolar RNA, C/D box 109A 0.83 0.91 -0.08 0.038 
CKS1BP7 137529 CDC28 protein kinase regulatory subunit 1A pseudogene 0.12 0.23 -0.10 0.085 
 
Note: Gene descriptions were obtained by using DAVID algorithm, National Institute of Allergy and 
Infectious Diseases (NIAID), NIH.   
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Table 5: List of Molecular Functions and Biological Processes that were over-represented in preeclamptic 
blood vessels and are pertinent to the pathophysiology of preeclampsia. 
Biological Processes Molecular Functions 
activation of Rac GTPase activity amino acid transmembrane transporter activity 
cellular glucan metabolic process beta-galactosidase activity 
GDP-L-fucose metabolic process CCR chemokine receptor binding 
GDP-mannose metabolic process CCR2 chemokine receptor binding 
glucan metabolic process CXCR chemokine receptor binding 
glycogen metabolic process cyclase inhibitor activity 
Hemostasis galactose binding 
histidine catabolic process galactosidase activity 
inactivation of MAPK activity GDP-mannose 4,6-dehydratase activity 
L-amino acid transport glycogen (starch) synthase activity 
leukocyte migration during inflammatory response glycogen phosphorylase activity 
negative regulation of cGMP production glycosylceramidase activity 
negative regulation of MAP kinase activity GTPase regulator activity 
negative regulation of nitric oxide production guanylate cyclase inhibitor activity 
negative regulation of phosphoinositide 3-kinase 
cascade heparanase activity 
negative regulation of vasodilation interferon-gamma receptor activity 
positive regulation of calcium ion transport interleukin-8 receptor binding 
positive regulation of calcium ion transport into 
cytosol lactase activity 
positive regulation of GTPase activity phosphoprotein phosphatase inhibitor activity 
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Biological Processes Molecular Functions 
positive regulation of interferon-alpha production vitamin E binding 
positive regulation of interferon-beta production 
positive regulation of Rac GTPase activity 
positive regulation of vasoconstriction 
vitamin E metabolic process 
 
  
 
 
163 
 
Table 6: Canonical pathways identified by Ingenuity Pathway Analysis software at a p-value < 0.05. 
Ingenuity Canonical 
Pathways Molecules 
LPS/IL-1 Mediated 
Inhibition of RXR 
Function 
IL18RAP, ABCG5, IL1RL1, APOC4, GSTA5, ABCG1, 
FMO5, NR0B2, ALDH1A3, NR1I2, CYP3A7, ACSL5, 
GSTM4, FABP1, CHST11, FABP4, ACSL4, CHST10, 
FMO1, ALDH3A1, IL1RAP, FMO3, MYD88, MGMT, 
CHST12, IL1R1, ACSBG2, ALDH9A1, TLR4, NR1H2, 
MGST2, SULT1A1, CPT2, SULT1B1, MGST3 
Role of Cytokines in 
Mediating 
Communication 
between Immune Cells 
IL1A, IL5, IFNA8, IL10, IL27, IL1F10, IFNA16, IL24, 
IL25, IL17A, IL1F9, IFNA21, IL4 
IL-10 Signaling 
IL18RAP, MAP3K14, IL1A, IL1RL1, IL10, FCGR2A, 
NFKBIE, IL1F10, MAPK13, IL1R1, NFKB2, FOS, IL1F9, 
SP1, IL1RAP 
LXR/RXR Activation 
IL18RAP, ABCG5, IL1A, MSR1, IL1RL1, APOC4, 
ABCG1, NFKB2, IL1F10, IL1R1, TLR4, IL1F9, NR1H2, 
PTGS2, NCOR2, IL1RAP 
Mismatch Repair in 
Eukaryotes PCNA, MSH6, FEN1, RFC1, MLH1, EXO1 
Aryl Hydrocarbon 
Receptor Signaling 
SRC, IL1A, TP73, NQO2, GSTA5, NFKB2, CCND1, 
ALDH9A1, AHRR, FOS, RB1, HSP90B1, CCND2, SP1, 
MGST2, NR0B2, ALDH1A3, GSTM4, NCOR2, ALDH3A1, 
CDK2, MGST3 
PPAR Signaling 
IL18RAP, MAP3K14, IL1A, IL1RL1, RRAS, NFKBIE, 
CREBBP, IL1F10, IL1R1, NFKB2, FOS, HSP90B1, IL1F9, 
NR0B2, PTGS2, NCOR2, IL1RAP 
Altered T Cell and B 
Cell Signaling in 
Rheumatoid Arthritis 
MAP3K14, IL1A, IL10, LTB, IL1F10, NFKB2, TNFRSF17, 
IL17A, TLR4, IL1F9, LTA, TLR6, CCL21, FCER1G, IL4 
Xenobiotic Metabolism 
Signaling 
IL1A, MAP3K11, NQO2, GSTA5, MAPK13, FMO5, CEL, 
HSP90B1, CAMK2A, UGT2B4, NR1I2, CYP3A7, 
ALDH1A3, GSTM4, CHST11, CHST10, FMO1, PRKD3, 
ALDH3A1, MAP3K14, FMO3, RRAS, MGMT, CREBBP, 
CHST12, NFKB2, UGT1A1, ALDH9A1, AHRR, MGST2, 
SULT1A1, NCOR2, MAP2K5, SULT1B1, MGST3 
Glycosphingolipid 
Biosynthesis - 
Neolactoseries 
ST8SIA4, FUT5, ABO, UGT2A3, GCNT2, B3GNT1, 
ST3GAL5 
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Ingenuity Canonical 
Pathways Molecules 
IL-1 Signaling 
MAP3K14, IL1A, MYD88, NFKBIE, MAPK13, IL1R1, 
NFKB2, GNG7, FOS, GNAT2, PRKACG, GNAO1, 
GNB1L, IL1RAP, GNG4 
HMGB1 Signaling IL1A, RRAS, DIRAS3, RBBP7, MAPK13, IL1R1, NFKB2, FOS, TLR4, KAT2B, RND3, SP1, RHOD, AKT3, MAP2K5 
Hepatic Cholestasis 
IL18RAP, MAP3K14, CYP7B1, ABCG5, IL1A, IL1RL1, 
MYD88, NFKBIE, NFKB2, IL1F10, IL1R1, TLR4, IL1F9, 
ABCB4, NR0B2, NR1I2, PRKACG, HNF4A, IL1RAP, 
PRKD3, FGF19 
Starch and Sucrose 
Metabolism 
PLA2R1, ENPP5, MTAP, UGT1A1, LTK, GYS2, ENPP3, 
HK1, DDX6, PYGM, UGT2B4, GCK, SLC3A1, AMY2B 
CCR5 Signaling in 
Macrophages 
CD3G, FOS, PLCG2, FCER1G, MAPK13, CCL5, GNB1L, 
PRKD3, CD3D, GNG4, GNG7 
Parkinson's Signaling CASP3, PARK7, CYCS, MAPK13, SNCA 
FXR/RXR Activation 
IL1A, ABCG5, CREBBP, IL1F10, IL1F9, UGT2B4, 
ABCB4, NR0B2, CYP19A1, NR1I2, AKT3, FBP1, HNF4A, 
FGF19 
Biosynthesis of Steroids FDPS, CYP7B1, NQO2, FNTB, SC5DL, GGPS1 
DNA Methylation and 
Transcriptional 
Repression Signaling 
MECP2, RBBP7, SIN3A, SAP18, RBBP4 
Role of 
Hypercytokinemia/hype
rchemokinemia in the 
Pathogenesis of 
Influenza 
IL1F9, IL1A, IFNA8, IFNA21, IL1F10, CCL5, IFNA16, 
IL17A 
Nicotinate and 
Nicotinamide 
Metabolism 
DAPK1, CDK7, ENPP5, QPRT, TTK, VNN3, BRAF, 
ENPP3, NAPRT1, VNN2, PRKAA2, NMNAT2, CD38, 
MAK, CDK2 
Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 
IL18RAP, IL1A, SFRP2, IL1RL1, NFKBIE, MMP13, LTB, 
IL1F10, CCL5, CCND1, KLK11, IL1F9, CAMK2A, 
TMPRSS3, SFRP5, AKT3, IL1RAP, PRKD3, MMP1, 
KLK10, SRC, MAP3K14, IL10, RRAS, MYD88, C1S, 
IL1R1, NFATC4, IL7, APC, IL17A, PLCZ1, TLR4, FOS, 
FZD4, LTA, PLCG2, GNAO1, TLR6 
Assembly of RNA 
Polymerase I Complex POLR1C, UBTF, TAF1B 
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Ingenuity Canonical 
Pathways Molecules 
Fructose and Mannose 
Metabolism 
HK1, ALDOB, UGT2A3, GCK, FBP1, PFKFB2, LTK, 
PMM2, MPI 
Airway Inflammation in 
Asthma IL5, IL4 
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Figure 1: Boxplots of β-values for the six X-linked genes examined for quality assessment of 
hybridization. There were no quality concerns. 
 
 
167 
 
 
NP 
PE 
M
o
re
 m
e
th
y
la
te
d
 
L
e
s
s
 m
e
th
y
la
te
d
 
G
e
n
e
s
 
Figure 2: Heatmap of unsupervised hierarchical clustering. Unsupervised hierarchical clustering 
revealed natural grouping by diagnosis and methylation status. NP = normal pregnant, PE = 
preeclampsia, red indicates hypermethylated CpG sites, green indicates hypomethylated CpG 
sites. 
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Figure 3: Volcano plot comparing severe preeclampsia vs normal pregnancy. The difference in 
average proportion methylated between severe preeclampsia and normal pregnancy is plotted on 
the x-axis and –log10 (p-value) is plotted on the y-axis. Blue points represent CpG sites significant 
using a FDR of 10%; red points represent CpG sites significant using a FDR of 10% and having a 
difference between the two groups exceeding |0.10|. 
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Figure 4: A gene-to-gene network identified by IPA analysis in our data set. The network 
includes multiple inflammatory genes which were hypomethylated in preeclampsia (green) and 
show the direct (indicated by solid line) and indirect (indicated by broken line) interaction 
between these genes and other genes in the network. The Figure also shows the interaction 
between genes in the network with canonical pathways related to inflammation. 
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CHAPTER 4: REDUCED METHYLATION OF THROMBOXANE SYNTHASE GENE 
IS CORRELATED WITH ITS INCREASED VASCULAR EXPRESSION IN 
PREECLAMPSIA 
 
A. Abstract 
 
Preeclampsia is characterized by increased thromboxane and decreased prostacyclin levels, which 
predate symptoms and can explain some of the clinical manifestations of preeclampsia, including 
hypertension and thrombosis. In this study, we examined DNA methylation of the promoter region of the 
thromboxane synthase gene (TBXAS1) and the expression of thromboxane synthase in systemic blood 
vessels of normal pregnant and preeclamptic women. Thromboxane synthase is responsible for the 
synthesis of thromboxane A2, a potent vasoconstrictor and activator of platelets. We also examined the 
effect of experimentally induced DNA hypomethylation on the expression of thromboxane synthase in a 
neutrophil-like cell line (HL-60 cells), and in cultured vascular smooth muscle and endothelial cells. We 
found that DNA methylation of the TBXAS1 promoter was decreased, and thromboxane synthase 
expression was increased in omental arteries of preeclamptic women as compared to normal pregnant 
women. Increased thromboxane synthase expression was observed in vascular smooth muscles cells, 
endothelial cells and infiltrating neutrophils. Experimentally induced DNA hypomethylation increased the 
expression of thromboxane synthase in a neutrophil-like cell line, whereas TNFα, a neutrophil product, 
increased its expression in cultured vascular smooth muscle cells. Our study suggests that epigenetic 
mechanisms and release of TNFα by infiltrating neutrophils could contribute to the increased expression 
of thromboxane synthase in systemic blood vessels, contributing to the hypertension and coagulation 
abnormalities associated with preeclampsia. 
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B. Introduction 
 
Preeclampsia occurs in 5-7% of pregnancies, and is a leading cause of maternal and infant 
mortality and morbidity1. It is diagnosed clinically by the onset of hypertension and proteinuria, usually 
occurring after twenty weeks gestation. Preeclampsia is also associated with increased activation of the 
coagulation system evidenced by an increase in formation of fibrin, activation of the fibrinolytic system, 
activation of platelets and a decrease in platelet count204.  
In 1985, increased thromboxane and decreased prostacyclin levels were reported in placentas of 
women with preeclampsia95 and later confirmed for maternal blood96 and maternal urine97. The imbalance 
in thromboxane, a potent vasoconstrictor and activator of platelets, and prostacyclin, a vasodilator and 
inhibitor of platelet activation, could explain hypertension, reduced uteroplacental blood flow and 
hypercoagulopathy observed in women with preeclampsia 27.    
Thromboxane and prostacyclin have a common precursor, prostaglandin H2, but are synthesized 
by different enzymes207. Thromboxane synthase is the enzyme that catalyzes the isomerization of 
prostaglandin H2 into thromboxane94. An increase in thromboxane synthase has been demonstrated in 
trophoblast and decidua cells of placentas of preeclamptic women93 but increased expression in maternal 
tissue has heretofore not been shown. If thromboxane synthase was increased in maternal blood vessels, 
vasoconstriction and platelet activation could result due to increased thromboxane.  
Increased thromboxane production in preeclampsia could be related to altered expression of the 
TBXAS1 gene resulting from genomic variation or transcriptional activation. The latter could encompass 
epigenetic regulation, including DNA methylation. DNA methylation is a major epigenetic mechanism 
controlling gene expression110. In general, hypomethylation is associated with increased gene expression, 
whereas hypermethylation is associated with decreased gene expression. It has been reported that DNA 
methylation is involved in the regulation of thromboxane synthase gene (TBXAS1)152.  Thus, reduced 
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methylation of the TBXAS1 gene could result in increased thromboxane synthase and increased 
thromboxane A2 production. DNA methylation status in preeclampsia may be related to oxidative stress. 
Oxidation of DNA causes loss of methylation141,208,209 and preeclampsia is associated with oxidative 
stress89. Consistent with this notion is a preliminary report that found increased urinary levels of 8-
hydroxy-2-deoxyguanosine, an indicator of DNA oxidation, in preeclamptic women210.  
In the present study, we tested the hypothesis that reduced DNA methylation of the TBXAS1 gene 
leads to increased vascular expression of thromboxane synthase in preeclampsia. To test this, we 
examined the DNA methylation status of the TBXAS1 gene and correlated it with gene and protein 
expression of thromboxane synthase in omental arteries obtained from preeclamptic and normal pregnant 
women. We then experimentally induced hypomethylation in vascular smooth muscle and endothelial 
cells and in a neutrophil-like cell line and determined gene and protein expression of thromboxane 
synthase. We examined the expression of thromboxane synthase in omental arteries because these arteries 
are a component of the maternal systemic vasculature, and they play a role in blood pressure regulation by 
contributing to the total peripheral vascular resistance. We examined the effect of hypomethylation in the 
neutrophil-like cell line because of the extensive vascular infiltration of neutrophils that occurs in 
preeclampsia61-63 and neutrophils are a source of thromboxane86. 
   
C. Materials and methods 
1. Study subjects 
 
Omental fat biopsies of approximately 2 cm x 2cm x 2cm in size were collected from normal 
pregnant (n=16) and preeclamptic (n=22) women (28-38 weeks of gestation) during cesarean section at 
MCV Hospital, Virginia Commonwealth University Medical Center, Richmond, VA. Preeclampsia was 
diagnosed by new onset of hypertension (systolic blood pressure of ≥ 140 mm Hg and/or diastolic blood 
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pressure ≥ 90 mm Hg) and proteinuria (300 mg or more of protein in the urine per 24 hours collection) 
that occur in women who are otherwise normal1. Women with chorioamnionitis, infections, active 
sexually transmitted diseases, lupus or diabetes, and women who were smokers or in labor were excluded 
because these conditions are associated with inflammatory changes. Patient’s clinical data are shown in 
Table 7. All subjects gave informed consent. This study was approved by the Office of Research Subjects 
Protection, Virginia Commonwealth University, Richmond, VA. 
 
2. Methylation assay  
 
Omental arteries from 5 normal pregnant and 7 preeclamptic women were processed for DNA 
extraction. DNA was extracted from the arteries (~10 mg by weight) using QuickGene DNA tissue kit 
and QuickGene-Mini80 system (AutoGen, Holliston, MA). DNA was treated with RNase A (Qiagen, 
Valencia, CA). DNA (1µg) was bisulfite treated and used in Illumina Infinium HumanMethylation27 
BeadChip assay (Illumina, San Diego, CA) for DNA methylation analysis. The BeadChip was run by the 
Nucleic Acids Research Facilities at VCU using the protocol provided by Illumina.  
 
3. Immunohistochemistry 
 
Omental fat samples from 4 normal pregnant and 5 preeclamptic women were cut into small 
pieces approximately 0.5 cm x 0.5 cm x 0.5 cm in size, fixed immediately in 10% neutral buffered 
formalin and embedded in paraffin. Tissues were cut into 8 µm sections. Tissue slides were stained for 
rabbit antihuman polyclonal antibody specific for thromboxane synthase (1:50 titer, Proteintech, Chicago, 
IL). Rabbit primary antibody isotype control (Invitrogen, Camarillo, CA) was used as a negative control. 
A kit was used for immunohistochemical staining (SuperPicTure Polymer Detection Kit Broad Spectrum 
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(DAB), Invitrogen, Camarillo, CA). To quench endogenous tissue peroxidase activity, slides were 
incubated in 3% hydrogen peroxide in methanol for 30 minutes. For antigen retrieval, slides were heat 
treated in 10 mM citrate buffer for 5 minutes with a pressure cooker. Tissue slides were counterstained 
with 1:5 dilution of hematoxylin QS (Vector Laboratories, Burlingame, CA). 
For data analysis, vessels between 10 µm and 200 µm were examined. An average of 35 vessels 
was analyzed per slide. Vessel staining for thromboxane synthase was evaluated using a visual intensity 
score of 0, 1, 2, 3 or 4 where 0 was assigned for no staining and 4 for dark and extensive staining. Visual 
scoring was verified by a second investigator and by measuring the optical density of staining (OD) using 
image analysis software (cellSens Imaging Software, Olympus America, Center Valley, PA) as 
previously described61,62. Optical density of staining for thromboxane synthase in vessels was normalized 
to the optical density of the background.   Slides were also analyzed for percentage of vessels stained and 
percentage of vessels with leukocyte staining for thromboxane synthase.     
 
4. HL-60 cells  
 
HL-60 cells (ATCC, Manassas, VA), a neutrophil-like cell line, were used to evaluate the effect 
of DNA hypomethylation on the expression of thromboxane synthase. Cells were cultured in Iscove's 
Modified Dulbecco's Medium (IMDM, ATCC, Manassas, VA) supplemented with 10% fetal bovine 
serum (Gibco, Invitrogen, Carlsbad, CA) and 1% antibiotics and antimycotics (100 U/ml penicillin, 100 
µg/ml streptomycin, 25 µg/ml amphotericin B, Gibco, Invitrogen, Carlsbad, CA) as recommended by 
ATCC. Approximately 500,000 cells per ml were seeded in 5 ml of media in a T-25 flask for treatments. 
Cell treatments were: 1) 10 µM 5-Aza-2-deoxycytidine (5-Aza, Sigma-Aldrich, Saint-Louis, MO), an 
agent that inhibits DNA methylation when incorporated into DNA during cell division, for 48 hours 
followed by 10-8 M of phorbol 12-myristate 13-acetate (PMA, an activator of protein kinase C, Sigma-
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Aldrich, Saint-Louis, MO) for 24 hours; 2) 10 µM 5-Aza for 48 hours followed by no treatment for 24 
hours; 3) no treatment for 48 hours followed by 10-8 M PMA for 24 hours; or 4) no treatment for 72 
hours without treatment to serve as control. To study the effect of these treatments on the production of 
thromboxane B2, cells were also treated with 70 µM linoleic acid (Cayman Chemical, Ann Arbor, MI). 
Cells were collected for DNA, RNA or protein extraction and media was saved for enzyme immunoassay. 
 
5. Vascular Smooth Muscle and Endothelial Cell Culture and Treatments 
 
Human vascular smooth muscle cells (VSMC) were cultured from chorionic plate arteries of 
placentas collected at cesarean section from healthy pregnant women at term deliveries as previously 
described165. Human umbilical vein endothelial cells were purchased from Lifeline Cell Technology 
(Grand Island, NY) and cultured in T-25 flasks according to their protocol with their medium. VSMCs 
were cultured in T-25 flasks using Medium-199 (M-199, Gibco, Invitrogen, Carlsbad, CA) with 10% fetal 
bovine serum (FBS, Gibco, Invitrogen, Carlsbad, CA) and 1% antibiotics and antimycotics (100 U/ml 
penicillin, 100 µg/ml streptomycin, 25 µg/ml amphotericin B, Gibco, Invitrogen, Carlsbad, CA). Cells 
were treated with 1 ng/ml of human recombinant TNFα (R&D Systems, Minneapolis, MN) or with 5-Aza 
for 48 hours. Control flasks contained M-199 media with 10% FBS and 1% antibiotics and antimycotics. 
Treatments were refreshed every day. Cells were 50% confluent at the time of treatment and 100% 
confluent at the time of harvesting. Cells were washed with PBS and harvested for RNA and protein 
extraction.  
 
6. Quantitative RT-PCR 
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Omental arteries (25-30 mg) from 5 normal pregnant and 8 preeclamptic patients were 
homogenized with a rotor stator homogenizer (PRO200, PRO Scientific, Oxford, CT) and total RNA was 
extracted using Tri-reagent with spin columns (RiboPure kit, Ambion, Austin, TX). For cell cultures, 
RNA extraction was performed using QuickGene RNA cultured cell kit with QuickGene Mini-80 system 
(AutoGen, Holliston, MA). DNase treatment was performed using Turbo DNAse kit (Ambion, Austin, 
TX). RNA (0.25-1 µg) was reverse transcribed to cDNA using the IScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA). Quantitative RT-PCR reactions were performed with RT² SYBR® Green 
qPCR Mastermix (SABiosciences, Frederick, MD) on Eppendorf Realplex Thermal Cycler. For each 
reaction, 8 ng of cDNA was used.  Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene. For TBXAS1 gene, commercial primers were used (SABiosciences, Frederick, MD) 
and for GAPDH gene the following primers were used: forward primer: 
GATTCCACCCATGGCAAATT; reverse primer: AGATGGTGATGGGATTTCCATT. GAPDH primers 
were synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Data were normalized to 
GAPDH by the ∆∆Ct method. Melting curve analysis confirmed specificity of the primers. 
 
7. Western blotting 
 
Omental arterials (45-50 mg) from 4 normal pregnant and 6 preeclamptic patients were 
homogenized in RIPA buffer containing 150 mM sodium chloride, 1.0% NP-40, 0.5% sodium 
deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris (pH 8.0), and 1X Halt protease inhibitor 
(Thermo Scientific, Pittsburgh, PA) using a rotor stator homogenizer (PRO200, PRO Scientific, Oxford, 
CT) at 300 rpm for 1 min. VSMC or HL-60 cells were homogenized in the same buffer using a probe 
sonicator (EpiShear Probe Sonicator, Active Motif, Carlsbad, CA) at 25% amplitude for 10 one sec 
bursts. Protein concentrations were measured using BCA assay (Thermo Fisher Scientific, Rockford, IL). 
Denatured protein lysates (50-100 µg) were resolved by electrophoresis on sodium dodecyl sulphate 
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polyacrylamide gel and electrotransferred to polyvinylidene fluoride membrane (Immobilon-FL, 
Millipore, Billerica, MA). Membranes were probed for thromboxane synthase and β-actin. Primary 
antibodies used were rabbit anti-human thromboxane synthase (1:1000, Proteintech, Chicago, IL); mouse 
anti-human β-actin (1:1,000, Sigma, Saint Louis, MO). Secondery antibodies used included: Alexa Fluor 
680 donkey anti-rabbit (1:10,000, Invitrogen, Carlsbad, CA) for the detection of thromboxane synthase 
and IRDye800 goat anti-mouse (1:20,000, Rockland Immunochemicals, Gilbertsville, PA) for the 
detection of β-actin. LI-COR Odyssey Infrared Imaging System (Thermo Scientific, Pittsburgh, PA) was 
used to detect and analyze the immunoreactive proteins. Density values of protein bands were measured 
by multiplying the intensity of the bands by their area. Density values for thromboxane synthase bands 
were normalized by dividing them by the density values of their corresponding β-actin bands. The 
normalized thromboxane synthase density value of the reference group (control or normal pregnant) was 
considered 100% and changes in other groups were represented as relative to the reference group.     
   
8. Enzyme immunoassay 
 
The Thromboxane B2 (TXB2) Enzyme Immunoassay kit (Assay Designs, Ann Arbor, MI) was 
used to measure TXB2 secretion into the media. TXB2 is the stable metabolite of thromboxane A2211. The 
procedure for the assay was done as recommended by the manufacturer. Media was diluted by a factor of 
1:1 before it was used in the assay. TXB2 concentrations were measured in pg/ml using FLUOstar 
OPTIMA plate reader (BMG Labtech, Ortenberg, Germany). For normalization, the total amount of 
TXB2 (pg) in 5ml (volume of medium used in a T-25 flask) was divided by the total amount of DNA (µg) 
extracted from the cells of the same flask. DNA was extracted as described above.    
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9. Statistical analysis  
 
Data analysis of the HumanMethylation27 BeadChip assay was performed using the beadarray 
package in R programming environment212. To control for multiple hypothesis testing, the p-values were 
subsequently used in estimating the false discovery rates (FDR) using the q-value method166. Methylation 
values (β values) are expressed as range from 0 to 1 where 0 means not methylated and 1 means fully 
methylated. ∆β-values indicate the difference in methylation between normal pregnant and preeclamptic 
women.  
Student’s t test was used to make comparisons of parameters between two groups and one-way 
ANOVA with Newman-Keuls test was used to make comparisons of parameters between more than two 
groups for normally distributed data. Mann-Whitney U test was used for visual intensity score data. 
Quantitative results were presented as mean ± SEM. We considered a p-value of < 0.05 statistically 
significant. A statistical software program was used for data analysis (GraphPad Prism version 4.0, San 
Diego, CA). 
     
D. Results 
 
The Illumina Infinium HumanMethylation27 BeadChip assay revealed 4,184 CpG sites, 
corresponding to 3,736 genes, with significant differential methylation when comparing between normal 
pregnant and preeclamptic omental arteries at p-value of less than 0.05213. Many of these genes were 
genes involved in inflammation. Of these genes, thromboxane synthase (TBXAS1) was the most 
significantly less methylated with an average difference in methylation (∆β) of 0.24 at p-value of 0.00037 
corresponding to a false discovery rate (FDR) of 0.042. There was no overlap in the methylation values 
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(β-values) between the two groups demonstrating that all preeclamptic samples were less methylated as 
compared to normal pregnant samples (Figure 5).   
Representative staining images for thromboxane synthase are shown in Figure 6. Negative 
controls showed no staining for thromboxane synthase (Panel A). There was little or no staining in vessels 
of normal pregnant women (Panel B). However, preeclamptic vessels showed significant staining for 
thromboxane synthase (Panels C, D, E and F). Staining for thromboxane synthase in preeclamptic vessels 
was present in endothelium, vascular smooth muscle and in leukocytes, which were in the lumen, 
adherent to the endothelium and infiltrated into the walls of the vessels (Panel F).  
The staining intensity score for thromboxane synthase was significantly greater for preeclamptic 
women as compared to normal pregnant women (3.0 ± 0.1 vs 0.5 ± 0.1, respectively, p < 0.001, Figure 
7A), as was optical density (OD) of staining (88.0 ± 6.0 vs 19.0 ± 2.0 OD, respectively, p < 0.001, Figure 
7B). Staining intensity scores and ODs were highly correlated (r = 0.93). The percentage of vessels with 
staining for thromboxane synthase was significantly greater for preeclamptic women than for normal 
pregnant women (95.0 ± 2.0% vs 25.0 ± 4.0% respectively, p < 0.001, Figure 7C), as was the percentage 
of vessels with leukocytes stained for thromboxane synthase (80.0 ± 2.0% vs 12.0 ± 3.0% 
respectively, p <0.001, Figure 7D). 
To verify the immunohistochemistry results, we examined TBXAS1 gene expression in omental 
arteries of normal pregnant and preeclamptic women. TBXAS1 gene expression was 2.5-fold higher in 
omental arteries of preeclamptic women as compared to normal pregnant women (2.6 ± 0.2 vs 1.0 ± 0.1 
respectively, p < 0.01, Figure 8). Western blotting confirmed that increased gene expression for TBXAS1 
was associated with increased thromboxane synthase protein (Figure 9, A and B). Thromboxane synthase 
protein expression was 3-fold greater in preeclamptic arteries as compared to normal pregnant arteries as 
determined by Western blot density measurements (p < 0.01). 
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To examine the role of DNA methylation in regulating the expression of thromboxane synthase in 
neutrophils, it was necessary to use a neutrophil-like cell line (HL-60) because neutrophils isolated from 
patients do not divide and therefore the 5-Aza-2-deoxycytidine (5-Aza) could not be incorporated into the 
genomic DNA to induce hypomethylation. Treatment of HL-60 cells with 5-Aza resulted in a significant 
increase in TBXAS1 gene expression (2.6 ± 0.2-fold, p < 0.001). Treatment with PMA to activate the cells 
resulted in a 1.4 ± 0.1-fold increase in TBXAS1. Activation of the cells by PMA was evidenced by cell 
clumping and adhesion to the floor of the flask. Combining 5-Aza treatment with PMA resulted in a 
significant increase in TBXAS1 gene expression as compared to control (3.8 ± 0.4-fold, p < 0.001), PMA 
alone (p < 0.001) or 5-Aza alone (p < 0.001) (Figure 10). Western blotting confirmed that protein 
expression was altered in concert with gene expression (Figure 11, A and B). Treatment with 5-Aza 
significantly increased thromboxane synthase protein expression (347 ± 11% average density 
measurement of Western blot as compared to control, p < 0.001). Combining 5-Aza treatment with PMA 
resulted in significantly increased thromboxane synthase protein expression (515 ± 15% of control, p < 
0.001), PMA alone (p < 0.001) or 5-Aza alone (p < 0.001).  
To evaluate the effect of the same treatments on the production of thromboxane by the 
neutrophil-like HL-60 cells, cells were cultured with 70 µM linoleic acid, the precursor of arachidonic 
acid. Treatment with 5-Aza significantly increased the production of TXB2, the stable metabolite of 
TXA2, as compared to controls (619 ± 32 vs 115 ± 20 ng/µg DNA, respectively, p < 0.001, Figure 12). 
PMA treatment caused a significant increase in the production of TXB2 as compared to control (745 ± 36 
vs 115 ± 20 ng/µg DNA, respectively, p < 0.001). Combining 5-Aza and PMA treatments caused an even 
greater increase in the production of TXB2 (1228 ± 140 ng/µg DNA, p < 0.001).   
In contrast to HL-60 cells, 5-Aza treatment increased TBXAS1 gene expression by only 40% in 
cultured VSMCs and only 13% in cultured human umbilical vein endothelial cells, which were not 
statistically significant (data not shown). However, treatment of VSMCs with TNFα, a neutrophil product, 
significantly increased TBXAS1 gene expression as compared to controls (3.0 ± 0.2-fold, p < 0.001, 
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Figure 13). Western blotting confirmed increased protein expression induced by TNFα (Figure 14, A and 
B). TNFα resulted in a 2.6-fold increase in thromboxane synthase protein in VSMCs (263 ± 37% average 
density of control, P < 0.01). 
 
E. Discussion 
 
In this study we report a significant reduction in DNA methylation in the promoter region of the 
TBXAS1 gene associated with a significant increase in thromboxane synthase expression in omental fat 
arteries of preeclamptic women as compared to normal pregnant women. Increased expression of 
thromboxane synthase was observed in the endothelium, in the vascular smooth muscle cells and in 
leukocytes, which were flattened and adhered to the endothelium and infiltrated into the wall of the 
vessel. Increased expression of thromboxane synthase would lead to increased production of thromboxane 
A2 locally in the vessel, which could explain hypertension and coagulation abnormalities in preeclamptic 
patients because thromboxane is a potent vasoconstrictor and platelet activator84.  
Leukocyte infiltration requires leukocyte activation, which most likely occurs as they circulate 
through the intervillous space and are exposed to increased lipid peroxides secreted by the placenta41. The 
infiltrating leukocytes are most likely neutrophils because neutrophils normally comprise approximately 
60%-70% of all leukocytes33 , their numbers increase 2.5-fold by 30 weeks of gestation214 and their 
numbers are further increased in preeclampsia215. In addition, we previously reported that neutrophils, but 
not lymphocytes or monocytes, infiltrate systemic blood vessels of preeclamptic women61-63,216.  
To study the role of DNA methylation in the regulation of thromboxane synthase, we 
experimentally induced DNA hypomethylation in a neutrophil-like cell line and in cultured human 
VSMCs. Hypomethylation resulted in increased expression of thromboxane synthase in both cell types, 
however, the increase was only significant in the neutrophil-like cell line. Increased expression of 
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thromboxane synthase in the neutrophil-like cell line was associated with a parallel increase in the 
production of the stable metabolite of TXA2, TXB2. These data suggest that DNA methylation is 
important in regulating thromboxane synthase expression in neutrophils but not in vascular smooth 
muscle cells. However, treatment of vascular smooth muscle cells with TNFα, a neutrophil product, did 
significantly increase thromboxane synthase, so increased expression of thromboxane synthase in 
vascular tissue of preeclamptic women may be due to inflammation caused by neutrophil infiltration. 
Reduced DNA methylation in leukocytes has been reported in other diseases involving the cardiovascular 
system such as atherosclerosis134, ischemic heart disease and stroke130.  
Pertinent to our findings of increased expression of thromboxane synthase are previous findings 
of increased levels of serum arachidonic acid in preeclamptic women217 and significant activation of 
nuclear factor kappa B (NF-ĸB) and increased expression of cyclooxygenase-2 (COX-2) in preeclamptic 
blood vessels62. Similar to thromboxane synthase expression, activation of NF-ĸB and increased 
expression of COX-2 were observed in the endothelium, vascular smooth muscle and infiltrating 
neutrophils62. A possible scenario in preeclamptic blood vessels is that increased COX-2 converts 
increased arachidonic acid into prostaglandin H2 and increased thromboxane synthase then converts 
prostaglandin H2 into thromboxane. 
Preeclampsia is associated with oxidative stress41 and increased plasma levels of linoleic acid, the 
fatty acid precursor of arachidonic acid218. Neutrophils from normal pregnant women exposed to an 
oxidizing solution enriched with linoleic acid showed increased production of TNFα and thromboxane86. 
Also, exposure of cultured VSMCs to an oxidizing solution enriched with linoleic acid increased 
production of thromboxane85.  
Our study has several limitations. First, our findings are correlative in that they show reduced 
methylation is associated with increased expression of thromboxane synthase in omental arteries of 
preeclamptic women, but they do not prove cause and effect. In addition, we were not able to determine 
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the cell types where methylation changes were occurring in the omental arteries because of cellular 
heterogeneity, including endothelial cells, vascular smooth muscle cells and infiltrated neutrophils. 
Another limitation is that we cannot prove that reduced methylation in the TBXAS1 gene promoter per se 
is responsible for increased expression, as opposed to changes in the expression of other factors that 
regulate TBXAS1 (e.g., transcription factors or other regulatory factors) whose levels might be altered by 
changes in DNA methylation. However, by experimentally inducing hypomethylation in vascular smooth 
muscle cells and a neutrophil-like cell line we were able to demonstrate a strong association between 
DNA methylation status and thromboxane synthase expression in neutrophils, which have the highest 
thromboxane synthase content per cell in the vessels, but not in vascular smooth muscle cells, which have 
a lower content.  
In summary, we found that reduced methylation in the promoter region of TBXAS1 is correlated 
with increased gene and protein expression of thromboxane synthase in systemic blood vessels of 
preeclamptic women. Increased expression was present in endothelium, vascular smooth muscle cells and 
infiltrating neutrophils. We also showed that experimentally induced DNA hypomethylation increases the 
expression of thromboxane synthase in a neutrophil-like cell line and that TNFα a neutrophil product, 
increases thromboxane synthase expression in culture vascular smooth muscle cells. These data suggest 
that reduced DNA methylation is responsible for increased expression of thromboxane synthase in 
neutrophils that infiltrate maternal systemic blood vessels in preeclampsia, and that vascular inflammation 
caused by infiltrating neutrophils is responsible of increased expression of thromboxane synthase in the 
endothelium and vascular smooth muscle. Increased expression of thromboxane synthase in systemic 
vasculature of preeclamptic women may help explain hypertension and coagulation abnormalities.   
These findings suggest possible treatments for preeclampsia involving inhibition of thromboxane 
synthase, blockade of thromboxane receptors, or dietary supplementation with folate to increase 
methylation donors to protect against adverse changes in DNA methylation that affect thromboxane 
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synthase expression. In this regard, a large study of almost 3,000 pregnant women found supplementation 
with multivitamins containing folic acid was associated with reduced risk of preeclampsia206. 
  
 
 
185 
 
Table 7: Clinical Characteristics of Patient Groups. 
Variable 
Normal Pregnant 
(n=16) 
Preeclamptic 
(n=22)  
Maternal age (y) 26.8 ± 1.6 25.6 ± 1.0 
Pre-pregnancy BMI (kg/m2) 24.4 ± 0.8  30.2 ± 1.6 
Systolic blood pressure (mmHg) 114.2 ± 2.2 169.5 ± 3.2*** 
Diastolic blood pressure (mmHg) 70.0 ± 2.0 96.1 ± 2.4*** 
Proteinuria (mg/24 h) ND 260.1 ± 31.2 (n=11) 
Dipstick ND 2.6 ± 1.4 (n=11) 
Parity   
Primiparous 3 12 
Multiparous 13 10 
Gestational age (wk) 38.8 ± 0.2 33.0 ± 0.84*** 
Infant birth weight (g) 3226 ± 80.5 2060 ± 185.3*** 
Values are presented as mean ± SEM. 
***p < 0.001 by t-test. 
 ND, not detectable. 
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Figure 5: Boxplot of proportion methylated in omental arteries by subject group for TBXAS1 
gene. Methylation was significantly lower in preeclamptic patients (n=7) than in normal pregnant 
patients (n=5) with no overlap between the groups. ***p< 0.001 
 
 
187 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Representative sections for blood vessels in omental fat from normal pregnant and 
preeclamptic women immunostained for thromboxane synthase. A) There was no brown 
staining for thromboxane synthase in negative control sections. B) Blood vessels of normal 
pregnant women showed little or no staining for thromboxane synthase. Vessels of preeclamptic 
women showed significant brown staining for thromboxane synthase.  Staining for thromboxane 
synthase in preeclamptic blood vessels was observed in endothelium (red arrows), vascular 
smooth muscle cells (blue arrows), and neutrophils (black arrows), which were either adhered to 
the endothelium or infiltrated into the wall of the vessel (F). A: adipocyte; VL: vessel lumen. 
Magnification and scale bar are shown on each image. 
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Figure 7: Results for immunohistochemical staining for thromboxane synthase in omental blood 
vessels from normal pregnant (NP) and preeclamptic (PE) women. A) Visual staining score for 
thromboxane synthase was significantly higher in blood vessels of preeclamptic women as 
compared to normal pregnant women. B) Optical density of staining for thromboxane synthase 
was also significantly higher in preeclamptic blood vessels and significantly correlated with the 
visual score (r=0.93). C) Preeclamptic women had significantly higher percentage of blood 
vessels stained for thromboxane synthase as compared to normal pregnant women. D) 
Preeclamptic women had significantly higher percentage of blood vessels with leukocyte stained 
for thromboxane synthase as compared to normal pregnant women. Data are presented as means 
± SEM. ***p< 0.001. 
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Figure 8: Thromboxane synthase gene expression in omental fat arteries of normal pregnant (NP) 
and preeclampsia (PE) women. Gene expression of TBXAS1 was significantly increased in 
omental arteries from preeclamptic women (n=8) as compared to normal pregnant women (n=5). 
Data are shown as means ± SEM. **p < 0.01. 
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  Figure 9: Thromboxane synthase protein expression in omental fat arteries of normal pregnant 
(NP) and preeclampsia (PE) women. A) Representative Western blot for thromboxane synthase 
protein expression in omental arteries of normal pregnant and preeclamptic women. B) Density of 
thromboxane synthase plotted as percentage of average normal pregnant. Thromboxane synthase 
expression was significantly increased in arteries of preeclamptic women (n=6) as compared to 
normal pregnant women (n=4). Data are shown as means ± SEM. **p < 0.01. 
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Figure 10: Thromboxane synthase gene expression in HL-60 cells. The expression of 
TBXAS1 was significantly increased in 5-Aza treated cells as compared to controls. Activation 
with PMA after treatment with 5-Aza caused an even greater increase in TBXAS1 expression as 
compared to control, PMA alone or 5-Aza alone (n=8). Data are shown as means ± SEM. Groups 
with different letters are significantly different, p<0.001. 
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Figure 11: Thromboxane synthase protein expression in HL-60 cells. A) Representative Western 
blot for thromboxane synthase expression in HL-60 cells. B) Density of thromboxane synthase 
plotted as percentage of control. Treatment with 5-Aza significantly increased thromboxane 
synthase expression as compared to control. Activation with PMA after treatment with 5-Aza 
resulted in significant increase in thromboxane synthase expression as compared to control, PMA 
alone and 5-Aza alone (n=5). Data are shown as means ± SEM. Groups with different letters are 
significantly different, p<0.001. 
   A 
β-actin 
 (42 kDa) 
Thromboxane 
Synthase 
 (60.5 kDa) 
Control PMA 5-Aza PMA+ 
5-Aza 
Control PMA 5-Aza PMA+5-Aza
0
100
200
300
400
500
600
bb
C
a
cB 
 
 
193 
 
 
 
 
 
 
 
 
 
  
Control PMA 5-Aza PMA+5-Aza
0
250
500
750
1000
1250
1500
b
c
a
b
Figure 12: Thromboxane B2 (TXB2) secretion into the media by HL-60 cells. TXB2 secretion was 
significantly increased in 5-Aza or PMA treated cells as compared to controls. Combined 
treatment of PMA and 5-Aza caused an even greater increase in TXB2 secretion as compared to 
control, PMA alone or 5-Aza alone. Data are shown as means ± SEM, n=6. Groups with different 
letters are significantly different, p<0.001. 
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Figure 13: Thromboxane synthase gene expression in cultured human vascular smooth muscle 
cells treated with TNFα. A) Fold change in the expression for TBXAS1 gene in cultured VSMCs 
treated with TNFα for 48 hours. The expression of TBXAS1 was significantly increased in TNFα 
treated cells as compared to controls (n=6). Data are shown as means ± SEM. ***p < 0.001. 
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Figure 14: Thromboxane synthase expression in human vascular smooth muscle cells treated with 
TNFα. A) Representative Western blot for thromboxane synthase protein expression in cultured 
VSMCs. B) Density of thromboxane synthase plotted as percentage of control (n=6). Treatment 
with TNFα significantly increased thromboxane synthase protein expression as compared to 
control. Data are shown as means ± SEM,. **p<0.01 
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CHAPTER 5: PREECLAMPSIA IS ASSOCIATED WITH ALTERATIONS IN DNA 
METHYLATION OF GENES INVOLVED IN COLLAGEN METABOLISM 
 
A. Abstract 
 
Maternal vascular dysfunction is a hallmark of preeclampsia.  A recently described vascular 
phenotype of preeclampsia involves increased expression of matrix metalloproteinase-1 (MMP-1) in 
endothelial cells, vascular smooth muscle, and infiltrating neutrophils. In contrast, the expression of tissue 
inhibitor of matrix metalloproteinase-1 (TIMP-1) and collagen type 1α 1 (COL1A1) is either reduced or 
not changed in the vessels, suggesting an imbalance in vessel collagen degradation and synthesis in 
preeclampsia. In the present study, we explored the possible contribution of DNA methylation to the 
altered expression of genes involved in collagen metabolism. We assayed the differences in DNA 
methylation in omental arteries from normal pregnant and preeclamptic women, and determined whether 
reduced DNA methylation increases the expression of the MMP-1 in cultured vascular smooth muscle 
cells and a neutrophil-like cell line, HL-60. Several MMP genes, including MMP1 and MMP8, were 
significantly less methylated in preeclamptic omental arteries, whereas TIMP and COL genes were either 
significantly more methylated or had no significant change in their DNA methylation status as compared 
to normal pregnancy. Experimentally induced DNA hypomethylation increased MMP-1 expression in 
cultured vascular smooth muscle cells, and MMP-1 and MMP-8 expression in HL-60 cells. Our findings 
suggest that epigenetic regulation contributes to the imbalance in genes involved in collagen metabolism 
in blood vessels of preeclamptic women. 
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B. Introduction 
  
 Preeclampsia is a multisystemic disorder that is diagnosed by new onset of hypertension and 
proteinuria which occur after twenty weeks of gestation in pregnant women who are otherwise normal1. It 
is also associated with pathological edema due to increased vascular permeability. Preeclampsia and its 
complications are among the leading causes of obstetrical mortality and morbidity1. In the United States, 
preeclampsia occurs in approximately 6% to 8% of pregnant women, and is estimated to be responsible 
for 15% of obstetrical deaths17. Recently, neutrophil infiltration associated with marked inflammation of 
maternal systemic blood vessels was reported as a characteristic phenotype in women with 
preeclampsia61-63 
 We recently reported that MMP-1 expression is increased in systemic blood vessels of 
preeclamptic women as compared to normal pregnant women159. The increased expression of MMP-1 in 
omental arteries was detected in vascular smooth muscle cells (VSMCs), endothelial cells and infiltrating 
leukocytes. Plasma levels of MMP-1 were also increased in preeclamptic women. Interestingly, omental 
arteries collected from preeclamptic women showed no change in the expression of tissue inhibitor of 
matrix metalloproteinase-1 (TIMP-1), and decreased expression of collagen type 1α 1 (COL1A1), which 
is the main component of type-1 collagen. Collectively, these observations suggest an imbalance in 
vascular collagen metabolism that favors degradation in preeclampsia. In addition, MMP-1 was shown to 
be a regulator of arterial vessel tone, implicating this metalloproteinase in the pathogenesis of systemic 
hypertension associated with preeclampsia159. 
 The expression level of several MMP genes, including MMP1, 2, 3, 7, 9 and 14, is known to be 
regulated by DNA methylation219. DNA hypomethylation induced by 5-Aza-2-deoxycytidine (5-Aza) 
treatment resulted in a significant increase in MMP-1 expression in cultured amnion fibroblasts164. The 
increase in MMP-1 expression correlated with decreased DNA methylation at a particular location in the 
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MMP1 promoter 1538 base pairs upstream from the transcription start site. DNA methylation at the same 
site was significantly reduced in amnion tissues collected from pregnancies with preterm premature 
rupture of the fetal membranes164. 
 This evidence for epigenetic regulation of MMP1, as well as other MMP genes, led us to 
hypothesize that reduced DNA methylation might contribute to the increased expression of MMPs in the 
systemic vasculature of preeclamptic women leading to the imbalance in genes involved in collagen 
metabolism159. In this study, we examined DNA methylation in the promoter regions of MMP, TIMP and 
COL genes in omental arteries obtained from normal pregnant and preeclamptic women. We also studied 
the effect of DNA hypomethylation on a) the expression of MMP-1, TIMP-1, and COL1A1 in primary 
cultures of human VSMCs, and b) the expression of MMP-1 and the neutrophil collagenase, MMP-8, in a 
neutrophil-like cell line220. 
 
C. Materials and methods 
1. Study subjects 
  
 Omental and subcutaneous fat samples of approximately 2 cm x 2 cm x 0.5 cm in size were 
obtained at cesarean section from normal pregnant (n=18) and women clinically diagnosed with mild or 
severe preeclampsia (n=21) at MCV Hospital, Virginia Commonwealth University Medical Center, 
Richmond, VA. Mild preeclampsia was diagnosed when the blood pressure was more than 140 mm Hg 
systolic or 90 mm Hg diastolic and 0.3 g of urinary protein per 24 hours after 20 weeks of gestation. 
Severe preeclampsia was diagnosed when blood pressure was more than 160 mmHg systolic or 110 mm 
Hg diastolic with 5 g of protein in the urine within 24 hours after 20 weeks of gestation1. Omental fat was 
used because it contains arteries that are representative of systemic blood vessels and that contribute to 
total peripheral vascular resistance. Women with chorioamnionitis, infections, active sexually transmitted 
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diseases, lupus or diabetes, and women who were smokers or in labor were excluded because these 
conditions are associated with inflammatory changes. Patient clinical data are shown in Table 8. This 
study was approved by the Office of Research Subjects Protection, Virginia Commonwealth University, 
Richmond, Virginia. All subjects gave informed consent. 
 
2. Sample processing and bisulfite sequencing 
  
 Omental arteries from 9 normal pregnant women and 9 preeclamptic women (5 mild, 4 severe) 
were dissected and cleaned of adhering fat. DNA was extracted from the arteries (~10 mg by weight) 
using QuickGene DNA tissue kit and QuickGene-Mini80 system (AutoGen, Holliston, MA). DNA was 
treated with RNase A (Qiagen, Valencia, CA). DNA (1 µg) was bisulfite treated using MethylEasy 
Exceed kit (Human Genetic Signatures, Randwick, Australia), and DNA sequencing was performed as 
previously described164. Briefly, 100 ng of bisulfite treated DNA was PCR amplified for two rounds using 
our previously published primers for the -1538 site in the MMP1 promoter. PCR products were purified 
with QIAquick PCR Purification kit (Qiagen, Valencia, CA) and 1 µl of each product was cloned into 
pCR 2.1-TOPO vectors using the TOPO TA cloning kit (Invitrogen, Carlsbad, CA). After bacteria 
amplification, eight cloned PCR segments for each patient were sequenced in the Nucleic Acids Research 
Facilities at Virginia Commonwealth University. The -1538 site was selected because we previously 
demonstrated that its methylation correlates with the expression of MMP-1164. 
 
3. Illumina Infinium HumanMethylation27 BeadChip assay 
  
 Omental arteries from 5 normal pregnant and 7 severe preeclamptic women were processed for 
DNA extraction. DNA was bisulfite treated and used in the high throughput Illumina Infinium 
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HumanMethylation27 BeadChip assay (Illumina, San Diego, CA) for global DNA methylation analysis. 
The BeadChip was run by the Nucleic Acids Research Facilities at VCU using the protocol provided by 
Illumina. Data analysis was performed using the beadarray package in R programming environment212. 
Methylation values (β values) are expressed as range from 0 to 1 where 0 means not methylated and 1 
means fully methylated. Differences in methylation between normal pregnant and preeclamptic women 
were indicated by ∆β-values. 
 
4. Immunohistochemistry 
  
 Omental and subcutaneous fat samples from 6 normal pregnant and 6 preeclamptic women 
were cut into small pieces, fixed immediately in 10% neutral buffered formalin and embedded in paraffin. 
Tissues were cut into 8 µm sections which were stained for rabbit antihuman polyclonal antibody specific 
for MMP-8 (1:100 titer, Proteintech, Chicago, IL). Rabbit primary antibody isotype control (Invitrogen, 
Camarillo, CA) was used as a negative control. A kit was used for immunohistochemical staining 
(SuperPicTure Polymer Detection Kit Broad Spectrum (DAB), Invitrogen, Camarillo, CA). To quench 
endogenous tissue peroxidase activity, slides were incubated in 3% hydrogen peroxide in methanol for 30 
min. For antigen retrieval, slides were heat treated in 10 mM citrate buffer for 5 min with a pressure 
cooker. Tissue slides were counterstained with 1:5 dilution of hematoxylin QS (Vector Laboratories, 
Burlingame, CA). Vessel staining for MMP-8 was evaluated using an intensity scale ranging from 0 to 4 
where 0 was assigned for no staining, and 4 was dark and extensive staining. Scoring was verified by a 
second investigator and by measuring the optical density of staining (OD) using image analysis software 
(cellSens Imaging Software, Olympus America, Center Valley, PA) as previously described61,62. Optical 
density of staining for MMP-8 in vessels was normalized to the optical density of the background.  Slides 
were also analyzed for vessels with diffuse staining and leukocyte staining for MMP-8. Images were 
captured with cellSens Imaging Software. 
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5. Human vascular smooth muscle cells (VSMCs) 
  
 Human VSMCs were cultured from chorionic plate arteries of placentas collected at cesarean 
section from healthy pregnant women at term deliveries as previously described165. Cells were cultured in 
T-25 flasks using Medium-199 (M-199, Gibco, Invitrogen, Carlsbad, CA) with 10% fetal bovine serum 
(Gibco, Invitrogen, Carlsbad, CA) and 1% antibiotics and antimycotics (100 U/ml penicillin, 100 µg/ml 
streptomycin, 25 µg/ml amphotericin B, Gibco, Invitrogen, Carlsbad, CA). Cells were treated with 10 µM 
of 5-Aza, a hypomethylating agent (Sigma-Aldrich, Saint-Louis, MO) for 48 hours. Treatments were 
refreshed daily. Cells were 50% confluent at the time of treatment and nearly 100% confluent at the time 
of harvesting. Conditioned media were collected and centrifuged to remove cell debris. Cells were rinsed 
in phosphate buffer saline and harvested for RNA or protein extraction. 
 
6. HL-60 cells 
  
 HL-60 cells (ATCC, Manassas, VA), a neutrophil-like cell line, were cultured in  
Iscove's Modified Dulbecco's Medium (IMDM, ATCC, Manassas, VA) supplemented with 10% fetal 
bovine serum (Gibco, Invitrogen, Carlsbad, CA) and 1% antibiotics and antimycotics (100 U/ml 
penicillin, 100 µg/ml streptomycin, 25 µg/ml amphotericin B, Gibco, Invitrogen, Carlsbad, CA) as 
recommended by ATCC. Approximately 500,000 cells per ml were seeded in 5 ml of media in a T-25 
flask for treatments. Cell treatments were: 1) 10 µM 5-Aza for 48 hours followed by 10-8 M of phorbol 12-
myristate 13-acetate (PMA), a protein kinase C activator, (Sigma-Aldrich, Saint-Louis, MO) for 24 hours; 
2) 10 µM 5-Aza for 48 hours followed by no treatment for 24 hours; 3) no treatment for 48 hours 
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followed by 10-8 M PMA for 24 hours or 4) no treatment for 72 hours to serve as control. Cells were 
collected for RNA and protein extraction. 
 
7. Quantitative real time polymerase chain reaction (qRT-PCR) 
  
 RNA was extracted using QuickGene RNA cultured cell kit with QuickGene Mini-80 system 
(AutoGen, Holliston, MA). DNase treatment was performed using Turbo DNAse kit (Ambion, Austin, 
TX). RNA (1 µg) was reverse transcribed to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA). qRT-PCR reactions were performed with RT² SYBR® Green qPCR 
Mastermix (SABiosciences, Frederick, MD) as recommended by the user manual, and 8 ng of cDNA 
were used per reaction. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene. Commercial primers were used for MMP1 and MMP8 genes (SABiosciences, 
Frederick, MD). Primers for GAPDH, TIMP1 and COL1A1 genes, shown in Table 9, were synthesized by 
Integrated DNA Technologies (IDT, Coralville, IA). Fold changes were calculated by the ∆∆Ct method. 
 
8. Western blotting 
  
 Cells were lysed in RIPA buffer containing 150 mM sodium chloride, 1.0% NP-40, 0.5% 
sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris (pH 8.0) and 1X Halt protease 
inhibitor (Thermo Scientific, Pittsburgh, PA) using a tip sonicator (Active Motif, Carlsbad, CA). Protein 
concentrations were measured using BCA assay (Thermo Fisher Scientific, Rockford, IL). Denatured 
protein lysates (100 µg) were resolved by electrophoresis on 10% tris-glycine sodium dodecyl sulphate 
polyacrylamide gel and electrotransferred to polyvinylidene fluoride membrane (Immobilon-FL, 
Millipore, Billerica, MA). Primary antibodies used were goat anti-human MMP-1 (0.2 µg/ml, R&D 
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Systems, Minneapolis, MN); goat anti-human COL1A1 (1:1,000, Santa Cruz Biotechnology, Santa Cruz, 
CA); rabbit anti-human MMP-8 (1:250, Proteintech, Chicago, IL); rabbit anti-human β-actin (1:1,000, 
Sigma-Aldrich, Saint-Louis, MO); and mouse anti-human β-actin (1:1,000, Sigma-Aldrich, Saint-Louis, 
MO). Secondary antibodies used included Alexa Flour 680 donkey anti-rabbit (1:20,000, Invitrogen, 
Carlsbad, CA) for the detection of primary antibodies raised in rabbit for β-actin or MMP-8; IRDye800 
donkey anti-goat (1:20,000, Rockland, Gilbertsville, PA) for the detection of primary antibodies raised in 
goat for MMP-1 or COL1A1; and IRDye800 goat anti-mouse (1:20,000, Rockland Immunochemicals, 
Gilbertsville, PA) for the detection of primary antibody raised in mouse for β-actin. LI-COR Odyssey 
Infrared Imaging System (Thermo Scientific, Pittsburgh, PA) was used to detect the immunoreactive 
proteins. 
 
9. Enzyme linked immunosorbent assay (ELISA) 
  
 Commercial ELISA kits were used to quantify total MMP-1 (GE Healthcare, Piscataway, NJ) 
and TIMP-1 (GE Healthcare) in VSMC culture medium. For normalization, the total amount of MMP-1 
or TIMP-1 protein in 5 ml (volume of medium used in a T-25 flask) was divided by the total amount of 
DNA (µg) extracted from the cells of the same flask. 
 
10. Statistical analysis 
  
 Mann–Whitney U test was used to analyze the data from bisulfite sequencing. Student’s t test 
was used to make comparisons of parameters between two groups and one-way ANOVA with Newman-
Keuls test was used to make comparisons of parameters between more than two groups. Quantitative 
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results were presented as mean ± SEM. We considered a P value of < 0.05 statistically significant. A 
statistical software program was used for data analysis (GraphPad Prism version 4.0, San Diego, CA). 
 
D. Results 
  
 Illumina BeadChip assay revealed a significant decrease in DNA methylation in the promoter 
regions of MMP1 and MMP8 genes in omental arteries from preeclamptic women as compared to normal 
pregnant women. However, there were no significant changes in DNA methylation in the promoter 
regions of TIMP1 or COL1A1 genes. Other MMP, TIMP and COL genes that were differentially 
methylated in preeclamptic arteries are shown in Table 10. All MMP genes, except two, were less 
methylated, whereas TIMP and COL genes were in general relatively more methylated. Bisulfite DNA 
sequencing revealed a significant decrease in methylation at the -1538 site in the promoter region of the 
MMP1 gene in omental arteries from severe preeclamptic women as compared to normal pregnant women 
(p < 0.01, Figure 15). Methylation at the same site was not significantly different in arteries from women 
with mild preeclampsia as compared to arteries from normal pregnant women. 
 Immunohistochemical staining revealed increased expression of MMP-8 in omental and 
subcutaneous blood vessels of preeclamptic women as compared to normal pregnant women (Figure 16), 
similar to what we previously showed for MMP-1159. MMP-8 was mainly expressed in infiltrating 
leukocytes, although diffuse staining was also observed in the vessels. Scoring for MMP-8 staining 
intensity was significantly higher in preeclamptic women as compared to normal pregnant women (2.8 ± 
0.1 vs 1.2 ± 0.2, respectively, p < 0.001, Figure 17A) as was the density of staining for MMP-8 (121.6 ± 
5.2 vs 66.1 ± 7.0, respectively, p < 0.001, Figure 17B). Staining intensity scores and optical density of 
staining were highly correlated (r = 0.99). The percentage of vessels with neutrophils stained for MMP-8 
was significantly higher in preeclamptic women as compared to normal pregnant women (87.8 ± 1.5% vs 
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54.0 ± 7.2%, respectively, p < 0.001, Figure 17C). The percentage of vessels with diffuse staining for 
MMP-8 was also significantly higher in preeclamptic women as compared to normal pregnant women 
(79.8 ± 5.7 vs 38.4 ± 6.1%, respectively, p < 0.001, Figure 17D). 
 To determine whether DNA methylation could be involved in the regulation of MMP1 gene 
expression in VSMCs, 5-Aza was used to induce DNA hypomethylation in the cultured cells. Treatment 
with 5-Aza provoked a significant increase in MMP1 gene expression as compared to control cells (5.0 ± 
0.6-fold, p < 0.001, Figure 18A). To confirm that increased MMP1 gene expression was associated with 
an increase in protein production, ELISA was used to quantify MMP-1 secretion into the media. 
Treatment with 5-Aza significantly increased the production of MMP-1 protein (3.4 ± 0.3 vs 1.2 ± 0.3 
ng/µg DNA, p < 0.01, Figure 18B). In contrast to MMP-1, 5-Aza treatment caused no significant change 
in gene expression of TIMP1 or COL1A1 in cultured VSMCs (Figure19), and did not affect protein levels 
of TIMP-1 in the media (Figure 20A) or COL1A1 content in cells (Figure 20B). 
 The effect of reduced DNA methylation on the expression of MMP-1 was also examined in a 
neutrophil-like cell line, HL-60 cells. The expression of MMP-1 in untreated HL-60 cells was low, but 
treatment with 5-Aza resulted in a significant increase in MMP1 gene expression as compared to controls 
(62.4 ± 6.8-fold, p < 0.001). PMA treatment also resulted in significant increase in MMP1 gene 
expression (19.6 ± 3.2-fold, p < 0.001). Treatment with PMA caused activation of the cells as evidenced 
by cell adhesion to the culture flask surface. Combined treatment with 5-Aza and PMA resulted in a 
dramatic increase in MMP1 gene expression as compared to controls (2622 ± 167-fold p < 0.001), PMA 
alone (p < 0.001) or 5-Aza alone (p < 0.001) (Figure 21). The gene expression profiles resulting from 5-
Aza treatments were shown to correlate with protein expression as indicated by Western blotting (Figure 
22A and B). Treatment with 5-Aza significantly increased MMP-1 protein expression (164 ± 6% average 
density measurement of Western blot as compared to control, p < 0.001). PMA alone caused no 
significant change in MMP-1 protein expression as compared to controls. However, combining 5-Aza 
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with PMA significantly increased MMP-1 protein expression (261 ± 6% of control, p < 0.001), PMA 
alone (p < 0.001) or 5-Aza alone (p < 0.001). 
 The role of DNA methylation in the expression of MMP-8 was also examined in the 
neutrophil-like cell line. Treatment with 5-Aza caused a significant increase in MMP8 gene expression as 
compared to the control (3.2 ± 0.2-fold, p < 0.001). In contrast to MMP1, PMA treatment down-regulated 
MMP8 gene expression, whereas combined treatment of PMA and 5-Aza partially restored MMP8 gene 
expression (Figure 23). The changes in gene expression were associated with alterations in protein 
production as confirmed by Western blotting (Figure 24, B and C). 
 
E. Discussion 
  
 In this study we explored the possible contributions of epigenetic regulation to the imbalance in 
expression of genes involved in collagen metabolism in omental arteries of preeclamptic women159. We 
found that the promoter regions of the MMP1 and MMP8 genes had significantly reduced methylation in 
preeclamptic omental arteries as compared to normal pregnant arteries, but there was no significant 
difference in the methylation status for TIMP1 or COL1A1. In a global assessment of methylation status 
for these gene families, we found reduced methylation in several of the MMP genes, whereas increased 
methylation or no significant change was present for TIMP and COL genes. 
 In addition to global methylation assessment, we also examined a specific site (-1538) in 
MMP1 promoter that we previously showed was hypomethylated in the amnion of pregnancies 
complicated by preterm premature rupture of membranes164. DNA sequencing of that site demonstrated 
that it was significantly less methylated in omental arteries of sever preeclamptic women, but not mild 
preeclamptic women, as compared to normal pregnant women. This may suggest a relationship between 
the severity of the preeclampsia and decreased DNA methylation. These studies demonstrate that in both 
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preterm premature rupture of membranes and preeclampsia reduced DNA methylation is associated with 
increased expression of MMP-1 in tissues specific to their pathology. 
 Similar to the increased expression of MMP-1 we previously reported159, the expression of 
MMP-8 was also increased in omental and subcutaneous blood vessels of preeclamptic women as 
compared to normal pregnant women. MMP-8 was mainly expressed in neutrophils, but diffuse staining 
for MMP-8 was also present in the vessels, which may represent MMP-8 secreted by the neutrophils. 
 To study the role of DNA methylation in the regulation of these genes, we experimentally 
induced DNA hypomethylation in cultured human VSMCs. Hypomethylation resulted in a significant 
increase in MMP-1 expression, but did not significantly affect TIMP-1 or COL1A1. We also examined 
the effect of hypomethylation on MMP-1 and MMP-8 expression in a neutrophil-like cell line because 
neutrophils infiltrate maternal systemic blood vessels in preeclampsia and strongly express these MMPs. 
We found that DNA hypomethylation significantly increased MMP-1 and MMP-8 expression in HL-60 
cells. 
 Stimulation of HL-60 cells with PMA, a classical inducer of leukocyte activation, resulted in a 
significant increase in MMP-1 but not MMP-8, suggesting that MMP-1 and MMP-8 are differentially 
regulated in these cells. This is supported by the fact that when DNA hypomethylation was combined 
with PMA, there was a dramatic increase in the expression of MMP-1 but not MMP-8. On the other hand, 
results from 5-Aza treatment suggest that decreased DNA methylation in neutrophils contributes to the 
increased expression of both MMP-1 and MMP-8 in maternal systemic blood vessels of preeclamptic 
women by increasing the capacity of infiltrating neutrophils to produce these MMPs. A global decrease in 
DNA methylation in leukocytes was reported in other diseases involving the cardiovascular system 
including atherosclerosis134, ischemic heart disease and stroke130. Untreated HL-60 cells showed very low 
expression of MMP-1, which is similar to un-activated neutrophils. This suggests that MMP-1 expression 
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in un-activated cells is largely silenced by DNA methylation, and that reduced DNA methylation 
contributes to increase expression of MMP-1 in infiltrating neutrophils in preeclamptic women. 
 The increased expression of MMP-1159 and MMP-8 in maternal blood vessels of preeclamptic 
women was associated with a decrease or no change in TIMP-1 or COL1A1159. This suggests an increase 
in collagenolytic activity in these vessels, which could contribute to the development of edema and 
proteinuria by compromising the integrity of the vessels and increasing their permeability to proteins. 
Increased expression of MMP-1 also contributes to neutrophil infiltration and vasoconstriction in 
preeclampsia159. In regard to neutrophil infiltration, supernatants taken from VSMC cultures treated with 
MMP-1 stimulated neutrophil migration in vitro. This was associated with increased VSMC secretion of 
interleukin-8 and collagen type I C terminal telopeptide fragment, which are known neutrophil 
chemoattractants. With regard to vasoconstriction, MMP-1 caused contraction of omental arteries in a 
dose dependent manner through the activation of protease-activated receptor-1, which is also 
overexpressed in omental arteries of preeclamptic women159. Therefore, increased MMP-1 levels in blood 
vessels and plasma of preeclamptic women may play an important, but heretofore unrecognized, role in 
regulating vascular tone. 
Our study has several limitations in that our findings are correlative and do not prove a cause and 
effect relationship between reduced methylation and increased expression of MMP-1 and MMP-8. We 
also cannot prove that reduced methylation of the MMP1 or MMP8 gene promoters per se was 
responsible for increased expression, since methylation changes may have indirectly altered gene 
expression (e.g., resulting in increased expression of critical transcription factors). In addition, we were 
not able to determine the cell types where methylation changes were occurring in the omental arteries 
because of the cellular heterogeneity, which includes endothelial cells, VSMCs and infiltrated 
neutrophils. However, by experimentally inducing hypomethylation in VSMCs and a neutrophil-like cell 
line, we were able to document that reduced methylation is strongly associated with increased expression 
of MMPs in both cell types. 
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 In summary, we have shown that the promoter regions of the MMP1 and MMP8 genes have 
reduced methylation in omental arteries of preeclamptic women as compared to those of normal pregnant 
women, whereas the promoter regions of TIMP and COL genes tend to be more methylated or unchanged. 
By experimentally inducing DNA hypomethylation in cultured human VSMCs and a neutrophil-like cell 
line, we were able to mimic the imbalance in collagen regulating genes present in systemic blood vessels 
of preeclamptic women. These findings suggest the possibility that epigenetic mechanisms directly 
involving the promoters of the target collagen metabolism genes, or possibly genes that regulate their 
expression (e.g., transcription factors), play an important role in the vascular dysfunction associated with 
preeclampsia. 
Our study may have clinical implications for the treatment or prevention of preeclampsia based 
on restoring methylation. Folate is an essential component in the folate-methionine cycle that synthesizes 
methyl donors utilized by methyltransferases to methylate DNA. Therefore, dietary supplementation with 
folate might restore reduced methylation in MMP genes and protect against development of preeclampsia. 
Consistent with this notion is a recent large study comprised of almost 3,000 pregnant women, which 
found supplementation with multivitamins containing folic acid was associated with reduced risk of 
preeclampsia206. 
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Table 8: Clinical Characteristics of Patient Groups. 
Variable 
Normal Pregnant 
(n=18) 
Preeclamptic 
(n=21) 
Maternal age (y) 26.1 ± 1.3 24.6 ± 1.0 
Pre-pregnancy BMI (kg/m2) 26.2 ± 1.2 30.7 ± 1.6* 
Systolic blood pressure (mm Hg) 117.1 ± 2.3 166.8 ± 2.4*** 
Diastolic blood pressure (mm Hg) 70.18 ± 1.8 93.5 ± 2.6*** 
Proteinuria (mg/24 h) ND 286.8 ± 21.6 (n=8) 
Dipstick ND 2.7 ± 0.3 (n=13) 
Parity   
Primiparous 3 15 
Multiparous 15 6 
Gestational age (wk) 39.2 ± 0.2 35.4 ± 0.9*** 
Infant birth weight (g) 3503 ± 100 2452 ± 248*** 
Values are presented as mean ± SEM 
*p < 0.05, *** p < 0.001 by t-test. 
ND, not detectable.  
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Table 9: qRT-PCR primers used for gene expression. 
Gene Forward primer Reverse primer 
GAPDH GATTCCACCCATGGCAAATT AGATGGTGATGGGATTTCCATT 
TIMP1 CTGTGGCTCCCTGGAACA CCAACAGTGTAGGTCTTGGTGAAG 
COL1A1 ACG AAG ACA TCC CAC CAA TCAC CGTTGTCGCAGACGCAGA 
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Table 10: List of COL, MMP and TIMP genes that were significantly differentially methylated in 
preeclamptic omental arteries. NP = normal pregnant, PE = preeclamptic, β = methylation values. ∆β = 
difference in methylation. Minus values indicate less methylation and positive values more methylation in 
preeclamptic arteries as compared to normal pregnant arteries. 
Symbol Name Gene ID 
Mean β 
PE 
Mean β 
NP 
∆β p-value 
COL8A1 
collagen, type VIII, 
alpha 1 
1295 0.078 0.054 0.024 0.02 
COL9A3 
collagen, type IX, 
alpha 3 
1299 0.536 0.480 0.056 0.03 
COL19A1 
collagen, type XIX, 
alpha 1 
1310 0.202 0.154 0.047 0.02 
MMP1 
matrix 
metalloproteinase 1 
4312 0.736 0.816 -0.080 0.02 
MMP8 
matrix 
metalloproteinase 8 
4317 0.807 0.882 -0.075 0.03 
MMP12 
matrix 
metalloproteinase 12 
4321 0.683 0.740 -0.057 0.01 
MMP13 
matrix 
metalloproteinase 13 
4322 0.745 0.830 -0.085 0.01 
MMP16 
matrix 
metalloproteinase 16 
4325 0.025 0.014 0.011 0.02 
MMP21 
matrix 
metalloproteinase 21 
118856 0.411 0.543 -0.132 0.02 
MMP26 
matrix 
metalloproteinase 26 
56547 0.762 0.862 -0.100 0.02 
MMP27 
matrix 
metalloproteinase 27 
64066 0.769 0.726 0.043 0.04 
TIMP3 
tissue inhibitor of 
metalloproteinases 3 
7078 0.437 0.338 0.098 0.02 
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Figure 15: Bisulfite sequencing of the -1538 site in the MMP1 promoter region in omental 
arteries from normal pregnant (NP), mild preeclamptic (MPE) and severe preeclamptic (SPE) 
women. Methylation of the -1538 site was significantly reduced in omental arteries from SPE 
women (p < 0.01), but not significantly different in omental arteries form MPE women as 
compared to NP women. 
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  Figure 16: Representative sections of blood vessels in omental fat from normal pregnant and 
preeclamptic women immunostained for MMP-8. Results for subcutaneous fat were similar. A) 
There was no brown staining for MMP-8 in negative control sections. B) Blood vessels of normal 
pregnant women showed little or no staining for MMP-8. C, D) Vessels of preeclamptic women 
showed significant brown staining for MMP-8. Staining for MMP-8 in preeclamptic blood 
vessels was observed in neutrophils, which were in the lumen, adherent to the endothelium or 
infiltrated into the wall of the vessel. Diffused staining for MMP-8 was also present in the vessel 
wall.  A: adipocyte; VL: vessel lumen. Magnification and scale bar are shown on each image. 
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Figure 17: Quantitation of immunohistochemical staining for MMP-8 in omental and subcutaneous blood 
vessels from normal pregnant (NP) and preeclamptic (PE) women. A) Staining intensity score for MMP-8 
was significantly higher in blood vessels of preeclamptic women as compared to normal pregnant women. 
B) Optical density of staining for MMP-8 was significantly higher in preeclamptic blood vessels. C, D) 
Preeclamptic women had significantly higher percentage of blood vessels with neutrophils stained for 
MMP-8 and diffuse staining for MMP-8 as compared to normal pregnant women (n=5). Data are 
presented as means ± SEM.***p< 0.001. These data was done by Juhi Shukla. 
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Figure 18: MMP-1 expression in cultured human vascular smooth muscle cells treated with 5-
Aza. A) Fold change in gene expression for MMP1 was significantly increased in treated cells as 
compared to controls (p < 0.01, n=8). B) Levels of MMP-1 protein in media was significantly 
increased in treated cells as compared to controls (p < 0.05, n=4). Data are shown as means ± 
SEM. **p<0.01, ***p<0.001. 
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Figure 19: TIMP1 and COL1A1 gene expression in cultured human vascular smooth muscle cells 
treated with 5-Aza. Fold changes in the expression for TIMP1 and COL1A1 were not significantly 
changed by 5-Aza treatment as compared to control (n=8). Data are shown as means ± SEM. 
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Figure 20: TIMP-1 and COL1A1 protein expression in cultured human vascular smooth muscle 
cells treated with 5-Aza. A) TIMP-1 protein levels in media was not significantly changed as 
compared to controls (n=4). B) Western blot for pro-COL1A1 and COL1A1 demonstrated no 
effect of 5-Aza treatment on the protein expression of COL1A1 (n=3). Data are shown as means 
± SEM. 
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Figure 21: MMP1 gene expression in HL-60 cells. The expression of MMP1 gene was 
significantly increased in 5-Aza or PMA treated cells as compared to control cells. Treatment 
with PMA after 5-Aza caused a remarkable increase in MMP1 gene expression as compared to 
control, PMA alone or 5-Aza alone (n=8). Data are shown as means ± SEM. Groups with a 
different letter are significantly different from each other, p<0.001. 
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Figure 22: MMP-1 protein expression in HL-60 cells.  A) Western blot and B) density 
measurements of the Western blot showing treatment with 5-Aza significantly increased the 
expression of MMP-1 protein in HL-60 cells as compared to control. Activation with PMA after 
treatment with 5-Aza resulted in a greater increase in MMP-1 expression as compared to control, 
5-Aza alone or PMA alone (n=4). Data are shown as means ± SEM. Groups with a different letter 
are significantly different from each other, p<0.001. 
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Figure 23: MMP8 gene expression in HL-60 cells. Gene expression of MMP8 was significantly 
increased in 5-Aza treated cells as compared to control. PMA down-regulated MMP8 expression, 
but 5-Aza partially restored it (n=8). Data are shown as means ± SEM. Groups with a different 
letter are significantly different from each other at a minimum p-value of < 0.05. 
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Figure 24: MMP-8 protein expression in HL-60 cells A) Western blot and B) density 
measurements of the Western blot showing 5-Aza significantly increased the expression of MMP-
8. PMA down-regulated MMP-8 expression, but 5-Aza restored it (n=5). Data are shown as means 
± SEM. Groups with a different letter are significantly different from each other at a minimum p-
value of < 0.05 
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CHAPTER 6: PRELIMINARY STUDY OF THE EFFECT OF DNA HYPOMETHYLATION, 
NEUTROPHILS AND NEUTROPHIL PRODUCTS ON THE EXPRESSION OF 
TRANSCRIPTION FACTORS IN CULTURED VASCULAR SMOOTH MUSCLE CELLS  
 
We showed above in this thesis that decreased DNA methylation increased the expression of 
MMP-1 in cultures of human VSMCs. Our lab previously showed that activated neutrophils and two of 
their products, namely TNFα and ROS, also increased the expression of MMP-1 in VSMCs159. Some of 
the effect of these treatments on the expression of MMP-1, as well as other genes, may be due to the 
upregulation or downregulation of transcription factors that regulate the expression of those genes. In this 
chapter, a preliminary study was done on the effect of 5-Aza, activated neutrophils, TNFα and ROS on 
the expression of transcription factors in cultured human VSMCs using human transcription factors PCR 
arrays (Qiagen, Valencia, CA). 
 Human VSMCs were cultured in T-25 flasks and treated at 50% confluence with 10 µM of 5-
Aza, activated neutrophils (62,500 per T-25 flask), 1 ng/ml of TNFα or a ROS generating solution (0.05 
mM of hypoxanthine and 0.003 U/ml xanthine oxidase) for 48 hours as was described in the Materials 
and Methods section above. Treatments were refreshed every day. Cells were harvested and RNA was 
extracted. RNA (1 µg) was reversed transcribed and used in the expression microarrays. Microarrays 
were run and data were analyzed as was recommended by the user manual.  
 Preliminary results are summarized in Tables 11, 12, 13 and 14. Results are for factors that were 
either upregulated or downregulated by a factor of 2 or more. No p-values are provided because of the 
small sample number (3 controls vs 3 experiments for each treatment)  
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Table 11: List of transcription factors that were upregulated by 5-Aza. None were downregulated. 
Upregulated Genes Fold Change 
FOXA2  3.28 
GATA3  3.20 
NFATC2  2.96 
ESR1  2.65 
RELB  2.62 
IRF1  2.22 
PAX6  2.16 
HOXA5  2.11 
HAND1  2.01 
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Table 12:  List of transcription factors that were upregulated or downregulated by TNFα. 
  Upregulated Genes Fold Change 
HSF1  16.10 
MYC  6.79 
HDAC1  4.27 
ID1  3.47 
HIF1A  2.99 
ATF3  2.29 
HAND2  2.25 
RELB  2.22 
NFKB1  2.08 
Downregulated Genes Fold Change 
JUN  -2.12 
FOS  -2.12 
NFAT5  -2.14 
MEF2A  -2.37 
HAND1  -2.48 
PPARG  -2.84 
SMAD9  -3.08 
EGR1  -3.21 
MAX  -3.76 
GATA2  -4.21 
NFATC3  -5.10 
NFATC1  -7.16 
GATA1  -7.78 
MEF2B  -7.80 
NFATC2  -10.83 
HNF4A  -11.40 
GATA3  -13.03 
MYOD1  -17.93 
MYF5  -20.88 
MEF2C  -30.22 
MYB  -30.43 
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Table 13: List of transcription factors that were upregulated or downregulated by ROS. 
Upregulated Genes Fold Change 
CEBPA  4.01 
ATF3  3.09 
TGIF1  2.32 
NFATC2  2.20 
CEBPB  2.10 
MYB  2.08 
STAT6  2.03 
HOXA5  2.03 
PAX6  2.01 
Down-regulated Genes Fold Change 
SMAD9  -2.04 
E2F1  -2.06 
HNF4A  -2.16 
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Table 14: List of transcription factors that were downregulated by activated neutrophils. None were 
upregulated. 
Downregulated Genes Fold Change 
ESR1  -2.04 
EGR1  -2.12 
SMAD9  -2.20 
RB1  -2.33 
CREB1  -2.49 
FOS  -2.58 
HNF4A  -4.59 
SP3  -30.15 
TGIF1  -66.21 
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CHAPTER 7: GENERAL DISCUSSION 
  
 Using a high throughput assay for DNA methylation, 3,736 genes with significantly differentially 
methylated CpG sites were identified in omental arteries of normal pregnant women and preeclamptic 
women. Most of these genes were hypomethylated in preeclamptic women as compared to normal 
pregnant women. Of these genes with significant differences in methylation, 1,685 genes had a FDR of < 
10% with many of these genes hypomethylated and related to inflammation in preeclamptic women. A 
more stringent analysis revealed 65 significantly differentially methylated genes with a FDR of < 5% and 
difference in methylation (∆β) of > 0.10, all of which were hypomethylated in preeclamptic women.  
 It is interesting that inflammatory genes were primarily targeted by reduced methylation in 
preeclampsia. The mechanisms responsible for such selective changes in methylation are not known. It is 
known that DNA methylation is tissue specific, so tissue specific control mechanisms must be operative.  
  Pertinent with the systemic vascular inflammation and dysfunction associated with 
preeclampsia62, multiple canonical pathways related to inflammation and immune response were 
associated with the methylation changes in preeclampsia. In addition, multiple gene-to-gene interaction 
networks, which had inflammatory response, inflammatory disease and cardiovascular disease among 
their top associated biological functions were identified by the ingenuity pathway analysis (IPA) of genes 
with significant differences in methylation in preeclamptic women.   
 Preeclampsia is associated with increased vascular resistance, increased arterial pressure202, 
reduced uteroplacental blood flow203, hypercoagulopathy204, inflammation109, oxidative stress183 and 
altered carbohydrate and amino acid  metabolism152. Mapping significantly differentially methylated 
genes for gene ontology terms identified several molecular functions and biological processes, which 
were over-represented in preeclampsia and pertinent to its pathophysiology including smooth muscle 
contraction, thrombosis, inflammation, redox homeostasis, sugar metabolism and amino acid metabolism.  
 
 
229 
 
 Preeclampsia is also associated with an imbalance of increased thromboxane and decreased 
prostacyclin, which was first described in placenta95 and later confirmed for maternal blood96 and 
maternal urine97. Since thromboxane is a potent vasoconstrictor and platelet activator, whereas 
prostacyclin is a potent vasodilator and inhibitor of platelet activation27, this imbalance helps explain 
hypertension, reduced uteroplacental blood flow and hypercoagulopathy reported in women with 
preeclampsia. The thromboxane synthase gene (TBXAS1), which encodes the enzyme that catalyzes the 
conversion of prostaglandin H2 into thromboxane94, was the most hypomethylated gene in preeclamptic 
women.    
 Decreased DNA methylation in the promoter region of the TBXAS1 gene was associated with a 
significant increase in its expression in omental fat arteries of preeclamptic women as compared to 
normal pregnant women. Increased expression of thromboxane synthase was observed in the 
endothelium, in the VSMCs and in leukocytes, which were flattened and adhered to the endothelium and 
infiltrated into the wall of the vessel. Increased expression of thromboxane synthase would lead to 
increased production of thromboxane locally in the vessel, which could explain hypertension and 
coagulation abnormalities in preeclamptic patients because thromboxane is a potent vasoconstrictor and 
platelet activator84.  
 MMP1 and MMP8 were genes that also had significantly reduced methylation in omental arteries 
of preeclamptic women. Similar to thromboxane synthase, their gene and protein expression was 
significantly increased in preeclamptic omental arteries. The TBXAS1 gene was the most significantly 
hypomethylated gene in preeclamptic women with a Δβ of - 0.24 as compared to the Δβ for MMP1 of – 
0.080 and MMP8 of – 0.075. A more significant difference in methylation, however, does not necessarily 
mean it is more important. Increases in gene and protein expression were just as marked for MMP-1 and 
MMP-8 as for thromboxane synthase. 
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Leukocyte infiltration requires leukocyte activation, which most likely occurs as they circulate 
through the intervillous space and are exposed to increased lipid peroxides secreted by the placenta41. The 
infiltrating leukocytes are most likely neutrophils because neutrophils normally comprise approximately 
60%-70% of all leukocytes33 , their numbers increase 2.5-fold by 30 weeks of gestation214 and their 
numbers are further increased in preeclampsia215. In addition, we previously reported that neutrophils, but 
not lymphocytes or monocytes, infiltrate systemic blood vessels of preeclamptic women61,62,156,216.  
To study the role of DNA methylation in the regulation of thromboxane synthase, we 
experimentally induced DNA hypomethylation in a neutrophil-like cell line and in cultured human 
VSMCs. Hypomethylation resulted in increased expression of thromboxane synthase in both cell types, 
however, the increase was only significant in the neutrophil-like cell line. Increased expression of 
thromboxane synthase in the neutrophil-like cell line was associated with a parallel increase in the 
production of TXB2, the stable metabolite of thromboxane A2211. These data suggest that DNA 
methylation is important in regulating thromboxane synthase expression in neutrophils but not in VSMCs. 
In contrast, experimentally induced hypomethylation increased gene and protein expression for MMP-1 
and MMP-8 in both VSMCs and the neutrophil cell line. However, treatment of VSMCs with TNFα, a 
neutrophil product, did significantly increase thromboxane synthase, so increased expression of 
thromboxane synthase in vascular tissue of preeclamptic women may be due to inflammation caused by 
neutrophil infiltration. DNA hypomethylation in leukocytes has been reported in other diseases involving 
the cardiovascular system such as atherosclerosis134, ischemic heart disease and stroke26. 
 Pertinent to our findings of increased expression of thromboxane synthase are previous findings 
of increased levels of serum arachidonic acid in preeclamptic women217 and significant activation of NF-
ĸB and increased expression of COX-2 in preeclamptic blood vessels62. Similar to thromboxane synthase 
expression, activation of NF-ĸB and increased expression of COX-2 were observed in the endothelium, 
vascular smooth muscle and infiltrating neutrophils62. A possible scenario in preeclamptic blood vessels is 
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that increased COX-2 converts increased arachidonic acid into prostaglandin H2 and increased 
thromboxane synthase then converts prostaglandin H2 into thromboxane. 
 Preeclampsia is associated with oxidative stress41 and increased plasma levels of linoleic acid, the 
fatty acid precursor of arachidonic acid218. Neutrophils from normal pregnant women exposed to an 
oxidizing solution enriched with linoleic acid showed increased production of TNFα and thromboxane86. 
Also, exposure of cultured VSMCs to an oxidizing solution enriched with linoleic acid increased 
production of thromboxane85.  
Preexisting maternal genetic variation in key genes may also have an impact on DNA 
methylation. For example, allelic variation in the methylenetetrahydrofolate reductase gene have been 
associated with preeclampsia221, and methylenetetrahydrofolate reductase is an important enzyme 
regulating the synthesis of S-adenosyl methionine that modulates the availability of methyl groups for 
DNA methylation209.  
The changes in methylation observed may have been preexisting or the result of preeclampsia. If 
they were preexisting they could have contributed to an increased risk of preeclampsia. The changes 
could also be the result of the oxidative stress of preeclampsia because oxidative stress and DNA 
oxidation can result in a loss of DNA methylation. Once the DNA methylation pattern is altered, it is 
maintained by DNA methyltransferase 1 during future cell divisions, so alterations in DNA methylation 
occurring as a result of preeclampsia may be maintained and contribute to the increased risk of 
cardiovascular disease later-in-life experienced by women who have had preeclampsia. Additional 
alterations in the DNA methylation patterns may also occur after preeclampsia because many factors 
affect it, such as age, diet, environmental toxins and oxidative stress.  
 In summary, we found that hypomethylation in the promoter regions of TBXAS1, MMP1 and 
MMP8 are correlated with their increased gene and protein expression in systemic blood vessels of 
preeclamptic women. Increased expression was present in endothelium, VSMCs and infiltrating 
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neutrophils. We also showed that DNA hypomethylation increases the expression of thromboxane 
synthase in a neutrophil-like cell line and TNFα, a neutrophil product, increases thromboxane synthase 
expression in cultured VSMCs. DNA hypomethylation increased MMP-1 expression in both VSMCs and 
neutrophil-like cells and increased MMP-8 in the neutrophil-like cells. In contrast, experimentally 
induced hypomethylation did not affect the expression of COL1A1 or TIMP1 genes. These data suggest 
that hypomethylation is responsible for increased expression of thromboxane synthase, MMP-1 and 
MMP-8 in systemic blood vessels in women with preeclampsia. Increased expression of thromboxane 
synthase, MMP-1 and MMP-8 in the vasculature of preeclamptic women may help explain hypertension, 
edema, proteinuria, and coagulation abnormalities.   
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